AvHPPD-03

AvHPPD-03: Single-Dose Oral (Gavage) Toxicity Study in Mice with a 2-Day or 14-Day Observation Period

Final Report

DATA REQUIREMENT(S): European Community Guidelines for the Assessment of Additives in Feeding Stuffs
US FDA Redbook 2000
US EPA Health Effects Test Guidelines
US EPA Microbial Pesticide Test Guidelines

AUTHOR(S): [redacted]

STUDY COMPLETION DATE: 8 March 2012

PERFORMING LABORATORY: WIL Research Laboratories, LLC
1407 George Road
Ashland, OH 44805-8946 USA

LABORATORY PROJECT ID: Report Number: WIL-639061
Study Number: WIL-639061
Task Number: T007563-08

SPONSOR(S): Syngenta Crop Protection, LLC*
410 Swing Road
Greensboro, NC 27419-8300 USA

*Formerly Syngenta Crop Protection, Inc.

STATEMENT OF DATA CONFIDENTIALITY CLAIMS

This page intentionally left blank.

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study, designated WIL-639061, was conducted in compliance with the United States EPA GLP Standards (40 CFR Part 160), 16 October 1989; the SOPs of WIL (for activities conducted at WIL), and the protocol as approved by the Sponsor. Analyses of dosing formulations were not conducted as part of this study.

[redacted]

8-March-2012

Date

Study Director
Assistant Director, Toxicology

Performing Laboratory: WIL Research Laboratories, LLC
1407 George Road
Ashland, OH 44805-8946 USA

FLAGGING STATEMENT

This page intentionally left blank.

QUALITY ASSURANCE STATEMENT

Phases Inspected

Date(s) of Inspection(s)	Phase Inspected	Date(s) Findings Reported to Study Director	Date(s) Findings Reported to Management	Auditor(s)
20-Jan-2010	Necropsy	20-Jan-2010	22-Feb-2010	[redacted]
17-Feb-2010	Study Records (I-1)	17-Feb-2010	22-Mar-2010	[redacted]
17-Feb-2010 18-Feb-2010	Study Records (Rx-1)	18-Feb-2010	22-Mar-2010	[redacted]
18-Feb-2010	Study Records (N-1), (N-2)	18-Feb-2010	22-Mar-2010	[redacted]
18-Feb-2010	Study Records (C-1)	18-Feb-2010	22-Mar-2010	[redacted]
05-Mar-2010	Study Records (H-1), (H-2)	05-Mar-2010	20-Apr-2010	[redacted]
10-Mar-2010 11-Mar-2010 12-Mar-2010 16-Mar-2010	Study Records (P-1)	16-Mar-2010	20-Apr-2010	[redacted]
10-Mar-2010 11-Mar-2010 17-Mar-2010	Draft Report (Pathology Appendix)	17-Mar-2010	20-Apr-2010	[redacted]
01-Apr-2010 05-Apr-2010	Draft Report (without Anatomical Pathology Appendix)	05-Apr-2010	26-May-2010	[redacted]
06-Feb-2012	Final Pathology Report	06-Feb-2012	10-Feb-2012	[redacted]r
07-Feb-2012	Final Report	07-Feb-2012	10-Feb-2012	[redacted]

QUALITY ASSURANCE STATEMENT (Continued)

This study was inspected in accordance with the United States EPA GLP Standards (40 CFR Part 160), the WIL SOPs, and the Sponsor's protocol and protocol amendments, with the following exceptions. The data located in Appendix 2 (Certificate of Analysis) were the responsibility of the Sponsor. Quality Assurance findings, derived from the inspections during the conduct of the study and from the inspections of the raw data and draft report, are documented and have been reported to the Study Director. Review of the protocol and protocol amendments as well as a yearly internal facility inspection are conducted by the WIL Quality Assurance Unit. A status report is submitted to management monthly.

This report accurately reflects the data generated during the study. The methods and procedures used in the study were those specified in the protocol, its amendments, and the WIL SOPs.

Quality Assurance Approval

Lori J. Goodrich, RQAP-GLP*
Group Supervisor, Quality Assurance

[redacted] 08 Mar 2012

Date

Group Supervisor, Quality Assurance

Robyn A. Siburt, AAS, RLAT
Biologist

Report Released By:

[redacted] 08 Mar 2012

Date

Manager, Quality Assurance

* = No longer employed at WIL Research

KEY STUDY PERSONNEL AND REPORT APPROVAL

Report Approved By:

[redacted]

8-March 2012

Date

Study Director
Assistant Director, Toxicology

Report Prepared By:

[redacted]

8 March 2012

Date

Senior Study Analyst

Report Reviewed By:

[redacted]

8 March 2012

Date

Staff Toxicologist, Toxicology

[redacted]

7 March 2012

Date

Senior Director, General Toxicology

[redacted]

8 March 2012

Date

Group Supervisor, Reporting &
Technical Support Services

GENERAL INFORMATION

Test Facility: WIL Research Laboratories, LLC
1407 George Road
Ashland, OH 44805-8946 USA

Contributors

The following contributed to this report in the capacities indicated:

Name	Title
[redacted]	Study Director
[redacted]	Assistant Director, Analytical Chemistry
[redacted]	Operations Manager, Pathology
[redacted]	Senior Operations Manager, Vivarium
[redacted]	Manager, Gross Pathology and Developmental Toxicology Laboratory
[redacted]	Operations Manager, Toxicology
[redacted]	Clinical Veterinarian
[redacted]	Group Manager, Formulations Laboratory
[redacted]	Manager, Histology
[redacted]	Vice President, Chemistry Services
[redacted]	Director, Operations
[redacted]	Manager, Clinical Pathology
[redacted]	Group Manager, Sample Processing Laboratory
[redacted]	Operations Manager, Reporting & Technical Support Services
[redacted]	Syngenta Sponsor Representative

GENERAL INFORMATION (Continued)

Study Dates[1]

Study initiation date (protocol signed by the Study Director):	08 January 2010
Experimental starting date (animal receipt):	05 January 2010
Experimental start date (administration of single oral dose; study day 0)	18 January 2010
Scheduled interim necropsy (study day 2)	20 January 2010
Scheduled primary necropsy (study day 14)	01 February 2010
Experimental termination date (last histopathological examination):	01 March 2010

Deviations from the Guidelines

None

Data Retention and Retention of Samples

The Sponsor has title to all documentation records, raw data, specimens, or other work product generated during the performance of the study. Any remaining dosing formulations and clinical pathology samples will be discarded upon issuance of the final report; all remaining work product generated by WIL, including raw paper data and specimens, are retained in the WIL Archives as specified in the study protocol.

A reserve sample of AvHPPD-03 and pertinent electronic storage media are retained in the WIL Archives in compliance with regulatory requirements. The original final report is retained in the Archives of the Sponsor, at Syngenta Crop Protection, LLC, Greensboro, NC.

[1] = Date ranges represent the first and last dates of evaluation.

TABLE OF CONTENTS

STATEMENT OF DATA CONFIDENTIALITY CLAIMS **2**
GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT **3**
FLAGGING STATEMENT **4**
QUALITY ASSURANCE STATEMENT **5**
KEY STUDY PERSONNEL AND REPORT APPROVAL **7**
GENERAL INFORMATION **8**
TABLE OF CONTENTS **10**
1.0 EXECUTIVE SUMMARY **13**
1.1 Study Design 13
1.2 Results 13
1.3 Conclusion 13
2.0 INTRODUCTION **14**
2.1 Purpose 14
2.2 Regulatory Guidelines 14
2.3 General Study Information 14
3.0 MATERIALS AND METHODS **15**
3.1 AvHPPD-03 and Vehicle 15
3.1.1 AvHPPD-03 15
3.1.2 Vehicle Identification and Preparation 15
3.1.3 Preparation of AvHPPD-03 Dosing Formulations 16
3.1.4 Sampling and Analyses 16
3.2 Experimental Design 16
3.2.1 Test System, Animal Receipt, and Acclimation/Pre-test Period 16
3.2.2 Animal Housing 17
3.2.3 Diet, Drinking Water, and Maintenance 17
3.2.4 Environmental Conditions 17
3.2.5 Assignment of Animals to Treatment Groups 18
3.2.6 Organization of Test Groups, Dose Levels, and Treatment Regimen 18
3.3 *Antemortem* Investigations 19
3.3.1 Survival 19
3.3.2 Clinical Observations 19
3.3.3 Body Weights 19
3.3.4 Food Consumption 19
3.3.5 Clinical Pathology - Hematology 19

3.4 *Postmortem* Investigations 20
3.4.1 Macroscopic Examination 20
3.4.2 Slide Preparation and Microscopic Examination 21
3.5 Data Acquisition and Analysis 22
3.5.1 Acquisition and Reporting 22
3.5.2 Statistical Analysis 22
4.0 RESULTS AND DISCUSSION 23
4.1 Survival 23
4.2 Clinical Observations 23
4.3 Body Weights 23
4.4 Food Consumption 24
4.5 Clinical Pathology - Hematology 24
4.6 Anatomic Pathology 25
4.6.1 Macroscopic Examination 25
4.6.2 Microscopic Examination 25
5.0 CONCLUSIONS 25
6.0 REFERENCES 26
7.0 ABBREVIATIONS 27

TABLES SECTION 28
TABLE S1 Summary of Survival and Disposition 29
TABLE S2 Summary of Clinical Findings (Detailed Physical Examinations/Dispositions) 31
TABLE S3 Summary of Post-Dose Findings (Dosing Day Observations) 33
TABLE S4 Summary of Clinical Findings (Daily Observations - Nondosing Days) 35
TABLE S5 Summary of Body Weights [g] 37
TABLE S6 Summary of Body Weight Changes [g] 47
TABLE S7 Summary of Cumulative Body Weight Changes [g] 55
TABLE S8 Summary of Food Consumption [g/animal/day] 61
TABLE S9 Summary of Hematology Values 67
TABLE S10 Summary of Macroscopic Findings (Day 2 Interim Necropsy) 91
TABLE S11 Summary of Macroscopic Findings (Day 14 Primary Necropsy) 93
TABLE S12 Summary of Microscopic Findings (Day 2 Interim Necropsy) 95
TABLE S13 Summary of Microscopic Findings (Day 14 Primary Necropsy) 103

FIGURES SECTION **112**

FIGURE 1 Summary of Body Weights [g] - Males 113
FIGURE 2 Summary of Body Weights [g] - Females.....114

APPENDICES SECTION **115**

APPENDIX 1 Deviations from the Protocol 116
APPENDIX 2 Certificate of Analysis (Sponsor-Provided Data) 118
APPENDIX 3 Pre-test Clinical Observations.....120
APPENDIX 4 Animal Room Environmental Conditions.....123
APPENDIX 5 Clinical Pathology Methods, Procedures, and References.....128
APPENDIX 6 Pathology Report (WIL Research Laboratories, LLC) 131

INDIVIDUAL ANIMAL DATA VOLUME 1 OF 1 **140**

APPENDIX 7 Individual Animal Data.....141

1.0 EXECUTIVE SUMMARY

1.1 Study Design

The test substance, AvHPPD-03-0209 containing the active ingredient AvHPPD-03 protein (72.2% purity w/w), was administered as a single oral dose via gavage to 3 groups of Crl:CD1(ICR) mice (Groups 2, 3, and 4). Dose levels were 500, 1500, and 2000 mg active ingredient/kg body weight, respectively. The vehicle, deionized water, was administered to a concurrent control group (Group 1) on a comparable regimen. The dose volume was 20 mL/kg for all groups. Each group consisted of 10 animals/sex. Five animals/sex/group were euthanized a minimum of 48 hours following dose administration (study day 2). The remaining 5 animals/sex/group were euthanized following a 14 day observation period.

All animals were observed twice daily for mortality and moribundity. Clinical examinations were performed at the time of dosing and at approximately 1-2 and 4-5 hours post dosing on the day of dose administration (study day 0) and once daily during the observation period (study days 1 13). Detailed physical examinations were performed weekly and individual body weights and food consumption were recorded daily. Clinical pathology parameters (hematology) were analyzed at the interim necropsy (study day 2) and primary necropsy (study day 14) for those animals scheduled for necropsy. Complete necropsies were conducted and selected tissues were examined microscopically from all animals.

1.2 Results

All animals survived to the scheduled necropsies on study days 2 and 14. There were no AvHPPD-03-related clinical observations. There were no AvHPPD-03-related effects on body weights, food consumption, hematology parameters, or any histological or macroscopic findings at the scheduled necropsies.

1.3 Conclusion

The test substance, AvHPPD-03-0209 containing the active ingredient AvHPPD-03 protein (72.2% purity w/w) was administered as a single oral dose at 500, 1500, and 2000 mg active ingredient/kg of body weight to CD-1 mice. Following a 2-day and 14-day observation period, the results indicated that AvHPPD-03 was well tolerated. All mice survived to the scheduled 2-day interim necropsy or 14-day primary necropsy without clinical signs of distress or impairment, and anatomical pathology results did not identify any specific target organ toxicity. Therefore, under the conditions of this study, there was no evidence of toxicity resulting from oral administration of AvHPPD-03 protein. The no-observed-adverse-effect level (NOAEL) for a single oral dose (gavage) of AvHPPD-03-0209 containing the active ingredient AvHPPD-03 protein to Crl:CD 1(ICR) mice was 2000 mg of active ingredient/kg of body weight, the highest dose level examined in the study.

2.0 INTRODUCTION

2.1 Purpose

The objective of this study was to evaluate the potential toxicity of the *p*-hydroxyphenylpyruvate dioxygenase protein (AvHPPD-03) and to establish a no-observable-adverse-effect level (NOAEL) for AvHPPD-03 when administered as a single dose orally by gavage to mice, followed by a 2-day and 14-day observation period to assess the reversibility, persistence, or delayed occurrence of any toxic effects.

The AvHPPD-03 protein is a p-hydroxyphenylpyruvate dioxygenase (HPPD) enzyme that catalyzes the formation of homogentisic acid, the aromatic precursor in plastoquinone and vitamin E biosynthesis in plants.

2.2 Regulatory Guidelines

The study procedures described in this report are adapted from the following guidelines:

European Community Guidelines for the Assessment of Additives in Feeding Stuffs
US FDA Redbook 2000
US EPA Health Effects Test Guidelines
US EPA Microbial Pesticide Test Guidelines

2.3 General Study Information

This report presents the data from "AvHPPD-03: Single-Dose Oral (Gavage) Toxicity Study in Mice with a 2-Day or 14-Day Observation Period." Due to software spacing constraints, the study title appears as "A Single-Dose Oral Gavage Study of AvHPPD-03 in Mice" on the report tables. On 15 August 2011, [redacted] assumed the role of Study Director originally held by [redacted].

Deviations from the protocol are presented in Appendix 1. A list of abbreviations potentially used in this report is presented in Section 7.0 (Abbreviations).

For the data collection process, each phase of the study was separated into what were termed WIL computer protocols. The computer protocol reference numbers and types of data collected were identified as follows:

Computer Protocol	Type of Data Collected
WIL-639061	Main study data
WIL-639061P	Pre-test data
WIL-639061U	Nondosing day observations

3.0 MATERIALS AND METHODS

3.1 AvHPPD-03 and Vehicle

3.1.1 AvHPPD-03

AvHPPD-03 protein, as contained in the microbially produced, lyophilized test substance AvHPPD-03-0209, was received from Syngenta Biotechnology, Inc., Research Triangle Park, NC, on 12 January 2010, as follows:

Identification:	AvHPPD-03-0209
Description:	Brown lyophilized cake
Batch number:	J8373/189 [WIL ID no. 8348A]
Purity:	72.2% AvHPPD-03
Expiry date (retest date):	August 2019
Storage conditions:	Frozen (-20°C±8°C)

Documentation regarding the purity and stability of AvHPPD-03 is on file with the Sponsor and WIL. A Certificate of Analysis for AvHPPD-03 was provided by the Sponsor and is presented in Appendix 2. The purity of AvHPPD-03 was 72.2% w/w. AvHPPD-03 was stored frozen, and was considered stable under these conditions. A reserve sample of AvHPPD-03 (approximately 0.25 grams) was collected and stored in the WIL Archives.

3.1.2 Vehicle Identification and Preparation

The vehicle used in preparation of AvHPPD-03 formulations and for administration to the control group was deionized water, prepared on-site. A sufficient amount of deionized water was dispensed into a glass container and mixed with a magnetic stirrer throughout use. The vehicle was prepared on the day of dosing (study day 0) and stored at room temperature.

3.1.3 Preparation of AvHPPD-03 Dosing Formulations

Dosing formulations were prepared at the AvHPPD-03 concentrations indicated in the following table:

Group Number	Treatment	Dose Level [a] (mg/kg)	Dose Concentration [a] (mg/mL)	pH [b]
1	Vehicle [c]	0	0	6
2	AvHPPD-03	500	25	7
3	AvHPPD-03	1500	75	8
4	AvHPPD-03	2000	100	8

[a] - Dose level and dose concentration refer to the concentration of the active ingredient, the AvHPPD-03 protein, relative to the animal weight and the protein in the vehicle, respectively.
[b] - pH measurement of the study day 0 dosing formulations using litmus paper.
[c] - Deionized water prepared on-site.

The AvHPPD-03 formulations were weight/volume (AvHPPD-03/vehicle) mixtures. The AvHPPD-03 formulations were prepared once on 18 January 2010 (the day of dose administration) and kept at room temperature prior to dosing. The AvHPPD-03 formulations were stirred continuously throughout the preparation and dosing procedures.

Dose level and dose concentration for the test substance, AvHPPD-03-0209, were adjusted for the purity of the active ingredient (72.2% w/w AvHPPD-03). Therefore, the dose levels of AvHPPD-03 were 692.5, 2077.5, and 2770.0 mg/kg and the concentration of AvHPPD-03 in the dosing formulations was 34.6, 103.9, and 138.5 mg/mL for Groups 2, 3, and 4, respectively.

3.1.4 Sampling and Analyses

Analyses of the dosing formulations for concentration and homogeneity of the active ingredient, AvHPPD-03 protein, were not conducted as part of this study.

3.2 Experimental Design

3.2.1 Test System, Animal Receipt, and Acclimation/Pre-test Period

Crl:CD-1(ICR) mice were used as the test system for this study. This species and strain of animal has historically been the preferred and most commonly used for short-term (acute) toxicity studies. The mouse was selected because it is a commonly used model for evaluating toxicity of various classes of chemicals and a widely used species for which significant control data are available. The number of animals selected for this study (see Section 3.2.6.) was sufficient to provide adequate statistical evaluation of the data and is the recommended number (OECD, 2001; US EPA, 2002) to achieve the objectives of the study.

Crl:CD-1(ICR) mice (46 males and 46 females) were received in good health from Charles River Laboratories, Inc., Raleigh, NC on 5 January 2010. The animals were approximately 52 days old at receipt. Each animal was examined by a qualified technician on the day of receipt and weighed 3 days later. Each animal was uniquely identified with a subcutaneous microchip (BMDS system) implanted in the dorsoscapular area. All animals were housed for a 13 day acclimation/pre-test period. During this period, each animal was observed twice daily for mortality and changes in general appearance or behavior.

Pre-test data collection began on 8 January 2010. Individual body weights and food consumption were recorded and detailed physical examinations were performed periodically during the pre-test period. Pre-test clinical observations are presented in Appendix 3.

3.2.2 Animal Housing

Upon arrival, all animals were housed 2 to 3 per cage by sex for approximately 3 days. Thereafter, all animals were housed individually in clean, stainless steel, wire mesh cages suspended above cage board. Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996). The animal facilities at WIL are accredited by AAALAC International. Enrichment devices were provided to all animals as appropriate throughout the study for environmental enrichment and to aid in maintaining the animals' oral health, and were sanitized weekly.

3.2.3 Diet, Drinking Water, and Maintenance

The basal diet used in this study, PMI Nutrition International, LLC, Certified Rodent LabDiet® 5002 (meal), is a certified feed with appropriate analyses performed by the manufacturer and provided to WIL. Reverse osmosis treated (on site) drinking water, delivered by an automatic watering system, and the basal diet were provided ad libitum throughout the study. Municipal water supplying the facility was analyzed for contaminants according to SOPs. The results of the diet and water analyses are maintained at WIL. No contaminants were present in animal feed or water at concentrations sufficient to interfere with the objectives of this study.

3.2.4 Environmental Conditions

All animals were housed throughout the acclimation period and during the study in an environmentally controlled room. The room temperature and humidity controls were set to maintain environmental conditions of 71 ± 5°F (22 ± 3°C) and 50 ± 20%, respectively. Room temperature and relative humidity data were recorded approximately hourly and are summarized in Appendix 4. Actual mean daily temperature ranged from 70.1°F to 70.9°F (21.2°C to 21.6°C) and mean daily relative humidity ranged from 37.8% to 42.4% during the study. Fluorescent lighting provided illumination for a 12 hour light (0600 hours to 1800 hours)/12 hour dark photoperiod. Air handling units were set to provide a minimum of 10 fresh air changes per hour.

3.2.5 Assignment of Animals to Treatment Groups

On 14 January 2010 (4 days prior to the initiation of dose administration), all available mice were weighed and examined in detail for physical abnormalities. These data were collected using WTDMS™ and reviewed by the Study Director. The animals judged suitable for assignment to the study were selected for use in a computerized randomization procedure. A printout containing the animal numbers, corresponding body weights, and individual group assignments was generated based on body weight stratification in a block design. The animals were then arranged into groups according to the printout. Individual body weights at randomization were within ± 20% of the mean for each sex. Animals not assigned to study were transferred to the WIL stock colony or euthanized by carbon dioxide inhalation and discarded.

Each group (Groups 1-4) consisted of 10 males and 10 females. The animals were approximately 9 weeks old at the initiation of dose administration. Individual body weights ranged from 26.6 g to 34.8 g for males and from 24.2 g to 29.6 g for females at randomization (study day -4)

3.2.6 Organization of Test Groups, Dose Levels, and Treatment Regimen

The vehicle and AvHPPD-03 formulations were administered as a single oral dose via gavage using syringes of appropriate volume equipped with an appropriately sized flexible Teflon® shafted, stainless steel ball tipped dosing cannula (Natume, Japan). The dose volume for all groups was 20 mL/kg. Individual doses were based on the study day 0 individual body weights collected after the 3-hour fasting period to provide the appropriate mg/kg dose. The day of dosing was study day 0.

The following table presents the study group assignment:

Group Number	Vehicle/ AvHPPD-03	Dose Level [a] (mg/kg)	Dose Volume (mL/kg)	Number of Animals [b]	
				Males	Females
1	Vehicle [c]	0	20	10	10
2	AvHPPD-03	500	20	10	10
3	AvHPPD-03	1500	20	10	10
4	AvHPPD-03	2000	20	10	10

[a] - Dose level refers to the concentration of the active ingredient, the AvHPPD-03 protein, relative to the animal weight in kilograms.
[b] - Five animals/sex/group were euthanized following a minimum of 48 hours after dose administration; the remaining 5 animals/sex/group were euthanized following a 14-day observation period.
[c] - The vehicle was deionized water (prepared on-site).

The dose levels in this study were used to determine a no-observed-adverse-effect level (NOAEL) for the AvHPPD-03 protein. The highest dose level of 2000 mg AvHPPD-03 protein/kg body weight was selected because it represents a limit dose for this type of study (OECD, 2001; US EPA, 2002). The lower dose levels that were selected, 500 and 1500 mg AvHPPD-03 protein/kg of body weight, were included to account for possible non-specific

AvHPPD-03 effects and to determine any dose-response relationships. The selected route of administration for this study was oral (gavage), because the oral route presents a likely route of human exposure and other mammalian exposure to the test protein.

3.3 *Antemortem* Investigations

3.3.1 Survival

All animals were observed twice daily, once in the morning and once in the afternoon, for mortality and moribundity.

3.3.2 Clinical Observations

Clinical examinations were performed 3 times on each day of dosing, at the time of dose administration and approximately 1-2 hours and 4-5 hours following dose administration. On nondosing days, the animals were observed once daily. The absence or presence of findings was recorded for individual animals at the scheduled intervals. Detailed physical examinations were conducted on all animals weekly, beginning approximately 1 week prior to AvHPPD-03 administration and prior to the scheduled necropsies. Clinical observations were not performed on study days 7 and 14 when detailed physical examinations were conducted.

3.3.3 Body Weights

Individual body weights were recorded at least weekly during the pre-test period, at randomization, just prior to dosing (after at least 3 hours of fasting), and daily throughout the observation period. Mean body weights and mean body weight changes were calculated for the corresponding intervals.

3.3.4 Food Consumption

Individual food consumption was recorded at least weekly during the pre-test period, at randomization, and daily throughout the observation period. Food intake was calculated as g/animal/day for the corresponding body weight intervals. When food consumption could not be measured for a given interval (due to spillage, weighing error, obvious erroneous value, etc.), the appropriate interval was footnoted as "NA" (Not Applicable) on the individual tables.

3.3.5 Clinical Pathology - Hematology

Blood samples for clinical pathology evaluations (hematology) were collected from all animals scheduled for necropsy at the scheduled necropsies (study days 2 and 14). Blood was collected via the retro-orbital sinus of animals anesthetized by inhalation of isoflurane. Blood was collected into tubes containing potassium EDTA. Clinical pathology methods, procedures, and references are presented in Appendix 5. Interpretation of the clinical

pathology data was performed by Ann Radovsky, DVM, PhD, DACVP, DABT (Appendix 6). The following parameters were evaluated:

Total leukocyte count (WBC)
Erythrocyte count (RBC)
Hemoglobin (HGB)
Hematocrit (HCT)
Mean corpuscular volume (MCV)
Mean corpuscular hemoglobin (MCH)
Mean corpuscular hemoglobin concentration (MCHC)
Platelet count (PLATELET)
Reticulocyte count
Percent (RETIC)
Absolute (RETIC ABSOLUTE)

Differential leukocyte count -
Percent and absolute
-Neutrophil (NEU)
-Lymphocyte (LYMPH)
-Monocyte (MONO)
-Eosinophil (EOS)
-Basophil (BASO)
-Large unstained cell (LUC)
Red cell distribution width (RDW)
Hemoglobin Distribution Width (HDW)
Platelet estimate [a]
Red cell morphology (RBC Morphology) [a]

( ) - Designates tabular abbreviation
[a] - Presented on individual tables if a manual differential was performed, and the manual data were accepted and reported instead of the automated differential data

3.4 *Postmortem* Investigations

3.4.1 Macroscopic Examination

A complete necropsy was conducted on all animals. Animals were euthanized by carbon dioxide inhalation followed by exsanguination. The necropsies included, but were not limited to, examination of the external surface, all orifices, and the cranial, thoracic, abdominal, and pelvic cavities, including viscera. The following tissues and organs were collected and placed in 10% neutral buffered formalin (except as noted):

Adrenals (2)
Aorta
Bone with marrow
  Femur with joint
  Sternum
Bone marrow smear [a]
Brain
  Cerebrum level 1
  Cerebrum level 2
  Cerebellum with medulla/pons
Cervix
Epididymides (2) [b]
Eyes with optic nerve (2) [c]
Gallbladder
Gastrointestinal tract
  Esophagus*
  Stomach*
  Duodenum*
  Jejunum*
  Ileum*
  Cecum*
  Colon*
  Rectum*
Heart
Kidneys (2)*
Liver (sections of 2 lobes)*
Lungs (including bronchi, fixed by inflation with fixative)
Lymph nodes
  Axillary(2)
  Mandibular (2)*
  Mesenteric*
Ovaries with oviducts (2) [d]
Pancreas
Peripheral nerve (sciatic)
Peyer's patches*
Pituitary
Prostate
Salivary glands (mandibular [2])
Seminal vesicles (2)
Skeletal muscle (rectus femoris)
Skin (with mammary gland) [e]
Spinal cord (cervical, thoracic, lumbar)
Spleen*
Testes (2) [b]
Thymus*
Thyroid (with parathyroids, if present [2]) [d]
Trachea
Urinary bladder
Uterus
Vagina
Gross lesions (when possible)*

[a] - Bone marrow smears were obtained at scheduled necropsies, but not placed in formalin; slides were not examined.
[b] - Fixed in Bouin's solution
[c] - Fixed in Davidson's solution
[d] - Oviducts and parathyroids were examined histopathologically if in the plane of section and in all cases where a gross lesion was present.
[e] - For females; a corresponding section of skin was taken from the same anatomic area for males.
* - Tissues to be processed for histopathological examination from all animals at the scheduled necropsies.

3.4.2 Slide Preparation and Microscopic Examination

After fixation, protocol specified tissues were trimmed according to WIL SOPs and the protocol. Trimmed tissues were processed into paraffin blocks, sectioned at 4 to 8 microns, mounted on glass microscope slides and stained with hematoxylin and eosin.

Microscopic examination was performed on all tissues noted with an asterisk (*) in Section 3.4.1. from all animals at the scheduled necropsies. The remaining tissues were stored in 10% neutral-buffered formalin (except as noted) for possible future histopathology examination. Missing tissues were identified as not found at necropsy, lost at necropsy, lost

during processing, or other designations as appropriate. Tissues may appear on the report tables as not examined due to the tissue not being in the plane of section, not present at trimming, etc. Microscopic examination was performed by Ann Radovsky, DVM, PhD, DACVP, DABT (Appendix 6).

3.5 Data Acquisition and Analysis

3.5.1 Acquisition and Reporting

Program/System	Description
Archive Management System (AMS)	In-house developed application for storage, maintenance, and retrieval of information for archived materials (*e.g.*, lab books, study data, wet tissues, slides, *etc*.)
Formulations Dose Dispensing Management System (FDDMS)	In-house developed system used to assign unique barcodes to formulation containers and individual containers used for dispensing dosing formulations.
InSight® Publisher	Electronic publishing system (output is Adobe Acrobat, PDF)
Master Schedule	Maintains the master schedule for the company.
Metasys DDC Electronic Environmental Control System	Controls and monitors animal room environmental conditions.
Microsoft® Office 2002 and 2007; GraphPad Prism® 2008	Used in conjunction with the publishing software to generate study reports.
Provantis Dispense™	Comprehensive system (Instem LSS Limited) to manage test materials, including receipt, formulation instructions, and accountability.
SAS®	Statistical (non-WTDMS™) Analyses
WIL Formulations Dispense System (WFDS)	In-house developed system for use in conjunction with Provantis Dispense™ to ensure proper storage and use of formulations.
WIL Metasys	In-house developed system used to record and report animal room environmental conditions.
WIL Toxicology Data Management System™ (WTDMS™)	In-house developed system used for collection and reporting of in-life and *postmortem* data.

Note: Version numbers of WTDMS™ programs used for the study are presented on the report data tables (reporting programs); version numbers and release dates are otherwise maintained in the study records and/or facility records.

3.5.2 Statistical Analysis

Each mean was presented with the standard deviation (S.D.), standard error (S.E.), and the number of animals (N) used to calculate the mean. Due to the different rounding conventions inherent in the types of software used, the means and standard deviations on the summary and individual tables may differ by ±1 in the last significant figure.

All statistical tests were performed using the WTDMS™ software program unless otherwise noted. Analyses were conducted using two-tailed tests (except as noted otherwise) for minimum significance levels of 1% and 5%, comparing each AvHPPD-03-treated group to the control group by sex.

Body weight, body weight change, food consumption, and clinical pathology data were subjected to a parametric one way ANOVA (Snedecor and Cochran, 1980) to determine intergroup differences. If the ANOVA revealed statistically significant ($p<0.05$) intergroup variance, Dunnett's test (Dunnett, 1964) was used to compare the AvHPPD-03-treated groups to the control group.

4.0 RESULTS AND DISCUSSION

4.1 Survival

Summary Data: Table S1
Individual Data: Table I1

All animals survived to the scheduled necropsies.

4.2 Clinical Observations

Summary Data: Table S2, Table S3, Table S4
Individual Data: Table I2, Table I3, Table I4, Table I5

There were no AvHPPD-03 related clinical observations.

Clinical observations of wet and/or dry yellow material on the urogenital area were noted for 2 males (animal nos. 8703 and 8673) in the 2000 mg/kg/day group on study days 5, 6, 7, 8, 11, 13, and 14 for male no. 8703 and on study days 11, 13, and 14 for male 8673. Since these clinical observations were noted in 2 out of 10 males in the 2000 mg/kg/day group during the observation period, these findings were considered specific to these animals and not related to AvHPPD-03 administration. All other clinical findings in the AvHPPD-03 treated groups were noted with similar incidence in the control group, were limited to single animals, were not noted in a dose related manner and/or were common findings for laboratory mice of this age and strain.

4.3 Body Weights

Summary Data: Table S5, Table S6, Table S7; Figure 1, Figure 2
Individual Data: Table I6, Table I7, Table I8

There were no AvHPPD-03-related effects on body weights.

Statistically significantly lower mean body weight gains were noted for the 1500 mg/kg group males from study day 1 to 2 and for the 2000 mg/kg group females from study day 7 to 8 when compared to the control group.

These statistically significant differences were sporadic and did not occur in a dose-related manner; therefore, they were considered to be incidental in nature and unrelated to AvHPPD-03 administration.

For the 1500 mg/kg group females, statistically significantly higher mean cumulative body weight gains were noted from study days 0 to 13 and 0 to 14. These differences were not seen in the 2000 mg/kg group females, and therefore, were not considered to be dose-related.

4.4 Food Consumption

Summary Data: Table S8
Individual Data: Table I9

There were no AvHPPD-03-related effects on food consumption.

During the study day 0 to 1 interval, slightly lower (statistically significant) mean food consumption values were noted for the 2000 mg/kg group females; however, the mean food consumption value for the 2000 mg/kg group was within the WIL historical control reference range (version 3.1). This statistically significant difference was sporadic and was most likely due to the individual value for female no. 8706 which was outside of the reference range. Therefore, it was considered to be incidental in nature and unlikely related to AvHPPD-03 administration.

Mean food consumption values during the 2-day or 14-day observation periods for the AvHPPD-03-treated group males and females were similar to the control group.

4.5 Clinical Pathology - Hematology

Summary Data: Table S9
Individual Data: Table I10, Table I11
Pathology Report: Appendix 6

There were no AvHPPD-03-related alterations in hematology parameters.

At the study day 14 evaluation, there were statistically significantly lower mean hemoglobin values for the 1500 and 2000 mg/kg group females and lower mean hematocrit values for the 500, 1500, and 2000 mg/kg group females. The magnitude of these changes was small and the values were within the WIL historical control reference range (version 2.9); therefore, they were not considered to be related to administration of AvHPPD-03.

Statistically significantly higher mean red blood cell counts and lower mean corpuscular hemoglobin (MCH) values were noted on study day 14 in the 500 mg/kg group males. There

was no dose response and the mean MCH value was within the WIL historical control reference range (version 3.1); therefore, these changes were not considered related to AvHPPD-03 administration.

4.6 Anatomic Pathology

4.6.1 Macroscopic Examination

Summary Data: Table S10, Table S11
Individual Data: Table I12, Table I13
Pathology Report: Appendix 6

There were no AvHPPD-03-related gross findings at the study day 2 and study day 14 necropsies. All macroscopic findings noted were considered to be spontaneous and/or incidental in nature and unrelated to test substance administration.

4.6.2 Microscopic Examination

Summary Data: Table S12, Table S13
Individual Data: Table I12, Table I13
Pathology Report: Appendix 6

Histopathological examination revealed no AvHPPD-03-related findings. The small number of changes that were recorded were considered spontaneous in nature and were consistent with the normal background findings seen in this laboratory for healthy Crl:CD-1(ICR) mice.

5.0 CONCLUSIONS

The test substance, AvHPPD-03-0209 containing the active ingredient AvHPPD-03 protein (72.2% purity w/w), administered as a single oral dose at 500, 1500, and 2000 mg active ingredient/kg of body weight to CD-1 mice followed by a 2-day or 14-day observation period was well tolerated. All mice survived to the scheduled necropsy without clinical signs of distress or impairment, and anatomical pathology results did not identify any specific target organ toxicity. Therefore, under the conditions of this study, there was no evidence of toxicity resulting from administration of AvHPPD-03 protein. The no observed adverse-effect level (NOAEL) for a single oral dose (gavage) of AvHPPD-03-0209 containing the active ingredient AvHPPD-03 protein to Crl:CD 1(ICR) mice was 2000 mg of active ingredient/kg of body weight, the highest dose level examined in the study.

6.0 REFERENCES

Dunnett, C.W. New tables for multiple comparisons with a control. *Biometrics* **1964**, *20*, 482-491.

National Research Council. Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, Commission on Life Sciences; National Academy Press: Washington, DC, **1996**.

OECD (2001) OECD Test Guideline 425 Acute Oral Toxicity: Up-and-Down Procedure. http://www.oecd.org/dataoecd/17/51/1948378.pdf#search='OECD Test Guideline 425'.

Snedecor, G.W.; Cochran, W.G. One Way Classifications; Analysis of Variance. In Statistical Methods, 7th ed.; The Iowa State University Press: Ames, IA, **1980**; pp 215-237.

U.S. EPA (2002) Health Effects Test Guidelines-OPPTS 870.1100-Acute Oral Toxicity. http://www.epa.gov/opptsfrs/publications/OPPTS_harmonized/870_Health_Effects Test Guidelines/Series/Revised 870r-1100.pdf.

7.0 ABBREVIATIONS

The following abbreviations may apply to this report:

µ	-	micro
AAALAC	-	Association for Assessment and Accreditation of Laboratory Animal Care
ANOVA	-	analysis of variance
cm	-	centimeter
CEO	-	correlates with externally observed
dL	-	deciliter
EPA	-	Environmental Protection Agency
exp.	-	expiration
FIFRA	-	Federal Insecticide, Fungicide and Rodenticide Act
g	-	gram
GLP	-	Good Laboratory Practices
GMP	-	Good Manufacturing Practices
hr	-	hour(s)
kg	-	kilogram
L	-	liter
M	-	molar
mg	-	milligram
mL	-	milliliter
mm	-	millimeter
ms	-	milliseconds
mM	-	millimolar
NA	-	not applicable
no.	-	number
OECD	-	Organisation for Economic Cooperation and Development
OPPTS	-	Office of Prevention, Pesticides and Toxic Substances
SOP	-	standard operating procedure
US	-	United States
WIL Research	-	WIL Research Laboratories, LLC
WTDMS™	-	WIL Toxicology Data Management System

TABLES SECTION

TABLE S1

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF SURVIVAL AND DISPOSITION

SPONSOR NO.:T007563-08

MALES

GROUP :	1				2				3				4			
DAY	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE
0	10	0	0	0	10	0	0	0	10	0	0	0	10	0	0	0
1	10	0	0	0	10	0	0	0	10	0	0	0	10	0	0	0
2	5	0	0	5	5	0	0	5	5	0	0	5	5	0	0	5
3	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
4	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
5	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
6	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
7	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
8	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
9	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
10	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
11	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
12	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
13	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
14	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0	5

DAY = DAY OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S1

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF SURVIVAL AND DISPOSITION

SPONSOR NO.:T007563-08

FEMALES

GROUP :	1				2				3				4			
DAY	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE
0	10	0	0	0	10	0	0	0	10	0	0	0	10	0	0	0
1	10	0	0	0	10	0	0	0	10	0	0	0	10	0	0	0
2	5	0	0	5	5	0	0	5	5	0	0	5	5	0	0	5
3	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
4	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
5	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
6	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
7	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
8	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
9	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
10	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
11	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
12	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
13	5	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0
14	0	0	0	5	0	0	0	5	0	0	0	5	0	0	0	5

DAY = DAY OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

PSURVv4.10
03/12/2010

TABLE S2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 1

SPONSOR:SYNGENTA — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

SPONSOR NO.:T007563-08

----- M A L E -----

TABLE RANGE:	DAY 000 TO DAY 014			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	18/ 8	18/ 8	25/10	22/10
DISPOSITION				
-INTERIM NECROPSY (DAY 2)	5/ 5	5/ 5	5/ 5	5/ 5
-PRIMARY NECROPSY (DAY 14)	5/ 5	5/ 5	5/ 5	5/ 5
EYES/EARS/NOSE				
-ABNORMAL PUPIL POSITION LEFT EYE	3/ 1	3/ 1	0/ 0	0/ 0
-ABNORMAL PUPIL POSITION RIGHT EYE	3/ 1	3/ 1	0/ 0	0/ 0
BODY/INTEG II				
-SCABBING UROGENITAL AREA	1/ 1	0/ 0	0/ 0	0/ 0
BODY/INTEG III				
-WET YELLOW MATERIAL UROGENITAL AREA	0/ 0	0/ 0	0/ 0	1/ 1
-DRIED YELLOW MATERIAL UROGENITAL AREA	0/ 0	0/ 0	0/ 0	2/ 2
SPECIAL II				
-TAIL BROKEN	0/ 0	1/ 1	0/ 0	0/ 0

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

SPONSOR NO.:T007563-08

----- F E M A L E -----

TABLE RANGE:	DAY 000 TO DAY 014			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	25/10	25/10	21/ 9	25/10
DISPOSITION				
-INTERIM NECROPSY (DAY 2)	5/ 5	5/ 5	5/ 5	5/ 5
-PRIMARY NECROPSY (DAY 14)	5/ 5	5/ 5	5/ 5	5/ 5
EYES/EARS/NOSE				
-ABNORMAL PUPIL POSITION LEFT EYE	0/ 0	0/ 0	4/ 2	0/ 0

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

PCSUv4.07
03/12/2010

TABLE S3 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF POST-DOSE FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

SPONSOR NO.:T007563-08

----- M A L E -----

TABLE RANGE:	DAY 0			
GROUP:	1	2	3	4
NORMAL				
TIME OF DOSE				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	10/10	10/10	10/10	10/10
1-2 HOUR POST-DOSING				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	10/10	10/10	10/10	10/10
4-5 HOUR POST-DOSING				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	10/10	10/10	10/10	10/10

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S3 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF POST-DOSE FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

SPONSOR NO.:T007563-08

----- F E M A L E -----

TABLE RANGE:	DAY 0			
GROUP:	1	2	3	4
NORMAL				
TIME OF DOSE				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	10/10	10/10	10/10	10/10
1-2 HOUR POST-DOSING				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	10/10	10/10	10/10	10/10
4-5 HOUR POST-DOSING				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	10/10	10/10	10/10	10/10

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

PPDTSUv1.46
03/12/2010

TABLE S4 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 1

SPONSOR:SYNGENTA — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

SPONSOR NO.:T007563-08

----- M A L E -----

TABLE RANGE:	DAY 001 TO DAY 013			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	65/10	64/10	65/10	58/10
BODY/INTEG III				
-WET YELLOW MATERIAL UROGENITAL AREA	0/ 0	0/ 0	0/ 0	1/ 1
-DRIED YELLOW MATERIAL UROGENITAL AREA	0/ 0	1/ 1	0/ 0	6/ 2

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S4 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 2

SPONSOR:SYNGENTA — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

SPONSOR NO.:T007563-08

----- F E M A L E -----

TABLE RANGE:	DAY 001 TO DAY 013			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	65/10	65/10	65/10	65/10

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

PCSUv4.07
03/12/2010
R:03/07/2012

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

	MALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY -10				
MEAN	28.6	28.6	28.6	27.7
% DIFFERENCE		0.0	0.0	-3.1
S.D.	1.61	1.84	1.79	1.76
S.E.	0.51	0.58	0.57	0.56
N	10	10	10	10
-4				
MEAN	30.7	30.6	30.8	31.0
% DIFFERENCE		-0.3	0.3	1.0
S.D.	2.35	2.21	2.37	2.21
S.E.	0.74	0.70	0.75	0.70
N	10	10	10	10
0				
MEAN	31.2	29.9	30.7	30.6
% DIFFERENCE		-4.2	-1.6	-1.9
S.D.	2.15	2.05	2.38	1.37
S.E.	0.68	0.65	0.75	0.43
N	10	10	10	10
1				
MEAN	31.3	30.5	31.0	31.0
% DIFFERENCE		-2.6	-1.0	-1.0
S.D.	2.16	2.06	2.63	1.34
S.E.	0.68	0.65	0.83	0.42
N	10	10	10	10

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 2				
MEAN	32.6	31.3	31.7	32.5
% DIFFERENCE		-4.0	-2.8	-0.3
S.D.	2.31	2.06	2.79	1.22
S.E.	0.73	0.65	0.88	0.38
N	10	10	10	10
3				
MEAN	32.8	32.0	32.0	33.0
% DIFFERENCE		-2.4	-2.4	0.6
S.D.	2.02	3.10	3.64	1.46
S.E.	0.90	1.39	1.63	0.65
N	5	5	5	5
4				
MEAN	32.8	31.6	32.2	32.8
% DIFFERENCE		-3.7	-1.8	0.0
S.D.	2.22	3.06	3.71	1.54
S.E.	0.99	1.37	1.66	0.69
N	5	5	5	5
5				
MEAN	32.6	31.1	31.8	32.9
% DIFFERENCE		-4.6	-2.5	0.9
S.D.	2.47	3.04	3.50	1.71
S.E.	1.10	1.36	1.56	0.76
N	5	5	5	5

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 6				
MEAN	32.8	31.1	32.1	33.2
% DIFFERENCE		-5.2	-2.1	1.2
S.D.	2.40	3.20	3.50	1.70
S.E.	1.07	1.43	1.57	0.76
N	5	5	5	5
7				
MEAN	32.5	30.8	31.9	32.8
% DIFFERENCE		-5.2	-1.8	0.9
S.D.	2.74	3.18	3.62	1.50
S.E.	1.23	1.42	1.62	0.67
N	5	5	5	5
8				
MEAN	33.0	31.6	32.5	33.8
% DIFFERENCE		-4.2	-1.5	2.4
S.D.	2.94	2.91	3.42	1.47
S.E.	1.32	1.30	1.53	0.66
N	5	5	5	5
9				
MEAN	32.4	30.8	32.3	33.3
% DIFFERENCE		-4.9	-0.3	2.8
S.D.	2.96	3.07	3.73	1.55
S.E.	1.32	1.37	1.67	0.69
N	5	5	5	5

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 10				
MEAN	32.8	30.6	32.3	33.6
% DIFFERENCE		-6.7	-1.5	2.4
S.D.	3.06	3.09	3.72	1.47
S.E.	1.37	1.38	1.67	0.66
N	5	5	5	5
11				
MEAN	33.2	31.3	32.7	34.1
% DIFFERENCE		-5.7	-1.5	2.7
S.D.	3.18	2.84	3.63	1.46
S.E.	1.42	1.27	1.62	0.65
N	5	5	5	5
12				
MEAN	32.7	30.8	32.5	33.7
% DIFFERENCE		-5.8	-0.6	3.1
S.D.	3.16	2.92	4.00	1.72
S.E.	1.41	1.31	1.79	0.77
N	5	5	5	5
13				
MEAN	33.0	31.2	33.2	34.2
% DIFFERENCE		-5.5	0.6	3.6
S.D.	2.80	2.72	4.22	1.62
S.E.	1.25	1.22	1.89	0.72
N	5	5	5	5

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

	MALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 14				
MEAN	33.0	31.1	33.2	34.2
% DIFFERENCE		-5.8	0.6	3.6
S.D.	2.78	2.93	3.82	1.49
S.E.	1.24	1.31	1.71	0.67
N	5	5	5	5

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY -10				
MEAN	25.3	24.8	24.9	25.0
% DIFFERENCE		-2.0	-1.6	-1.2
S.D.	1.14	1.40	1.34	1.82
S.E.	0.36	0.44	0.42	0.58
N	10	10	10	10
-4				
MEAN	26.8	26.5	26.8	26.7
% DIFFERENCE		-1.1	0.0	-0.4
S.D.	1.30	1.47	1.54	1.47
S.E.	0.41	0.47	0.49	0.46
N	10	10	10	10
0				
MEAN	26.9	26.3	26.6	26.7
% DIFFERENCE		-2.2	-1.1	-0.7
S.D.	1.29	1.29	1.70	1.50
S.E.	0.41	0.41	0.54	0.47
N	10	10	10	10
1				
MEAN	26.7	26.3	26.6	26.5
% DIFFERENCE		-1.5	-0.4	-0.7
S.D.	1.31	1.22	2.10	1.49
S.E.	0.42	0.39	0.67	0.47
N	10	10	10	10

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 2				
MEAN	27.9	26.9	27.5	27.5
% DIFFERENCE		-3.6	-1.4	-1.4
S.D.	1.63	1.23	2.52	1.38
S.E.	0.51	0.39	0.80	0.44
N	10	10	10	10
3				
MEAN	28.0	28.4	26.6	28.0
% DIFFERENCE		1.4	-5.0	0.0
S.D.	1.12	1.07	1.40	2.53
S.E.	0.50	0.48	0.62	1.13
N	5	5	5	5
4				
MEAN	27.9	28.1	26.5	28.3
% DIFFERENCE		0.7	-5.0	1.4
S.D.	1.19	0.82	1.11	1.91
S.E.	0.53	0.37	0.49	0.85
N	5	5	5	5
5				
MEAN	27.5	27.8	26.6	28.3
% DIFFERENCE		1.1	-3.3	2.9
S.D.	0.80	0.63	0.89	1.77
S.E.	0.36	0.28	0.40	0.79
N	5	5	5	5

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 6				
MEAN	27.4	28.2	26.6	28.6
% DIFFERENCE		2.9	-2.9	4.4
S.D.	0.75	0.66	1.42	1.24
S.E.	0.34	0.30	0.63	0.56
N	5	5	5	5
7				
MEAN	27.4	27.6	26.1	28.5
% DIFFERENCE		0.7	-4.7	4.0
S.D.	0.55	0.47	1.61	1.44
S.E.	0.24	0.21	0.72	0.64
N	5	5	5	5
8				
MEAN	28.1	27.9	27.4	28.1
% DIFFERENCE		-0.7	-2.5	0.0
S.D.	0.96	0.60	1.31	1.33
S.E.	0.43	0.27	0.59	0.59
N	5	5	5	5
9				
MEAN	27.4	27.6	26.8	27.8
% DIFFERENCE		0.7	-2.2	1.5
S.D.	1.07	0.75	1.36	1.58
S.E.	0.48	0.34	0.61	0.70
N	5	5	5	5

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 9

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 10				
MEAN	27.5	27.8	27.0	28.2
% DIFFERENCE		1.1	-1.8	2.5
S.D.	0.72	0.57	1.25	1.51
S.E.	0.32	0.26	0.56	0.68
N	5	5	5	5
11				
MEAN	27.8	28.5	27.5	28.9
% DIFFERENCE		2.5	-1.1	4.0
S.D.	0.67	0.69	1.40	1.18
S.E.	0.30	0.31	0.63	0.53
N	5	5	5	5
12				
MEAN	27.4	27.6	27.0	28.1
% DIFFERENCE		0.7	-1.5	2.6
S.D.	0.82	0.73	1.59	1.20
S.E.	0.37	0.33	0.71	0.54
N	5	5	5	5
13				
MEAN	27.5	27.9	27.7	28.3
% DIFFERENCE		1.5	0.7	2.9
S.D.	1.01	0.63	1.51	1.53
S.E.	0.45	0.28	0.68	0.68
N	5	5	5	5

None significantly different from control group

TABLE S5

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 14				
MEAN	27.7	28.0	27.7	28.8
% DIFFERENCE		1.1	0.0	4.0
S.D.	0.98	0.57	1.11	1.38
S.E.	0.44	0.25	0.50	0.62
N	5	5	5	5

None significantly different from control group

PBFSTv5.30
03/16/2010

TABLE S6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY -10 TO -4				
MEAN	2.1	2.0	2.2	3.2
S.D.	0.99	1.28	1.08	1.85
S.E.	0.31	0.41	0.34	0.58
N	10	10	10	10
-4 TO 0				
MEAN	0.5	-0.7	0.0	-0.4
S.D.	1.00	1.06	0.86	1.71
S.E.	0.32	0.33	0.27	0.54
N	10	10	10	10
0 TO 1				
MEAN	0.1	0.5	0.3	0.4
S.D.	0.51	0.42	0.61	0.45
S.E.	0.16	0.13	0.19	0.14
N	10	10	10	10
1 TO 2				
MEAN	1.3	0.8	0.6**	1.5
S.D.	0.52	0.40	0.31	0.43
S.E.	0.16	0.13	0.10	0.14
N	10	10	10	10
2 TO 3				
MEAN	0.4	0.9	0.6	0.3
S.D.	0.50	0.58	0.45	0.47
S.E.	0.22	0.26	0.20	0.21
N	5	5	5	5

** = Significantly different from the control group at 0.01 using Dunnett's test

TABLE S6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 3 TO 4				
MEAN	-0.1	-0.4	0.2	-0.1
S.D.	0.25	0.21	0.22	0.48
S.E.	0.11	0.09	0.10	0.22
N	5	5	5	5
4 TO 5				
MEAN	-0.2	-0.5	-0.4	0.0
S.D.	0.48	0.27	0.33	0.34
S.E.	0.21	0.12	0.15	0.15
N	5	5	5	5
5 TO 6				
MEAN	0.2	0.0	0.3	0.3
S.D.	0.29	0.23	0.24	0.18
S.E.	0.13	0.10	0.11	0.08
N	5	5	5	5
6 TO 7				
MEAN	-0.3	-0.3	-0.2	-0.4
S.D.	0.45	0.24	0.41	0.41
S.E.	0.20	0.11	0.18	0.18
N	5	5	5	5
7 TO 8				
MEAN	0.6	0.7	0.6	1.0
S.D.	0.36	0.29	0.50	0.23
S.E.	0.16	0.13	0.22	0.10
N	5	5	5	5

None significantly different from control group

TABLE S6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 8 TO 9				
MEAN	-0.6	-0.8	-0.2	-0.5
S.D.	0.37	0.23	0.47	0.48
S.E.	0.17	0.10	0.21	0.22
N	5	5	5	5
9 TO 10				
MEAN	0.4	-0.2	0.0	0.2
S.D.	0.28	0.41	0.15	0.53
S.E.	0.13	0.18	0.07	0.24
N	5	5	5	5
10 TO 11				
MEAN	0.3	0.6	0.4	0.6
S.D.	0.13	0.44	0.15	0.18
S.E.	0.06	0.20	0.07	0.08
N	5	5	5	5
11 TO 12				
MEAN	-0.4	-0.5	-0.1	-0.4
S.D.	0.42	0.34	0.40	0.32
S.E.	0.19	0.15	0.18	0.14
N	5	5	5	5
12 TO 13				
MEAN	0.3	0.4	0.7	0.5
S.D.	0.42	0.28	0.28	0.20
S.E.	0.19	0.12	0.12	0.09
N	5	5	5	5

None significantly different from control group

TABLE S6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

	MALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 13 TO 14				
MEAN	0.0	-0.1	0.0	0.0
S.D.	0.29	0.45	0.45	0.27
S.E.	0.13	0.20	0.20	0.12
N	5	5	5	5

None significantly different from control group

TABLE S6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY -10 TO -4				
MEAN	1.4	1.8	1.9	1.7
S.D.	0.69	0.53	0.99	1.11
S.E.	0.22	0.17	0.31	0.35
N	10	10	10	10
-4 TO 0				
MEAN	0.2	-0.2	-0.1	0.0
S.D.	0.69	0.58	0.58	0.86
S.E.	0.22	0.18	0.18	0.27
N	10	10	10	10
0 TO 1				
MEAN	-0.3	-0.1	-0.1	-0.2
S.D.	0.48	0.50	0.54	0.33
S.E.	0.15	0.16	0.17	0.10
N	10	10	10	10
1 TO 2				
MEAN	1.2	0.6	0.9	1.0
S.D.	0.61	0.38	0.83	0.46
S.E.	0.19	0.12	0.26	0.15
N	10	10	10	10
2 TO 3				
MEAN	0.5	1.1	1.0	0.2
S.D.	0.38	0.86	0.70	0.83
S.E.	0.17	0.38	0.31	0.37
N	5	5	5	5

None significantly different from control group

TABLE S6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

		FEMALES			
	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY	3 TO 4				
	MEAN	-0.1	-0.3	-0.1	0.3
	S.D.	0.41	0.33	0.54	0.89
	S.E.	0.19	0.15	0.24	0.40
	N	5	5	5	5
	4 TO 5				
	MEAN	-0.5	-0.2	0.1	0.0
	S.D.	0.54	0.23	0.40	0.43
	S.E.	0.24	0.10	0.18	0.19
	N	5	5	5	5
	5 TO 6				
	MEAN	-0.1	0.4	0.1	0.3
	S.D.	0.28	0.70	0.77	0.67
	S.E.	0.12	0.31	0.34	0.30
	N	5	5	5	5
	6 TO 7				
	MEAN	0.0	-0.6	-0.6	0.0
	S.D.	0.49	0.34	0.31	0.35
	S.E.	0.22	0.15	0.14	0.16
	N	5	5	5	5
	7 TO 8				
	MEAN	0.7	0.3	1.3	-0.4**
	S.D.	0.43	0.36	0.69	0.35
	S.E.	0.19	0.16	0.31	0.16
	N	5	5	5	5

** = Significantly different from the control group at 0.01 using Dunnett's test

TABLE S6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 8 TO 9				
MEAN	-0.7	-0.3	-0.5	-0.3
S.D.	0.54	0.23	0.38	0.29
S.E.	0.24	0.10	0.17	0.13
N	5	5	5	5
9 TO 10				
MEAN	0.1	0.1	0.2	0.3
S.D.	0.38	0.38	0.50	0.18
S.E.	0.17	0.17	0.22	0.08
N	5	5	5	5
10 TO 11				
MEAN	0.3	0.7	0.5	0.8
S.D.	0.34	0.46	0.29	0.61
S.E.	0.15	0.21	0.13	0.27
N	5	5	5	5
11 TO 12				
MEAN	-0.4	-0.9	-0.6	-0.8
S.D.	0.40	0.36	0.48	0.33
S.E.	0.18	0.16	0.22	0.15
N	5	5	5	5
12 TO 13				
MEAN	0.1	0.3	0.7	0.2
S.D.	0.36	0.33	0.37	0.40
S.E.	0.16	0.15	0.17	0.18
N	5	5	5	5

None significantly different from control group

TABLE S6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA SUMMARY OF BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 13 TO 14				
MEAN	0.2	0.0	0.1	0.5
S.D.	0.35	0.28	0.59	0.33
S.E.	0.16	0.12	0.26	0.15
N	5	5	5	5

None significantly different from control group

PBFSTv5.30
03/16/2010

TABLE S7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALES

GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY	0 TO 1				
	MEAN	0.1	0.5	0.3	0.4
	S.D.	0.51	0.42	0.61	0.45
	S.E.	0.16	0.13	0.19	0.14
	N	10	10	10	10
	0 TO 2				
	MEAN	1.4	1.4	0.9	1.9
	S.D.	0.57	0.63	0.72	0.50
	S.E.	0.18	0.20	0.23	0.16
	N	10	10	10	10
	0 TO 3				
	MEAN	1.7	2.0	1.4	2.2
	S.D.	0.56	0.83	0.83	0.59
	S.E.	0.25	0.37	0.37	0.26
	N	5	5	5	5
	0 TO 4				
	MEAN	1.6	1.6	1.6	2.0
	S.D.	0.68	0.73	0.78	0.33
	S.E.	0.30	0.33	0.35	0.15
	N	5	5	5	5
	0 TO 5				
	MEAN	1.5	1.2	1.2	2.1
	S.D.	0.77	0.60	0.85	0.54
	S.E.	0.34	0.27	0.38	0.24
	N	5	5	5	5

None significantly different from control group

TABLE S7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALES

GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY	0 TO 6				
	MEAN	1.6	1.1	1.5	2.4
	S.D.	0.79	0.68	0.68	0.53
	S.E.	0.35	0.30	0.30	0.24
	N	5	5	5	5
	0 TO 7				
	MEAN	1.3	0.9	1.3	2.0
	S.D.	0.96	0.73	1.00	0.28
	S.E.	0.43	0.32	0.45	0.13
	N	5	5	5	5
	0 TO 8				
	MEAN	1.9	1.6	1.9	3.0
	S.D.	1.23	0.68	0.84	0.46
	S.E.	0.55	0.30	0.38	0.21
	N	5	5	5	5
	0 TO 9				
	MEAN	1.3	0.8	1.7	2.5
	S.D.	1.12	0.88	1.24	0.44
	S.E.	0.50	0.39	0.55	0.20
	N	5	5	5	5
	0 TO 10				
	MEAN	1.7	0.6	1.7	2.8
	S.D.	1.19	0.80	1.18	0.71
	S.E.	0.53	0.36	0.53	0.32
	N	5	5	5	5

None significantly different from control group

TABLE S7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

		MALES			
GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY	0 TO 11				
	MEAN	2.0	1.3	2.1	3.3
	S.D.	1.31	0.82	1.15	0.70
	S.E.	0.58	0.37	0.52	0.31
	N	5	5	5	5
	0 TO 12				
	MEAN	1.6	0.8	1.9	2.9
	S.D.	1.32	0.83	1.34	0.70
	S.E.	0.59	0.37	0.60	0.31
	N	5	5	5	5
	0 TO 13				
	MEAN	1.9	1.2	2.6	3.4
	S.D.	1.03	0.92	1.60	0.70
	S.E.	0.46	0.41	0.72	0.31
	N	5	5	5	5
	0 TO 14				
	MEAN	1.9	1.1	2.6	3.4
	S.D.	0.98	1.16	1.22	0.76
	S.E.	0.44	0.52	0.55	0.34
	N	5	5	5	5

None significantly different from control group

TABLE S7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

		FEMALES			
GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY	0 TO 1				
	MEAN	-0.3	-0.1	-0.1	-0.2
	S.D.	0.48	0.50	0.54	0.33
	S.E.	0.15	0.16	0.17	0.10
	N	10	10	10	10
	0 TO 2				
	MEAN	1.0	0.5	0.9	0.8
	S.D.	0.60	0.55	1.09	0.59
	S.E.	0.19	0.17	0.34	0.19
	N	10	10	10	10
	0 TO 3				
	MEAN	1.0	1.4	1.0	0.9
	S.D.	0.25	0.68	0.98	1.39
	S.E.	0.11	0.31	0.44	0.62
	N	5	5	5	5
	0 TO 4				
	MEAN	0.9	1.1	0.9	1.2
	S.D.	0.46	0.60	0.50	0.68
	S.E.	0.21	0.27	0.22	0.30
	N	5	5	5	5
	0 TO 5				
	MEAN	0.5	0.9	1.0	1.2
	S.D.	0.33	0.62	0.29	0.86
	S.E.	0.15	0.28	0.13	0.38
	N	5	5	5	5

None significantly different from control group

TABLE S7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

		FEMALES			
GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY	0 TO 6				
	MEAN	0.4	1.3	1.0	1.5
	S.D.	0.45	0.55	0.76	0.69
	S.E.	0.20	0.25	0.34	0.31
	N	5	5	5	5
	0 TO 7				
	MEAN	0.4	0.7	0.5	1.4
	S.D.	0.43	0.58	1.06	0.63
	S.E.	0.19	0.26	0.47	0.28
	N	5	5	5	5
	0 TO 8				
	MEAN	1.1	1.0	1.8	1.0
	S.D.	0.38	0.64	0.46	0.86
	S.E.	0.17	0.29	0.21	0.38
	N	5	5	5	5
	0 TO 9				
	MEAN	0.4	0.7	1.2	0.7
	S.D.	0.72	0.59	0.36	0.83
	S.E.	0.32	0.27	0.16	0.37
	N	5	5	5	5
	0 TO 10				
	MEAN	0.5	0.8	1.4	1.1
	S.D.	0.75	0.50	0.48	0.72
	S.E.	0.34	0.22	0.22	0.32
	N	5	5	5	5

None significantly different from control group

TABLE S7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

		FEMALES			
	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY	0 TO 11				
	MEAN	0.8	1.5	1.9	1.8
	S.D.	0.58	0.65	0.74	0.96
	S.E.	0.26	0.29	0.33	0.43
	N	5	5	5	5
	0 TO 12				
	MEAN	0.4	0.7	1.4	1.0
	S.D.	0.41	0.48	0.68	1.00
	S.E.	0.18	0.22	0.30	0.45
	N	5	5	5	5
	0 TO 13				
	MEAN	0.5	1.0	2.1**	1.2
	S.D.	0.68	0.50	0.62	0.97
	S.E.	0.30	0.23	0.28	0.43
	N	5	5	5	5
	0 TO 14				
	MEAN	0.7	1.0	2.1*	1.7
	S.D.	0.85	0.51	0.31	0.81
	S.E.	0.38	0.23	0.14	0.36
	N	5	5	5	5

* = Significantly different from the control group at 0.05 using Dunnett's test

** = Significantly different from the control group at 0.01 using Dunnett's test

PBFSTv5.30
03/16/2010

TABLE S8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY -10 TO -4				
MEAN	5.8	5.9	5.7	5.9
S.D.	0.76	1.06	0.84	1.16
S.E.	0.24	0.34	0.27	0.37
N	10	10	10	10
0 TO 1				
MEAN	6.3	5.1	6.1	5.5
S.D.	0.98	1.39	1.07	0.85
S.E.	0.31	0.44	0.34	0.27
N	10	10	10	10
1 TO 2				
MEAN	6.5	5.4	6.3	5.6
S.D.	1.43	0.98	1.39	0.87
S.E.	0.45	0.31	0.44	0.31
N	10	10	10	8
2 TO 3				
MEAN	6.5	5.8	6.1	5.4
S.D.	1.07	1.75	0.72	1.77
S.E.	0.48	0.78	0.32	0.79
N	5	5	5	5
3 TO 4				
MEAN	5.8	6.3	6.2	7.5
S.D.	0.59	1.77	0.74	0.76
S.E.	0.26	0.79	0.33	0.34
N	5	5	5	5

None significantly different from control group

TABLE S8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 4 TO 5				
MEAN	6.0	5.9	5.9	6.5
S.D.	1.04	1.02	0.48	0.52
S.E.	0.47	0.45	0.22	0.23
N	5	5	5	5
5 TO 6				
MEAN	5.5	6.2	5.3	5.9
S.D.	1.02	1.90	0.45	0.42
S.E.	0.46	0.85	0.20	0.19
N	5	5	5	5
6 TO 7				
MEAN	6.5	6.1	6.4	7.5
S.D.	1.11	1.72	0.73	0.81
S.E.	0.50	0.77	0.36	0.40
N	5	5	4	4
7 TO 8				
MEAN	4.1	6.2	4.9	5.8
S.D.	1.04	2.08	1.35	2.69
S.E.	0.46	1.04	0.68	1.20
N	5	4	4	5
8 TO 9				
MEAN	6.3	6.2	7.9	7.6
S.D.	1.01	1.47	0.60	1.01
S.E.	0.45	0.73	0.27	0.58
N	5	4	5	3

None significantly different from control group

TABLE S8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALES

GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 9 TO 10				
MEAN	6.0	5.6	6.2	5.8
S.D.	0.65	0.57	0.39	1.58
S.E.	0.29	0.25	0.17	0.71
N	5	5	5	5
10 TO 11				
MEAN	5.3	5.5	5.5	6.3
S.D.	0.64	1.04	0.20	0.41
S.E.	0.32	0.46	0.09	0.18
N	4	5	5	5
11 TO 12				
MEAN	6.0	5.5	5.9	6.6
S.D.	0.29	0.99	0.83	0.69
S.E.	0.13	0.44	0.37	0.31
N	5	5	5	5
12 TO 13				
MEAN	5.5	5.7	5.8	6.5
S.D.	0.73	0.82	0.31	0.28
S.E.	0.33	0.37	0.14	0.12
N	5	5	5	5
13 TO 14				
MEAN	5.9	5.1	5.7	6.4
S.D.	1.12	1.03	0.53	0.25
S.E.	0.50	0.46	0.24	0.11
N	5	5	5	5

None significantly different from control group

TABLE S8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY -10 TO -4				
MEAN	5.9	5.0	6.3	5.4
S.D.	1.59	0.91	1.48	1.95
S.E.	0.50	0.29	0.47	0.62
N	10	10	10	10
0 TO 1				
MEAN	5.9	4.7	5.5	3.9**
S.D.	1.98	0.56	1.24	1.19
S.E.	0.75	0.18	0.47	0.38
N	7	10	7	10
1 TO 2				
MEAN	5.6	5.2	6.0	4.9
S.D.	1.92	0.51	1.39	0.66
S.E.	0.64	0.16	0.46	0.21
N	9	10	9	10
2 TO 3				
MEAN	7.0	4.9	6.1	5.5
S.D.	1.70	0.38	1.35	2.47
S.E.	0.76	0.17	0.60	1.10
N	5	5	5	5
3 TO 4				
MEAN	6.3	5.7	6.2	5.5
S.D.	1.55	0.88	1.05	0.32
S.E.	0.78	0.39	0.47	0.14
N	4	5	5	5

** = Significantly different from the control group at 0.01 using Dunnett's test

TABLE S8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

		FEMALES			
GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY	4 TO 5				
	MEAN	7.3	6.8	6.1	5.9
	S.D.	1.86	0.93	0.95	0.48
	S.E.	0.83	0.41	0.43	0.22
	N	5	5	5	5
	5 TO 6				
	MEAN	5.5	5.2	5.7	5.1
	S.D.	0.58	0.65	1.31	0.43
	S.E.	0.26	0.29	0.58	0.19
	N	5	5	5	5
	6 TO 7				
	MEAN	6.7	5.7	6.1	6.1
	S.D.	1.05	1.22	1.24	0.97
	S.E.	0.47	0.55	0.55	0.43
	N	5	5	5	5
	7 TO 8				
	MEAN	5.0	5.3	5.3	4.5
	S.D.	1.49	2.01	1.47	1.39
	S.E.	0.74	0.90	0.66	0.62
	N	4	5	5	5
	8 TO 9				
	MEAN	8.4	7.1	7.8	6.9
	S.D.	0.92	1.54	0.32	0.22
	S.E.	0.65	0.69	0.14	0.10
	N	2	5	5	5

None significantly different from control group

TABLE S8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

	FEMALES			
GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
DAY 9 TO 10				
MEAN	4.4	5.8	6.5	5.8
S.D.	2.70	0.64	1.55	0.40
S.E.	1.21	0.29	0.77	0.18
N	5	5	4	5
10 TO 11				
MEAN	6.0	5.3	6.7	5.3
S.D.	0.65	0.57	1.77	0.46
S.E.	0.32	0.26	0.88	0.21
N	4	5	4	5
11 TO 12				
MEAN	5.8	5.3	6.3	6.3
S.D.	0.65	0.59	0.80	1.86
S.E.	0.32	0.26	0.40	0.83
N	4	5	4	5
12 TO 13				
MEAN	4.0	5.1	5.2	5.4
S.D.	2.08	0.63	1.49	0.36
S.E.	0.93	0.28	0.67	0.16
N	5	5	5	5
13 TO 14				
MEAN	6.0	5.4	5.9	5.7
S.D.	0.97	0.94	0.65	0.75
S.E.	0.43	0.42	0.29	0.34
N	5	5	5	5

None significantly different from control group

PBFSTv5.30
03/12/2010

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		MALES 0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
WBC (thous/uL)					
DAY 2	MEAN	5.68	4.22	4.04	4.53
	% DIFFERENCE		-25.7	-28.9	-20.2
	S.D.	2.542	1.711	0.561	1.036
	S.E.	1.137	0.765	0.251	0.463
	N	5	5	5	5
DAY 14	MEAN	5.20	6.74	6.31	6.54
	% DIFFERENCE		29.6	21.3	25.8
	S.D.	0.745	1.382	0.969	1.985
	S.E.	0.333	0.618	0.433	0.888
	N	5	5	5	5
RBC (mil/uL)					
DAY 2	MEAN	9.54	9.90	9.57	9.15
	% DIFFERENCE		3.8	0.3	-4.1
	S.D.	0.224	0.602	0.658	0.454
	S.E.	0.100	0.269	0.294	0.203
	N	5	5	5	5
DAY 14	MEAN	9.76	10.51*	9.73	9.78
	% DIFFERENCE		7.7	-0.3	0.2
	S.D.	0.640	0.196	0.388	0.392
	S.E.	0.286	0.088	0.174	0.175
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

* = Significantly different from the control group at 0.05 using Dunnett's test

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
		MALES			
HGB (g/dL)					
DAY 2	MEAN	14.9	15.4	15.1	14.8
	% DIFFERENCE		3.4	1.3	-0.7
	S.D.	0.36	0.70	0.51	0.46
	S.E.	0.16	0.31	0.23	0.21
	N	5	5	5	5
DAY 14	MEAN	15.4	15.5	15.1	15.2
	% DIFFERENCE		0.6	-1.9	-1.3
	S.D.	0.48	0.70	0.57	0.32
	S.E.	0.22	0.31	0.25	0.14
	N	5	5	5	5
HCT (%)					
DAY 2	MEAN	43.7	45.4	43.9	43.2
	% DIFFERENCE		3.9	0.5	-1.1
	S.D.	0.89	2.10	1.27	1.14
	S.E.	0.40	0.94	0.57	0.51
	N	5	5	5	5
DAY 14	MEAN	44.1	45.1	43.3	44.5
	% DIFFERENCE		2.3	-1.8	0.9
	S.D.	1.48	2.03	1.62	0.87
	S.E.	0.66	0.91	0.73	0.39
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
		MALES			
MCV (fL)					
DAY 2	MEAN	45.9	45.9	46.0	47.3
	% DIFFERENCE		0.0	0.2	3.1
	S.D.	1.53	1.83	2.06	1.56
	S.E.	0.68	0.82	0.92	0.70
	N	5	5	5	5
DAY 14	MEAN	45.3	43.0	44.6	45.5
	% DIFFERENCE		-5.1	-1.5	0.4
	S.D.	1.93	1.39	1.12	1.08
	S.E.	0.87	0.62	0.50	0.48
	N	5	5	5	5
MCH (pg)					
DAY 2	MEAN	15.7	15.6	15.8	16.2
	% DIFFERENCE		-0.6	0.6	3.2
	S.D.	0.57	0.65	0.68	0.51
	S.E.	0.26	0.29	0.30	0.23
	N	5	5	5	5
DAY 14	MEAN	15.8	14.7**	15.6	15.6
	% DIFFERENCE		-7.0	-1.3	-1.3
	S.D.	0.59	0.51	0.32	0.42
	S.E.	0.27	0.23	0.14	0.19
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

** = Significantly different from the control group at 0.01 using Dunnett's test

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
		MALES			
MCHC (g/dL)					
DAY 2	MEAN	34.1	34.0	34.4	34.3
	% DIFFERENCE		-0.3	0.9	0.6
	S.D.	0.48	0.13	0.40	0.46
	S.E.	0.22	0.06	0.18	0.21
	N	5	5	5	5
DAY 14	MEAN	34.9	34.3	34.9	34.2
	% DIFFERENCE		-1.7	0.0	-2.0
	S.D.	0.50	0.69	0.44	0.47
	S.E.	0.22	0.31	0.20	0.21
	N	5	5	5	5
PLATELET (thous/uL)					
DAY 2	MEAN	1422.	1363.	1270.	1556.
	% DIFFERENCE		-4.1	-10.7	9.4
	S.D.	246.2	172.3	354.9	367.6
	S.E.	110.1	77.0	158.7	164.4
	N	5	5	5	5
DAY 14	MEAN	1329.	1303.	1436.	1255.
	% DIFFERENCE		-2.0	8.1	-5.6
	S.D.	107.9	173.8	121.6	172.2
	S.E.	48.3	77.7	54.4	77.0
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		MALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
RETIC (%)					
DAY 2	MEAN	3.0	2.5	2.6	3.1
	% DIFFERENCE		-16.7	-13.3	3.3
	S.D.	0.59	0.26	0.15	0.45
	S.E.	0.26	0.12	0.07	0.20
	N	5	5	5	5
DAY 14	MEAN	3.0	2.4	2.7	2.9
	% DIFFERENCE		-20.0	-10.0	-3.3
	S.D.	0.59	0.35	0.37	0.52
	S.E.	0.27	0.16	0.17	0.23
	N	5	5	5	5
RETIC ABSOLUTE (thous/uL)					
DAY 2	MEAN	283.9	249.9	245.8	285.4
	% DIFFERENCE		-12.0	-13.4	0.5
	S.D.	54.93	15.94	24.12	34.00
	S.E.	24.57	7.13	10.79	15.21
	N	5	5	5	5
DAY 14	MEAN	286.5	253.4	261.0	286.8
	% DIFFERENCE		-11.6	-8.9	0.1
	S.D.	47.04	36.80	34.64	43.40
	S.E.	21.03	16.46	15.49	19.41
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		MALES 0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
NEU (%)					
DAY 2	MEAN	25.6	20.5	19.1	21.1
	% DIFFERENCE		-19.9	-25.4	-17.6
	S.D.	16.82	4.31	6.66	4.45
	S.E.	7.52	1.93	2.98	1.99
	N	5	5	5	5
DAY 14	MEAN	16.3	17.5	14.7	15.7
	% DIFFERENCE		7.4	-9.8	-3.7
	S.D.	5.04	5.70	3.48	5.28
	S.E.	2.25	2.55	1.56	2.36
	N	5	5	5	5
LYMPH (%)					
DAY 2	MEAN	68.2	73.5	75.7	73.7
	% DIFFERENCE		7.8	11.0	8.1
	S.D.	17.32	4.94	7.07	5.97
	S.E.	7.75	2.21	3.16	2.67
	N	5	5	5	5
DAY 14	MEAN	78.5	77.3	80.4	79.8
	% DIFFERENCE		-1.5	2.4	1.7
	S.D.	5.88	6.59	4.05	4.36
	S.E.	2.63	2.95	1.81	1.95
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
		MALES			
MONO (%)					
DAY 2	MEAN	2.1	2.1	1.4	1.6
	% DIFFERENCE		0.0	-33.3	-23.8
	S.D.	1.56	0.72	0.24	0.75
	S.E.	0.70	0.32	0.11	0.34
	N	5	5	5	5
DAY 14	MEAN	2.1	2.4	2.0	2.1
	% DIFFERENCE		14.3	-4.8	0.0
	S.D.	0.87	0.82	0.73	0.75
	S.E.	0.39	0.37	0.33	0.34
	N	5	5	5	5
EOS (%)					
DAY 2	MEAN	3.5	3.5	3.3	3.2
	% DIFFERENCE		0.0	-5.7	-8.6
	S.D.	1.13	0.66	0.48	1.98
	S.E.	0.51	0.30	0.22	0.89
	N	5	5	5	5
DAY 14	MEAN	2.5	2.2	2.2	2.0
	% DIFFERENCE		-12.0	-12.0	-20.0
	S.D.	1.28	0.88	1.01	0.60
	S.E.	0.57	0.39	0.45	0.27
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		MALES 0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
BASO (%)					
DAY 2	MEAN	0.1	0.2	0.1	0.2
	% DIFFERENCE		100.0	0.0	100.0
	S.D.	0.08	0.05	0.05	0.05
	S.E.	0.04	0.02	0.02	0.02
	N	5	5	5	5
DAY 14	MEAN	0.1	0.1	0.1	0.1
	% DIFFERENCE		0.0	0.0	0.0
	S.D.	0.09	0.04	0.05	0.11
	S.E.	0.04	0.02	0.02	0.05
	N	5	5	5	5
LUC (%)					
DAY 2	MEAN	0.5	0.3	0.4	0.4
	% DIFFERENCE		-40.0	-20.0	-20.0
	S.D.	0.16	0.19	0.09	0.19
	S.E.	0.07	0.09	0.04	0.08
	N	5	5	5	5
DAY 14	MEAN	0.4	0.5	0.5	0.4
	% DIFFERENCE		25.0	25.0	0.0
	S.D.	0.13	0.16	0.10	0.23
	S.E.	0.06	0.07	0.04	0.10
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 9

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		MALES 0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
NEU ABSOLUTE (thous/uL)					
DAY 2	MEAN	1.76	0.86	0.79	0.96
	% DIFFERENCE		-51.1	-55.1	-45.5
	S.D.	2.099	0.368	0.343	0.339
	S.E.	0.939	0.165	0.154	0.152
	N	5	5	5	5
DAY 14	MEAN	0.83	1.20	0.94	0.97
	% DIFFERENCE		44.6	13.3	16.9
	S.D.	0.224	0.578	0.326	0.242
	S.E.	0.100	0.258	0.146	0.108
	N	5	5	5	5
LYMPH ABSOLUTE (thous/uL)					
DAY 2	MEAN	3.56	3.12	3.04	3.33
	% DIFFERENCE		-12.4	-14.6	-6.5
	S.D.	0.620	1.289	0.407	0.735
	S.E.	0.277	0.576	0.182	0.329
	N	5	5	5	5
DAY 14	MEAN	4.09	5.18	5.07	5.27
	% DIFFERENCE		26.7	24.0	28.9
	S.D.	0.716	0.996	0.732	1.782
	S.E.	0.320	0.446	0.327	0.797
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		MALES 0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
MONO ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.15	0.08	0.06	0.07
	% DIFFERENCE		-46.7	-60.0	-53.3
	S.D.	0.179	0.046	0.013	0.047
	S.E.	0.080	0.020	0.006	0.021
	N	5	5	5	5
DAY 14	MEAN	0.11	0.16	0.13	0.14
	% DIFFERENCE		45.5	18.2	27.3
	S.D.	0.047	0.078	0.061	0.086
	S.E.	0.021	0.035	0.027	0.039
	N	5	5	5	5
EOS ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.18	0.15	0.14	0.14
	% DIFFERENCE		-16.7	-22.2	-22.2
	S.D.	0.033	0.057	0.032	0.065
	S.E.	0.015	0.025	0.014	0.029
	N	5	5	5	5
DAY 14	MEAN	0.14	0.15	0.13	0.12
	% DIFFERENCE		7.1	-7.1	-14.3
	S.D.	0.086	0.060	0.037	0.034
	S.E.	0.038	0.027	0.017	0.015
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 11

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		MALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
BASO ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.01	0.01	0.00	0.01
	% DIFFERENCE		0.0	-100.0	0.0
	S.D.	0.009	0.005	0.005	0.004
	S.E.	0.004	0.002	0.002	0.002
	N	5	5	5	5
DAY 14	MEAN	0.01	0.01	0.01	0.01
	% DIFFERENCE		0.0	0.0	0.0
	S.D.	0.007	0.004	0.007	0.005
	S.E.	0.003	0.002	0.003	0.002
	N	5	5	5	5
LUC ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.03	0.01	0.01	0.02
	% DIFFERENCE		-66.7	-66.7	-33.3
	S.D.	0.022	0.013	0.005	0.013
	S.E.	0.010	0.006	0.002	0.006
	N	5	5	5	5
DAY 14	MEAN	0.02	0.04	0.03	0.03
	% DIFFERENCE		100.0	50.0	50.0
	S.D.	0.007	0.015	0.010	0.019
	S.E.	0.003	0.007	0.004	0.009
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 12

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
		MALES			
RDW (%)					
DAY 2	MEAN	13.0	12.8	12.5	13.1
	% DIFFERENCE		-1.5	-3.8	0.8
	S.D.	0.55	0.93	0.28	0.19
	S.E.	0.25	0.42	0.12	0.09
	N	5	5	5	5
DAY 14	MEAN	12.2	12.1	12.1	12.6
	% DIFFERENCE		-0.8	-0.8	3.3
	S.D.	0.58	0.63	0.36	0.50
	S.E.	0.26	0.28	0.16	0.22
	N	5	5	5	5
HDW (g/dL)					
DAY 2	MEAN	1.94	1.87	1.80	1.87
	% DIFFERENCE		-3.6	-7.2	-3.6
	S.D.	0.154	0.128	0.095	0.095
	S.E.	0.069	0.057	0.043	0.043
	N	5	5	5	5
DAY 14	MEAN	2.11	2.10	2.01	2.01
	% DIFFERENCE		-0.5	-4.7	-4.7
	S.D.	0.138	0.123	0.049	0.132
	S.E.	0.062	0.055	0.022	0.059
	N	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 13

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
WBC (thous/uL)					
DAY 2	MEAN	4.14	4.13	5.46	3.72
	% DIFFERENCE		-0.2	31.9	-10.1
	S.D.	0.857	1.285	1.683	1.156
	S.E.	0.383	0.575	0.752	0.517
	N	5	5	5	5
DAY 14	MEAN	6.94	5.78	6.90	6.12
	% DIFFERENCE		-16.7	-0.6	-11.8
	S.D.	1.441	0.567	1.179	1.027
	S.E.	0.645	0.254	0.527	0.514
	N	5	5	5	4
RBC (mil/uL)					
DAY 2	MEAN	9.80	9.63	9.96	10.14
	% DIFFERENCE		-1.7	1.6	3.5
	S.D.	0.438	0.147	0.503	0.301
	S.E.	0.196	0.066	0.225	0.135
	N	5	5	5	5
DAY 14	MEAN	10.16	9.81	9.74	9.38
	% DIFFERENCE		-3.4	-4.1	-7.7
	S.D.	0.399	0.441	0.378	0.268
	S.E.	0.179	0.197	0.169	0.134
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 14

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
HGB (g/dL)					
DAY 2	MEAN	15.5	15.5	15.4	15.8
	% DIFFERENCE		0.0	-0.6	1.9
	S.D.	0.59	0.23	0.47	0.27
	S.E.	0.26	0.10	0.21	0.12
	N	5	5	5	5
DAY 14	MEAN	16.0	15.3	15.1**	14.9**
	% DIFFERENCE		-4.4	-5.6	-6.9
	S.D.	0.38	0.46	0.37	0.31
	S.E.	0.17	0.20	0.17	0.16
	N	5	5	5	4
HCT (%)					
DAY 2	MEAN	44.7	45.0	44.7	45.1
	% DIFFERENCE		0.7	0.0	0.9
	S.D.	1.38	1.02	1.53	0.74
	S.E.	0.62	0.46	0.68	0.33
	N	5	5	5	5
DAY 14	MEAN	46.0	44.0*	43.6*	43.0**
	% DIFFERENCE		-4.3	-5.2	-6.5
	S.D.	1.18	1.13	1.24	0.89
	S.E.	0.53	0.50	0.56	0.44
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

* = Significantly different from the control group at 0.05 using Dunnett's test

** = Significantly different from the control group at 0.01 using Dunnett's test

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 15

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
MCV (fL)					
DAY 2	MEAN	45.6	46.7	44.9	44.5
	% DIFFERENCE		2.4	-1.5	-2.4
	S.D.	1.53	0.96	1.30	1.17
	S.E.	0.68	0.43	0.58	0.52
	N	5	5	5	5
DAY 14	MEAN	45.3	44.9	44.8	45.9
	% DIFFERENCE		-0.9	-1.1	1.3
	S.D.	0.65	1.27	0.66	0.90
	S.E.	0.29	0.57	0.29	0.45
	N	5	5	5	4
MCH (pg)					
DAY 2	MEAN	15.9	16.2	15.5	15.5
	% DIFFERENCE		1.9	-2.5	-2.5
	S.D.	0.40	0.15	0.41	0.25
	S.E.	0.18	0.07	0.18	0.11
	N	5	5	5	5
DAY 14	MEAN	15.7	15.7	15.5	15.8
	% DIFFERENCE		0.0	-1.3	0.6
	S.D.	0.23	0.30	0.34	0.33
	S.E.	0.10	0.14	0.15	0.17
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 16

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
MCHC (g/dL)					
DAY 2	MEAN	34.8	34.5	34.5	34.9
	% DIFFERENCE		-0.9	-0.9	0.3
	S.D.	0.59	0.47	0.52	0.64
	S.E.	0.26	0.21	0.23	0.29
	N	5	5	5	5
DAY 14	MEAN	34.7	34.9	34.6	34.5
	% DIFFERENCE		0.6	-0.3	-0.6
	S.D.	0.09	0.60	0.63	0.17
	S.E.	0.04	0.27	0.28	0.09
	N	5	5	5	4
PLATELET (thous/uL)					
DAY 2	MEAN	1170.	1219.	1117.	1170.
	% DIFFERENCE		4.2	-4.5	0.0
	S.D.	98.5	175.5	201.2	131.2
	S.E.	44.1	78.5	90.0	58.7
	N	5	5	5	5
DAY 14	MEAN	1090.	1113.	1236.	1199.
	% DIFFERENCE		2.1	13.4	10.0
	S.D.	185.7	112.1	147.4	112.9
	S.E.	83.1	50.1	65.9	56.5
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
RETIC (%)					
DAY 2	MEAN	3.0	3.6	3.5	3.1
	% DIFFERENCE		20.0	16.7	3.3
	S.D.	0.60	0.67	0.71	0.43
	S.E.	0.27	0.30	0.32	0.19
	N	5	5	5	5
DAY 14	MEAN	2.2	2.6	2.8	2.7
	% DIFFERENCE		18.2	27.3	22.7
	S.D.	0.19	0.27	0.67	0.14
	S.E.	0.09	0.12	0.30	0.07
	N	5	5	5	4
RETIC ABSOLUTE (thous/uL)					
DAY 2	MEAN	292.3	344.4	349.0	312.5
	% DIFFERENCE		17.8	19.4	6.9
	S.D.	56.42	62.77	51.59	52.50
	S.E.	25.23	28.07	23.07	23.48
	N	5	5	5	5
DAY 14	MEAN	229.4	252.5	271.4	254.2
	% DIFFERENCE		10.1	18.3	10.8
	S.D.	20.43	31.01	56.93	9.64
	S.E.	9.14	13.87	25.46	4.82
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 18

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
NEU (%)					
DAY 2	MEAN	18.7	19.2	14.5	18.4
	% DIFFERENCE		2.7	-22.5	-1.6
	S.D.	5.69	5.85	2.11	9.77
	S.E.	2.54	2.62	0.94	4.37
	N	5	5	5	5
DAY 14	MEAN	11.8	13.9	16.5	16.8
	% DIFFERENCE		17.8	39.8	42.4
	S.D.	1.86	3.67	8.63	4.52
	S.E.	0.83	1.64	3.86	2.26
	N	5	5	5	4
LYMPH (%)					
DAY 2	MEAN	75.8	73.4	77.4	74.4
	% DIFFERENCE		-3.2	2.1	-1.8
	S.D.	6.10	8.12	2.63	11.04
	S.E.	2.73	3.63	1.18	4.94
	N	5	5	5	5
DAY 14	MEAN	84.3	81.0	77.4	78.0
	% DIFFERENCE		-3.9	-8.2	-7.5
	S.D.	2.55	4.55	8.02	4.32
	S.E.	1.14	2.03	3.59	2.16
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 19

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
MONO (%)					
DAY 2	MEAN	1.3	0.7	1.2	1.5
	% DIFFERENCE		-46.2	-7.7	15.4
	S.D.	0.46	0.44	0.32	0.54
	S.E.	0.21	0.20	0.14	0.24
	N	5	5	5	5
DAY 14	MEAN	1.4	1.2	2.1	2.0
	% DIFFERENCE		-14.3	50.0	42.9
	S.D.	1.51	0.82	1.87	0.71
	S.E.	0.67	0.37	0.84	0.36
	N	5	5	5	4
EOS (%)					
DAY 2	MEAN	3.5	6.2	6.3	5.3
	% DIFFERENCE		77.1	80.0	51.4
	S.D.	0.86	2.71	2.07	1.87
	S.E.	0.39	1.21	0.92	0.84
	N	5	5	5	5
DAY 14	MEAN	2.1	3.2	3.2	2.7
	% DIFFERENCE		52.4	52.4	28.6
	S.D.	1.42	2.20	2.05	0.97
	S.E.	0.64	0.98	0.92	0.49
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
BASO (%)					
DAY 2	MEAN	0.2	0.1	0.2	0.1
	% DIFFERENCE		-50.0	0.0	-50.0
	S.D.	0.04	0.08	0.05	0.07
	S.E.	0.02	0.04	0.02	0.03
	N	5	5	5	5
DAY 14	MEAN	0.1	0.1	0.1	0.1
	% DIFFERENCE		0.0	0.0	0.0
	S.D.	0.11	0.11	0.09	0.10
	S.E.	0.05	0.05	0.04	0.05
	N	5	5	5	4
LUC (%)					
DAY 2	MEAN	0.5	0.3	0.5	0.3
	% DIFFERENCE		-40.0	0.0	-40.0
	S.D.	0.22	0.20	0.15	0.20
	S.E.	0.10	0.09	0.07	0.09
	N	5	5	5	5
DAY 14	MEAN	0.3	0.5	0.6	0.5
	% DIFFERENCE		66.7	100.0	66.7
	S.D.	0.36	0.36	0.16	0.35
	S.E.	0.16	0.16	0.07	0.17
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 21

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
NEU ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.79	0.76	0.78	0.62
	% DIFFERENCE		-3.8	-1.3	-21.5
	S.D.	0.308	0.265	0.176	0.208
	S.E.	0.138	0.119	0.079	0.093
	N	5	5	5	5
DAY 14	MEAN	0.82	0.79	1.20	1.01
	% DIFFERENCE		-3.7	46.3	23.2
	S.D.	0.226	0.189	0.773	0.190
	S.E.	0.101	0.084	0.346	0.095
	N	5	5	5	4
LYMPH ABSOLUTE (thous/uL)					
DAY 2	MEAN	3.12	3.06	4.23	2.84
	% DIFFERENCE		-1.9	35.6	-9.0
	S.D.	0.593	1.146	1.354	1.161
	S.E.	0.265	0.513	0.605	0.519
	N	5	5	5	5
DAY 14	MEAN	5.85	4.69	5.29	4.79
	% DIFFERENCE		-19.8	-9.6	-18.1
	S.D.	1.250	0.657	0.716	1.012
	S.E.	0.559	0.294	0.320	0.506
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 22

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
MONO ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.05	0.03	0.06	0.05
	% DIFFERENCE		-40.0	20.0	0.0
	S.D.	0.022	0.019	0.022	0.005
	S.E.	0.010	0.009	0.010	0.002
	N	5	5	5	5
DAY 14	MEAN	0.09	0.07	0.13	0.12
	% DIFFERENCE		-22.2	44.4	33.3
	S.D.	0.083	0.044	0.095	0.053
	S.E.	0.037	0.019	0.043	0.026
	N	5	5	5	4
EOS ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.15	0.25	0.35	0.19
	% DIFFERENCE		66.7	133.3	26.7
	S.D.	0.064	0.133	0.188	0.090
	S.E.	0.029	0.059	0.084	0.040
	N	5	5	5	5
DAY 14	MEAN	0.15	0.18	0.22	0.16
	% DIFFERENCE		20.0	46.7	6.7
	S.D.	0.114	0.123	0.141	0.052
	S.E.	0.051	0.055	0.063	0.026
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 23

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

		FEMALES			
ANALYSIS	GROUP:	0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
BASO ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.01	0.00	0.01	0.00
	% DIFFERENCE		-100.0	0.0	-100.0
	S.D.	0.005	0.005	0.004	0.004
	S.E.	0.002	0.002	0.002	0.002
	N	5	5	5	5
DAY 14	MEAN	0.01	0.01	0.01	0.01
	% DIFFERENCE		0.0	0.0	0.0
	S.D.	0.009	0.008	0.007	0.006
	S.E.	0.004	0.004	0.003	0.003
	N	5	5	5	4
LUC ABSOLUTE (thous/uL)					
DAY 2	MEAN	0.02	0.01	0.03	0.01
	% DIFFERENCE		-50.0	50.0	-50.0
	S.D.	0.008	0.008	0.020	0.013
	S.E.	0.004	0.004	0.009	0.006
	N	5	5	5	5
DAY 14	MEAN	0.02	0.03	0.04	0.04
	% DIFFERENCE		50.0	100.0	100.0
	S.D.	0.025	0.022	0.013	0.024
	S.E.	0.011	0.010	0.006	0.012
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

TABLE S9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 24

SPONSOR:SYNGENTA SUMMARY OF HEMATOLOGY VALUES

SPONSOR NO.:T007563-08

ANALYSIS GROUP:		FEMALES 0 MG/KG	500 MG/KG	1500 MG/KG	2000 MG/KG
RDW (%)					
DAY 2	MEAN	13.0	13.6	13.5	12.9
	% DIFFERENCE		4.6	3.8	-0.8
	S.D.	0.75	0.55	0.48	0.51
	S.E.	0.34	0.25	0.21	0.23
	N	5	5	5	5
DAY 14	MEAN	13.1	13.2	13.4	13.3
	% DIFFERENCE		0.8	2.3	1.5
	S.D.	0.26	0.45	0.40	0.42
	S.E.	0.12	0.20	0.18	0.21
	N	5	5	5	4
HDW (g/dL)					
DAY 2	MEAN	2.12	2.09	2.19	2.02
	% DIFFERENCE		-1.4	3.3	-4.7
	S.D.	0.162	0.210	0.065	0.127
	S.E.	0.072	0.094	0.029	0.057
	N	5	5	5	5
DAY 14	MEAN	2.09	2.18	2.11	2.15
	% DIFFERENCE		4.3	1.0	2.9
	S.D.	0.063	0.131	0.076	0.139
	S.E.	0.028	0.059	0.034	0.070
	N	5	5	5	4

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PCPSv5.28
03/12/2010

TABLE S10 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF MACROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

SCHEDULED NECROPSY

	----- M A L E -----			
GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
TAIL				
-FRACTURED	0	1	0	0
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	5	4	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S10 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 2

SPONSOR:SYNGENTA — SUMMARY OF MACROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

SCHEDULED NECROPSY

	----- F E M A L E -----			
GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
LIVER				
-ACCESSORY LOBULE(S)	1	0	0	0
UTERUS				
-CONTENTS, CLEAR FLUID	1	0	0	1
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	3	5	5	4

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

PGRSI2v4.07
03/12/2010

TABLE S11 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF MACROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

SCHEDULED NECROPSY

	----- M A L E -----			
GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	5	5	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S11 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 2

SPONSOR:SYNGENTA — SUMMARY OF MACROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

SCHEDULED NECROPSY

	----- F E M A L E -----			
GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
LIVER				
-DISCOLORATION, DARK RED	0	0	1	0
LN, AXILLARY				
-ENLARGED	0	0	1	0
TAIL				
-SCABBING	1	0	0	0
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	4	5	4	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

PGRSI2v4.07
03/12/2010

TABLE S12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- MALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
CECUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
COLON				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
DUODENUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
ESOPHAGUS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	4	5
-DEGENERATION, MUSCLE	0	0	1	0
MILD	NONE	NONE	1	NONE
ILEUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- MALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
JEJUNUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
KIDNEYS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	3	4	3
-BASOPHILIC TUBULES	0	2	1	0
MINIMAL	NONE	2	1	NONE
-INFARCT	0	0	0	1
MODERATE	NONE	NONE	NONE	1
-INFLAMMATION, SUBACUTE	0	0	1	1
MINIMAL	NONE	NONE	1	1
LIVER				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	3	3	3	2
-INFLAMMATION, SUBACUTE	2	2	2	2
MINIMAL	2	2	2	2
-NECROSIS, HEPATOCELLULAR	1	0	0	1
MINIMAL	1	NONE	NONE	1

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- MALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
LN, MANDIBULAR				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
LN, MESENTERIC				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
PEYER'S PATCHES				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
RECTUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	4	5
-INFLAMMATION, SUBACUTE	0	0	1	0
MINIMAL	NONE	NONE	1	NONE
SPLEEN				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- MALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
STOMACH, GLAN				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
STOMACH, NON				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
TAIL				
TOTAL NUMBER EXAMINED	NA	1	NA	NA
EXAMINED, UNREMARKABLE	NA	0	NA	NA
-FRACTURE	NA	1	NA	NA
PRESENT	NA	1	NA	NA
THYMUS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	4	4
-HEMORRHAGE	0	0	1	1
MINIMAL	NONE	NONE	1	1

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

NA = NOT APPLICABLE

TABLE S12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
CECUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
COLON				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
DUODENUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
ESOPHAGUS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	3	5	5
-DEGENERATION, MUSCLE	0	1	0	0
MINIMAL	NONE	1	NONE	NONE
-INFLAMMATION, SUBACUTE	0	1	0	0
MINIMAL	NONE	1	NONE	NONE
ILEUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
JEJUNUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
KIDNEYS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	3	3	1	2
-BASOPHILIC TUBULES	2	1	3	2
MINIMAL	2	1	3	2
-CYST	0	0	1	1
PRESENT	NONE	NONE	1	1
-INFLAMMATION, SUBACUTE	0	1	0	0
MINIMAL	NONE	1	NONE	NONE
LIVER				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	0	1	2	0
-INFLAMMATION, SUBACUTE	5	4	3	5
MINIMAL	5	4	3	5
-MINERALIZATION	0	0	0	1
MINIMAL	NONE	NONE	NONE	1
-NECROSIS, HEPATOCELLULAR	1	1	0	0
MINIMAL	NONE	1	NONE	NONE
MILD	1	NONE	NONE	NONE

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
LN, MANDIBULAR				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	4	5	5	5
-HEMORRHAGE	1	0	0	0
MINIMAL	1	NONE	NONE	NONE
LN, MESENTERIC				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
PEYER'S PATCHES				
TOTAL NUMBER EXAMINED	4	5	5	3
EXAMINED, UNREMARKABLE	4	5	5	3
NOT PRESENT FOR EXAMINATION	1	0	0	2
RECTUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
SPLEEN				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 2	5	5	5	5
STOMACH, GLAN				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
STOMACH, NON				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
THYMUS				
TOTAL NUMBER EXAMINED	5	5	5	4
EXAMINED, UNREMARKABLE	5	3	5	3
NOT PRESENT FOR EXAMINATION	0	0	0	1
-HEMORRHAGE	0	2	0	1
MINIMAL	NONE	2	NONE	1
UTERUS				
TOTAL NUMBER EXAMINED	1	NA	NA	1
EXAMINED, UNREMARKABLE	0	NA	NA	0
-DILATATION, LUMEN	1	NA	NA	1
MINIMAL	1	NA	NA	NA
MILD	NA	NA	NA	1

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

NA = NOT APPLICABLE

PHSI2v4.30
03/16/2010
R:03/07/2012

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- MALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
CECUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
COLON				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
DUODENUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
ESOPHAGUS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	4	5	5
-INFLAMMATION, SUBACUTE	0	1	0	0
MINIMAL	NONE	1	NONE	NONE
ILEUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 2

SPONSOR:SYNGENTA — SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- MALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
JEJUNUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
KIDNEYS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	1	3	1	0
-BASOPHILIC TUBULES	1	0	2	0
MINIMAL	1	NONE	2	NONE
-DILATATION, TUBULAR	0	0	1	0
MINIMAL	NONE	NONE	1	NONE
-HYDRONEPHROSIS	0	1	0	0
MINIMAL	NONE	1	NONE	NONE
-INFLAMMATION, SUBACUTE	4	2	4	5
MINIMAL	4	2	4	5
LIVER				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	1	2	2	1
-INFLAMMATION, SUBACUTE	4	3	3	4
MINIMAL	4	3	3	4
-NECROSIS, HEPATOCELLULAR	0	0	1	0
MINIMAL	NONE	NONE	1	NONE

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 3

SPONSOR:SYNGENTA — SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- MALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
LN, MANDIBULAR				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	4	5	5	5
-HEMORRHAGE	1	0	0	0
MINIMAL	1	NONE	NONE	NONE
LN, MESENTERIC				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
PEYER'S PATCHES				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
RECTUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
SPLEEN				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- MALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
STOMACH, GLAN				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	4	5
-CELLULAR DEBRIS	0	0	1	0
MINIMAL	NONE	NONE	1	NONE
STOMACH, NON				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
THYMUS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	2	5	4	3
-HEMORRHAGE	3	0	1	2
MINIMAL	3	NONE	1	2

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
CECUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
COLON				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
DUODENUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
ESOPHAGUS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	4	5	5	5
-DEGENERATION, MUSCLE	1	0	0	0
MINIMAL	1	NONE	NONE	NONE
ILEUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
JEJUNUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
KIDNEYS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	3	3	3	3
-BASOPHILIC TUBULES	1	1	1	0
MINIMAL	1	1	1	NONE
-INFLAMMATION, SUBACUTE	1	1	1	2
MINIMAL	1	1	1	2
-VACUOLATION, TUBULAR EPITHELIUM	0	0	1	0
MILD	NONE	NONE	1	NONE
LIVER				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	0	0	0	1
-INFLAMMATION, SUBACUTE	5	5	5	4
MINIMAL	5	5	5	4
-NECROSIS, HEPATOCELLULAR	0	1	1	0
MINIMAL	NONE	1	NONE	NONE
SEVERE	NONE	NONE	1	NONE

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
LN, AXILLARY				
TOTAL NUMBER EXAMINED	NA	NA	1	NA
EXAMINED, UNREMARKABLE	NA	NA	1	NA
LN, MANDIBULAR				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	4	3	5	5
-HEMORRHAGE	1	2	0	0
MINIMAL	1	2	NONE	NONE
LN, MESENTERIC				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
PEYER'S PATCHES				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
RECTUM				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	4	4	5
-INFLAMMATION, ACUTE	0	0	1	0
MINIMAL	NONE	NONE	1	NONE
-INFLAMMATION, SUBACUTE	0	1	0	0
MINIMAL	NONE	1	NONE	NONE

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

NA = NOT APPLICABLE

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
SPLEEN				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
STOMACH, GLAN				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	4
-CELLULAR DEBRIS	0	0	0	1
MINIMAL	NONE	NONE	NONE	1
STOMACH, NON				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	5	5	5	5
TAIL				
TOTAL NUMBER EXAMINED	1	NA	NA	NA
EXAMINED, UNREMARKABLE	0	NA	NA	NA
-HYPERKERATOSIS	1	NA	NA	NA
MILD	1	NA	NA	NA
-NECROSIS, EPIDERMAL	1	NA	NA	NA
MILD	1	NA	NA	NA

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

NA = NOT APPLICABLE

TABLE S13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 9

SPONSOR:SYNGENTA SUMMARY OF MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

----- FEMALE -----

GROUP:	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	10	10	10	10
NUMBER OF ANIMALS EXAMINED DAY 14	5	5	5	5
THYMUS				
TOTAL NUMBER EXAMINED	5	5	5	5
EXAMINED, UNREMARKABLE	4	5	4	4
-HEMORRHAGE	1	0	1	1
MINIMAL	1	NONE	1	1

1- 0 MG/KG 2- 500 MG/KG 3- 1500 MG/KG 4- 2000 MG/KG

PHSI2v4.30
03/16/2010
R:03/07/2012

FIGURES SECTION


PROJECT NO.:WIL-639061
SPONSOR:SYNGENTA
SPONSOR NO.:T007563-08
FIGURE 1
SUMMARY OF BODY WEIGHTS (G) - MALES
DATA PRESENTED AS MEAN ± SE
BODY WEIGHT (GRAMS)
36
35
34
33
32
31
30
29
28
27
26
-10
-4
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
STUDY DAY
0 MG/KG
500 MG/KG
1500 MG/KG
2000 MG/KG
BW v1.00 03/16/2010


PROJECT NO.:WIL-639061
SPONSOR:SYNGENTA
SPONSOR NO.:T007563-08
FIGURE 2
SUMMARY OF BODY WEIGHTS (G) - FEMALES
DATA PRESENTED AS MEAN ± SE
BODY WEIGHT (GRAMS)
30
29
28
27
26
25
24
23
22
21
20
-10
-4
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
STUDY DAY
0 MG/KG
500 MG/KG
1500 MG/KG
2000 MG/KG
BW v1.00 03/16/2010

APPENDICES SECTION

APPENDIX 1 Deviations from the Protocol

DEVIATIONS FROM THE PROTOCOL

This study was conducted in accordance with the protocol and protocol amendments, except for the following.

- **Protocol Section 2.4.** states that the study pathologist will be added by amendment; however, the study pathologist, [redacted], was not amended to the protocol.

  Reason for Deviation: Amendment not prepared to designate the study pathologist as indicated in the protocol.

- **Protocol Section 4.1.2.** states that the batch number of the test substance provided for this study will be AvHPPD-03-0209; however, the batch number of the test substance provided and used for the study was J8373/189 (vials 92, 94, and 95).

  Reason for Deviation: Incorrect batch number provided by the Sponsor.

These deviations did not negatively impact the quality or integrity of the data or the outcome of the study.

APPENDIX 2 Certificate of Analysis (Sponsor-Provided Data)

Certificate of Analysis

syngenta

Syngenta Biotechnology, Inc.
Regulatory Science
Research Triangle Park, North Carolina USA

Test Substance	AVHPPD-03-0209
Date Received/Prepared	August 2009
Study Number	TKRS0000169
Active Ingredient	*p*-hydroxyphenylpyruvate dioxygenase (AvHPPD-03)
Event/Production Strain	*E. coli* strain BL21 (DE3)
Lab Notebook Reference	SY2704
Solubility	100 mg/ml in all of the following: (1) Milli-Q water, (2)10% Ethanol in Milli-Q water, (3) 10 mM Tris buffer (pH 8.9) containing 0.4 mM EDTA and 0.1% Tween 20, (4) 50 mM Tris (pH 7.5) containing 2 mM EDTA, and (5) 50mM Tris (pH 8.5) containing 2mM EDTA
Working Solvent	(1) Milli-Q water, (2)10% Ethanol in Milli-Q water, (3) 10 mM Tris buffer (pH 8.9) containing 0.4 mM EDTA and 0.1% Tween 20, (4) 50 mM Tris (pH 7.5) containing 2 mM EDTA, and (5) 50 mM Tris buffer (pH 8.5) containing 2 mM EDTA
Total Protein by weight	76.5%
% AvHPPD-03 of Total Protein	94.4%
Purity	72.2%
Glycosylation Analysis	Not Determined
Activity	Not Determined
Molecular Weight	47.0 kDa
N-terminal Sequence	Not Determined
Storage Conditions	-20°C +/- 8°C
Expiration Date	August 2019

JAN 1 4 2010

Summary Gel and Western Blot:



General Comments:

This Certificate of Analysis is summarizing data from a study that was performed in compliance with Good Laboratory Practices per 40 CFR Part 160. Raw data, documentation, protocols, protocol ammendments, or reports pertaining to this study are maintained in the Syngenta Biotechnology, Inc. Archives, 3054 East Cornwallis Rd., Research Triangle Park, NC USA 27709 in accordance with SOP 1.6.

Study Director: [redacted] 10/15/2009

SOP 4.05.1

APPENDIX 3 Pre-test Clinical Observations

TABLE P1 (DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-639061P — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 1

SPONSOR:SYNGENTA — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

SPONSOR NO.:T007563-08

----- M A L E -----

TABLE RANGE: 01-08-10 TO 01-17-10

GROUP:	1
NORMAL	
-NO SIGNIFICANT CLINICAL OBSERVATIONS	89/45
DISPOSITION	
-SENT TO NECROPSY TO BE EUTHANIZED IN EXTREMIS- PHYSICAL CONDITION	1/ 1
BEHAVIOR/CNS	
-PARTIAL CLOSURE LEFT EYE	1/ 1
-PARTIAL CLOSURE RIGHT EYE	1/ 1
CARDIO-PULMONARY	
-BODY COOL TO TOUCH	1/ 1
BODY/INTEG III	
-DRIED YELLOW MATERIAL UROGENITAL AREA	1/ 1
-DRIED YELLOW MATERIAL ANOGENITAL AREA	1/ 1
SPECIAL II	
-ATROPHIC RIGHT EYE	2/ 1
-WATER BOTTLE ADDED-POOR BODY CONDITION	1/ 1

1- PRETEST

TABLE P1 (DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-639061P — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 2

SPONSOR:SYNGENTA — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

SPONSOR NO.:T007563-08

----- F E M A L E -----

TABLE RANGE: 01-08-10 TO 01-17-10

GROUP:	1
NORMAL	
-NO SIGNIFICANT CLINICAL OBSERVATIONS	91/46
SPECIAL II	
-TAIL BROKEN	1/ 1

1- PRETEST

PCSUv4.07
03/12/2010

APPENDIX 4 Animal Room Environmental Conditions

A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

PROJECT NO.:WIL- 639061 TEMPERATURE/HUMIDITY - STUDY SUMMARY REPORT

SPONSOR: 639 - SYNGENTA

STUDY SPECIFICATIONS: 639061 DATE IN 01/05/10 TIME IN 07:00

DATE OUT 02/01/10 TIME OUT 16:00

ROOM SPECIFICATIONS: B ROOM 112 LOW TEMPERATURE °F: 66.0 HIGH TEMPERATURE °F: 76.0 LOW HUMIDITY %RH: 30.0

TEST SYSTEM: MOUSE LOW TEMPERATURE °C: 18.9 HIGH TEMPERATURE °C: 24.4 HIGH HUMIDITY %RH: 70.0

	PRIMARY TEMP		SECONDARY TEMP		PRIMARY HUM	SECONDARY HUM
DATE	MEAN (°F)	MEAN (°C)	MEAN (°F)	MEAN (°C)	MEAN (%RH)	MEAN (%RH)
01/05/10	70.9	21.6	71.0	21.7	40.2	41.6
01/06/10	70.3	21.3	70.5	21.4	40.6	42.0
01/07/10	70.5	21.4	70.6	21.4	40.4	41.7
01/08/10	70.5	21.4	70.6	21.4	40.6	42.0
01/09/10	70.5	21.4	70.6	21.4	41.7	43.0
01/10/10	70.2	21.2	70.3	21.3	42.0	43.4
01/11/10	70.6	21.4	70.8	21.6	42.4	43.8
01/12/10	70.5	21.4	70.6	21.4	39.7	41.0
01/13/10	70.5	21.4	70.7	21.5	40.1	41.5
01/14/10	70.1	21.2	70.3	21.3	39.9	41.2
01/15/10	70.8	21.6	70.9	21.6	40.3	41.7
01/16/10	70.5	21.4	70.6	21.4	39.7	41.1
01/17/10	70.6	21.4	70.7	21.5	38.7	40.0
01/18/10	70.5	21.4	70.6	21.4	38.1	39.6
01/19/10	70.6	21.4	70.7	21.5	37.8	39.2
01/20/10	70.5	21.4	70.6	21.4	38.7	40.1
01/21/10	70.6	21.4	70.7	21.5	39.8	41.1
01/22/10	70.5	21.4	70.6	21.4	41.7	43.1
01/23/10	70.4	21.3	70.5	21.4	42.0	43.3

	PRIMARY TEMP		SECONDARY TEMP		PRIMARY HUM	SECONDARY HUM
DATE	MEAN (°F)	MEAN (°C)	MEAN (°F)	MEAN (°C)	MEAN (%RH)	MEAN (%RH)
01/24/10	70.3	21.3	70.4	21.3	41.3	42.6
01/25/10	70.5	21.4	70.6	21.4	38.5	39.9
01/26/10	70.8	21.6	70.9	21.6	39.9	41.3
01/27/10	70.5	21.4	70.7	21.5	41.2	42.6
01/28/10	70.7	21.5	70.8	21.6	39.0	40.5
01/29/10	70.7	21.5	70.8	21.6	38.8	40.2
01/30/10	70.7	21.5	70.9	21.6	41.0	42.4
01/31/10	70.3	21.3	70.4	21.3	40.4	41.8
02/01/10	70.7	21.5	70.7	21.5	40.8	42.1

SUMMARY OF DAILY MEANS	MEAN	MIN	MAX
PRIMARY TEMP °F:	70.5	70.1	70.9
PRIMARY TEMP °C:	21.4	21.2	21.6
SECONDARY TEMP °F:	70.6	70.3	71.0
SECONDARY TEMP °C:	21.4	21.3	21.7
PRIMARY HUM %RH:	40.2	37.8	42.4
SECONDARY HUM %RH:	41.6	39.2	43.8
N DAYS	28		

B ROOM 112 SUMMARY OF HOURLY VALUES

	PRIMARY TEMP				SECONDARY TEMP				PRIMARY HUM		SECONDARY HUM	
MEAN	70.5	°F	21.4	°C	70.6	°F	21.4	°C	40.2	%RH	41.6	%RH
MIN	67.7	°F	19.8	°C	67.8	°F	19.9	°C	15.7	%RH	16.9	%RH
MAX	74.1	°F	23.4	°C	74.4	°F	23.6	°C	59.3	%RH	57.4	%RH
SD	1.91		1.06		1.94		1.08		3.69		3.51	
SE	0.07		0.04		0.08		0.04		0.14		0.14	
N SAMPLES	656				656				656		656	
FIRST DAY	01/05/10											
LAST DAY	02/01/10											
N DAYS	28											

STUDY 639061 SUMMARY OF HOURLY VALUES

	PRIMARY TEMP				SECONDARY TEMP				PRIMARY HUM		SECONDARY HUM	
MEAN	70.5	°F	21.4	°C	70.6	°F	21.4	°C	40.2	%RH	41.6	%RH
MIN	67.7	°F	19.8	°C	67.8	°F	19.9	°C	15.7	%RH	16.9	%RH
MAX	74.1	°F	23.4	°C	74.4	°F	23.6	°C	59.3	%RH	57.4	%RH
SD	1.91		1.06		1.94		1.08		3.69		3.51	
SE	0.07		0.04		0.08		0.04		0.14		0.14	
N SAMPLES	656				656				656		656	
FIRST DAY	01/05/10											
LAST DAY	02/01/10											
N DAYS	28											

APPENDIX 5 Clinical Pathology Methods, Procedures, and References

CLINICAL PATHOLOGY METHODS, PROCEDURES, AND REFERENCES

Hematology - Manual Methods

White Cell Differential - Manual method of counting 100 white cells stained with Wright Giemsa and entered on-line into the data files.

Reticulocyte Count - Manual method of counting the reticulocytes present in 1000 red blood cells stained with New Methylene Blue and entered on-line into the data files.

Red Blood Cell Morphology - Manual method of evaluating red blood cells on a Wright Giemsa-stained slide and entered on-line into the data files.

Platelet Estimate- Manual method of evaluating platelets on a Wright Giemsa-stained slide. Platelet estimation is evaluated and entered on-line into the data files as decreased, adequate, or increased. Platelet clumps present on the slide will be reported as part of the RBC morphology.

Hematology-Bayer Advia® 120-Siemens Healthcare Diagnostics/(Formerly: Bayer Advia®120)

WBC Count - The whole blood sample is mixed with ADVIA® 120 BASO reagent that contains acid and surfactant. The red cells are hemolyzed, and the white blood cells are then analyzed using two angle laser light scatter signals. Default unit: x 10^3 cells/↘L

RBC / Platelet Count - Both red blood cells and platelets are analyzed by a single optical cytometer after appropriate dilution of the blood sample with ADVIA® 120 RBC/PLT reagent. The red blood cells are isovolumetrically sphered and lightly fixed with glutaraldehyde to preserve the spherical shape. Red cells and platelets are counted from the signals from a common detector with 2 different gain settings. Default unit RBC: x 10^6cells/↘L. Default unit PLT: x 10^3 cells/↘L

HGB - Hemoglobin: The hemoglobin method is a modification of the manual cyanmethemoglobin method developed by the International Committee for standardization in Hematology (ICSH). Default unit: g/dL.

HCT – Hematocrit: The percentage of blood volume that is occupied by red blood cells. Also referred to as the packed red cell volume. On the ADVIA® 120 Hematology System this parameter is derived from the measured red cell volume (MCV) and the red cell count (RBC). Default unit: %.

MCH - Mean Corpuscular Hemoglobin: the average weight of hemoglobin in the red blood cells, calculated from the RBC and Hgb measurements. Default unit: pg.

MCHC - Mean Corpuscular Hemoglobin Concentration: the average concentration of hemoglobin in the red blood cells. This parameter is computed from the measured hemoglobin and the computed hematocrit. Default unit: g/dL.

MCV - Mean Corpuscular Volume: the average volume of the red blood cells. Default unit: fL

HDW - Hemoglobin concentration distribution width. This parameter is derived from direct flow cytometric measurements of red cell hemoglobin concentration, and is increased in conditions of red cell anisochromasia. Default unit: g/dL.

RDW - Red Cell Distribution Width: the CV of the RBC volume histogram, calculated from the RBC volume SD and the MCV. Default unit: %.

White blood cell differential - The ADVIA® 120 Hematology System White Blood Cell Differential (WBC DIFF) methods, consists of both the Peroxidase method and the Basophil/Lobularity method. The ADVIA® 120 Hematology System performs a six-part differential that consists of basophils, eosinophils, large unstained cells, lymphocytes, monocytes, and neutrophils. The white blood cell differential count is reported in percent and the actual number of each type of cell per microliter of blood.

Reticulocyte - This method uses a nucleic acid dye (oxazine 750) to stain cellular RNA.
The ADVIA® 120 autoRETIC reagent isovolumetrically spheres the erythroid cells and stains cellular RNA. Low-angle laser light scatter, high-angle laser light scatter, and absorption characteristics of all cells are counted and measured. The absorption data are used to classify each cell as a reticulocyte or mature red blood cell based on its RNA content. The reticulocyte is reported in percent and actual number x 10^9cells/Liter = thous/µl.

References:

ADVIA® 120 Hematology System Operator's Guide: Copyright© 1997, 1998. Siemens Healthcare Diagnostics/(Formerly: Bayer Corporation Diagnostics Division).

APPENDIX 6 Pathology Report (WIL Research Laboratories, LLC)

AvHPPD-03

AvHPPD-03: Single-Dose Oral (Gavage) Toxicity Study in Mice with a 2-Day or 14-Day Observation Period

Pathology Report

AUTHOR(S): [redacted]

PERFORMING LABORATORY: WIL Research Laboratories, LLC
1407 George Road
Ashland, OH 44805-8946 USA

LABORATORY PROJECT ID: Report Number: WIL-639061
Study Number: WIL-639061
Task Number: T007563-08

SPONSOR(S): Syngenta Crop Protection, LLC*
410 Swing Road
Greensboro, NC 27409 USA

*Formerly Syngenta Crop Protection, Inc.

KEY STUDY PERSONNEL AND REPORT APPROVAL

Report Submitted By:

[redacted] 6 Feb 2012

Date

Study Pathologist

Report Reviewed By:

[redacted] 8 Feb 2012

Date

Reviewing Pathologist

TABLE OF CONTENTS

KEY STUDY PERSONNEL AND REPORT APPROVAL **2**
TABLE OF CONTENTS **3**
1.0 INTRODUCTION **4**
2.0 STUDY DESIGN **4**
3.0 METHODS **4**
3.1 Ante Mortem Investigations....4
3.1.1 Clinical Pathology - Hematology....4
3.2 *Post Mortem* Investigations....5
3.2.1 Macroscopic Examination....5
3.2.2 Microscopic Examination....6
3.3 Data Interpretation....7
4.0 RESULTS **7**
4.1 Survival....7
4.2 Clinical Pathology - Hematology....7
4.3 Macroscopic Examination....7
4.4 Histologic Changes....8
5.0 CONCLUSIONS **8**

1.0 INTRODUCTION

The objective of this study was to evaluate the potential toxicity of the p-hydroxyphenylpyruvate dioxygenase protein (AvHPPD-03) and to establish a no-observable-adverse-effect-level (NOAEL) for AvHPPD-03 when administered as a single dose orally by gavage to mice, followed by a 2-day and 14-day observation period to assess the reversibility, persistence, or delayed occurrence of any toxic effects.

2.0 STUDY DESIGN

Male and female Crl:CD-1 (ICR) mice, approximately 9-10 weeks of age, were administered vehicle or AvHPPD-03 formulations once by oral gavage as indicated in the following table. The dosage volume was 20 mL/kg for all groups.

Group Number	Treatment	Dose Level (mg/kg)	Number of Animals[a] Males	Females
1	Vehicle [b]	0	10	10
2	AvHPPD-03	500	10	10
3	AvHPPD-03	1500	10	10
4	AvHPPD-03	2000	10	10

[a] - 5 animals/sex/group were euthanized following a minimum of 48 hours after dose administration (interim necropsy, study day 2). The remaining animals were euthanized following a 14-day observation period after dose administration (primary necropsy, study day 14).

[b] - The vehicle was deionized water.

3.0 METHODS

3.1 *Ante Mortem* Investigations

3.1.1 Clinical Pathology - Hematology

Hematology parameters were evaluated on all animals just prior to the scheduled necropsies for those animals scheduled for necropsy. Blood was collected via the retro-orbital sinus of animals anesthetized by inhalation of isoflurane. The anticoagulant was potassium EDTA.

The following parameters were evaluated.

Total leukocyte count (WBC)
Erythrocyte count (RBC)
Hemoglobin (HGB)
Hematocrit (HCT)
Mean corpuscular volume (MCV)
Mean corpuscular hemoglobin (MCH)
Mean corpuscular hemoglobin concentration (MCHC)
Platelet count (Platelet)
Reticulocyte count
Percent (Retic)
Absolute (Retic Absolute)
Red cell distribution width (RDW)
Hemoglobin distribution width (HDW)
Differential leukocyte count - Percent and absolute
-Neutrophil (NEU)
-Lymphocyte (LYMPH)
-Monocyte (MONO)
-Eosinophil (EOS)
-Basophil (BASO)
-Large unstained cell (LUC)
Platelet estimate [a]
Red cell morphology (RBC Morphology) [a]

( ) - Designates abbreviations used in data tables
[a] - Presented on individual tables if a manual differential was performed, and the manual data were accepted and reported instead of the automated differential data

3.2 *Post Mortem* Investigations

3.2.1 Macroscopic Examination

Complete postmortem examinations were performed on all animals at the scheduled necropsies. Animals were euthanized by carbon dioxide inhalation and exsanguinated. At the time of necropsy, the following tissues and organs were collected and placed in 10% neutral-buffered formalin fixative unless otherwise noted:

Adrenal glands (2)
Aorta
Bone (with marrow)
  Femur with joint
  Sternum
Bone marrow smear [a]
Brain
  Cerebrum (2 levels)
  Cerebellum with pons/medulla
Cervix
Epididymides (2) [b]
Eyes with optic nerves (2) [c]
Gallbladder
Gastrointestinal tract
  Esophagus*
  Stomach*
  Duodenum*
  Jejunum*
  Ileum*
  Cecum*
  Colon*
  Rectum*
Heart
Kidneys (2)*
Liver*
Lungs (fixed by inflation with fixative)
Lymph nodes
  Axillary (2)
  Mandibular*
  Mesenteric*
Ovaries (2) with oviducts [d]
Pancreas
Peripheral nerve (sciatic)
Peyer's patches*
Pituitary
Prostate
Salivary glands [mandibular (2)]
Seminal vesicles (2)
Skeletal muscle (rectus femoris)
Skin with mammary gland[e]
Spinal cord (cervical, thoracic, lumbar)
Spleen*
Testes (2) [b]
Thymus*
Thyroids (2) with parathyroids [d]
Trachea
Urinary bladder
Uterus
Vagina
Gross lesions (when possible)*

[a] - Bone marrow smears were not placed in formalin, slides were not examined.
[b] - Fixed in Bouin's solution
[c] - Fixed in Davidson's solution
[d] - Oviducts and parathyroids were examined microscopically when in the plane of section and in all cases where a gross lesion was present.
[e] - For females; a corresponding section of skin was taken from the same anatomical area for males.
* - Tissues were processed for histopathological examination from all animals at the scheduled necropsies.

3.2.2 Microscopic Examination

Microscopic examination of routinely prepared hematoxylin-eosin stained paraffin sections was performed for all animals at the scheduled interim and primary necropsies on selected tissues [liver, kidneys, gastrointestinal tract (esophagus, stomach, duodenum, jejunum, Peyer's patches, ileum, cecum, colon and rectum), mesenteric and mandibular lymph nodes, spleen, thymus and all gross lesions (when possible)] as identified by asterisks in Section 3.2.1. Stained histologic sections were examined by light microscopy and

observations were entered in the WIL Toxicology Data Management System (WTDMS™) by the pathologist. All gross necropsy observations were addressed. Histologic sections were of adequate size and quality for detailed evaluation, and the number of tissues examined from each treatment group was sufficient to allow detection of test substance-related histologic alterations. Histopathologic lesions were classified using standard published terminology to the extent possible. The WTDMS™ histopathology tables contain all of the recorded data and serve as the basis for this narrative report.

3.3 Data Interpretation

In the discussion of clinical pathology parameters, values derived from the control group animals at all time points evaluated were considered as concurrent control values for purposes of constructing a 'normal' range for the present study. In addition, historical control values for this laboratory were consulted to refine data interpretation. Unless otherwise stated in this report, the 'normal' historical control range was represented by values within the WIL historical control reference range (the central 95% values).

4.0 RESULTS

4.1 Survival

All mice survived until the scheduled necropsies.

4.2 Clinical Pathology - Hematology

For the presentation of clinical pathology results in this report, the terms "higher" or "lower" refer to comparisons between test substance-treated groups versus the concurrent control group.

There were no AvHPPD-03-related alterations in hematology parameters. At study day 14, there were statistically significantly lower mean hemoglobin values for the 1500 and 2000 mg/kg group females and lower mean hematocrit values for the 500, 1500, and 2000 mg/kg group females. The values were within the WIL historical control reference range (version 2.9) and were not considered AvHPPD-03-related. Although the magnitude of change from the control group was low, the changes were statistically significant because mean control group values for these parameters were on the high end of the WIL historical control reference range (version 2.9). A higher mean red blood cell count and lower mean corpuscular hemoglobin value at study day 14 in the 500 mg/kg group males were statistically significantly different from the control group but occurred without a dose relationship, and hence, were not considered AvHPPD-03-related.

4.3 Macroscopic Examination

There were no test substance-related gross findings at the scheduled necropsies. All macroscopic findings noted were considered to be spontaneous and/or incidental in nature and unrelated to test article administration.

4.4 Histologic Changes

There were no AvHPPD-03-related histologic changes. All histologic changes were considered to be incidental findings or related to some aspect of experimental manipulation other than administration of AvHPPD-03. There was no AvHPPD-03-related alteration in the prevalence, severity, or histologic character of those incidental tissue alterations.

5.0 CONCLUSIONS

Administration of a single oral (gavage) dose of AvHPPD-03 at 0, 500, 1500, or 2000 mg/kg to 9-10 week-old male and female Crl:CD-1 (ICR) mice (10/sex/group) resulted in no hematologic, macroscopic, or histologic AvHPPD-03-related changes when 5 animals/sex/group were examined at either 2 days or 14 days post-dosing. All mice survived until the scheduled necropsies. The no-observable-adverse-effect-level (NOAEL) in this study was 2000 mg/kg.

AvHPPD-03

AvHPPD-03: Single-Dose Oral (Gavage) Toxicity Study in Mice with a 2-Day or 14-Day Observation Period

Individual Animal Data

Volume 1 of 1

DATA REQUIREMENT(S): European Community Guidelines for the Assessment of Additives in Feeding Stuffs
US FDA Redbook 2000
US EPA Health Effects Test Guidelines
US EPA Microbial Pesticide Test Guidelines

AUTHOR(S): [redacted]

STUDY COMPLETION DATE: 8 March 2012

PERFORMING LABORATORY: WIL Research Laboratories, LLC
1407 George Road
Ashland, OH 44805-8946 USA

LABORATORY PROJECT ID: Report Number: WIL-639061
Study Number: WIL-639061
Task Number: T007563-08

SPONSOR(S): Syngenta Crop Protection, Inc.*
410 Swing Road
Greensboro, NC 27419-8300 USA

* = Formerly Syngenta Crop Protection, Inc.

APPENDIX 7 Individual Animal Data

TABLE I1

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL SURVIVAL AND DISPOSITION

SPONSOR NO.:T007563-08

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH	DAYS ON STUDY
8660	M	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8662	M	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8668	M	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8672	M	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8680	M	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8684	M	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8693	M	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8696	M	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8697	M	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8704	M	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8664	M	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8670	M	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8674	M	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8675	M	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8677	M	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8682	M	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8686	M	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8688	M	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8692	M	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8702	M	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8659	M	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8661	M	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8665	M	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8671	M	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8676	M	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8681	M	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8687	M	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8691	M	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (9)

TABLE I1

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYGNENTA INDIVIDUAL SURVIVAL AND DISPOSITION

SPONSOR NO.:T007563-08

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH	DAYS ON STUDY
8694	M	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8699	M	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8663	M	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8667	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8669	M	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8673	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8679	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8683	M	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8690	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8695	M	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8701	M	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8703	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (9)

TABLE I1

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL SURVIVAL AND DISPOSITION

SPONSOR NO.:T007563-08

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH	DAYS ON STUDY
8712	F	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8713	F	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8715	F	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8716	F	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8719	F	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8722	F	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8728	F	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8733	F	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8748	F	0 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8749	F	0 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8708	F	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8717	F	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8726	F	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8729	F	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8730	F	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8735	F	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8737	F	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8738	F	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8745	F	500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8747	F	500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8707	F	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8710	F	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8714	F	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8718	F	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8720	F	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8721	F	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8724	F	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8727	F	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (9)

TABLE I1

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYGNENTA INDIVIDUAL SURVIVAL AND DISPOSITION

SPONSOR NO.:T007563-08

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH	DAYS ON STUDY
8732	F	1500 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8750	F	1500 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8706	F	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8725	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8734	F	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8736	F	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8739	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8740	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8741	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8742	F	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2
8744	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	01-FEB-10	14
8746	F	2000 MG/KG	SCHEDULED EUTHANASIA	9	20-JAN-10	2

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (9)

PDEADv4.06
03/12/2010
R:03/07/2012

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8660	M	0 MG/KG	NORMAL	2	8:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8660	M	0 MG/KG	DISPOSITION	2	12:34	P	INTERIM NECROPSY (DAY 2)
8660	M	0 MG/KG	BODY/INTEG II	0	7:05	P	SCABBING UROGENITAL AREA
8662	M	0 MG/KG	NORMAL	0	7:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8662	M	0 MG/KG	DISPOSITION	2	12:36	P	INTERIM NECROPSY (DAY 2)
8668	M	0 MG/KG	NORMAL	0	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8668	M	0 MG/KG	DISPOSITION	14	13:53	P	PRIMARY NECROPSY (DAY 14)
8672	M	0 MG/KG	DISPOSITION	14	13:53	P	PRIMARY NECROPSY (DAY 14)
8672	M	0 MG/KG	EYES/EARS/NOSE	0	7:07	P	ABNORMAL PUPIL POSITION LEFT EYE
				7	12:28	P	ABNORMAL PUPIL POSITION LEFT EYE
				14	9:05	P	ABNORMAL PUPIL POSITION LEFT EYE
8680	M	0 MG/KG	NORMAL	0	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8680	M	0 MG/KG	DISPOSITION	2	12:37	P	INTERIM NECROPSY (DAY 2)
8684	M	0 MG/KG	NORMAL	0	7:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8684	M	0 MG/KG	DISPOSITION	2	12:38	P	INTERIM NECROPSY (DAY 2)
8693	M	0 MG/KG	NORMAL	0	7:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8693	M	0 MG/KG	DISPOSITION	14	13:53	P	PRIMARY NECROPSY (DAY 14)
8696	M	0 MG/KG	NORMAL	0	7:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8696	M	0 MG/KG	DISPOSITION	14	13:54	P	PRIMARY NECROPSY (DAY 14)
8697	M	0 MG/KG	DISPOSITION	14	13:54	P	PRIMARY NECROPSY (DAY 14)

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8697	M	0 MG/KG	EYES/EARS/NOSE	0	7:09	P	ABNORMAL PUPIL POSITION RIGHT EYE
				7	12:30	P	ABNORMAL PUPIL POSITION RIGHT EYE
				14	9:06	P	ABNORMAL PUPIL POSITION RIGHT EYE
8704	M	0 MG/KG	NORMAL	0	7:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8704	M	0 MG/KG	DISPOSITION	2	12:39	P	INTERIM NECROPSY (DAY 2)
8664	M	500 MG/KG	NORMAL	0	7:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8664	M	500 MG/KG	DISPOSITION	2	12:35	P	INTERIM NECROPSY (DAY 2)
8670	M	500 MG/KG	DISPOSITION	14	13:55	P	PRIMARY NECROPSY (DAY 14)
8670	M	500 MG/KG	EYES/EARS/NOSE	0	7:13	P	ABNORMAL PUPIL POSITION RIGHT EYE
				7	12:34	P	ABNORMAL PUPIL POSITION RIGHT EYE
				14	9:10	P	ABNORMAL PUPIL POSITION RIGHT EYE
8674	M	500 MG/KG	NORMAL	0	7:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8674	M	500 MG/KG	DISPOSITION	2	12:36	P	INTERIM NECROPSY (DAY 2)
8675	M	500 MG/KG	NORMAL	0	7:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8675	M	500 MG/KG	DISPOSITION	2	12:37	P	INTERIM NECROPSY (DAY 2)
8677	M	500 MG/KG	DISPOSITION	14	13:55	P	PRIMARY NECROPSY (DAY 14)
8677	M	500 MG/KG	EYES/EARS/NOSE	0	7:14	P	ABNORMAL PUPIL POSITION LEFT EYE
				7	12:35	P	ABNORMAL PUPIL POSITION LEFT EYE
				14	9:10	P	ABNORMAL PUPIL POSITION LEFT EYE
8682	M	500 MG/KG	NORMAL	0	7:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8682	M	500 MG/KG	DISPOSITION	14	13:55	P	PRIMARY NECROPSY (DAY 14)
8686	M	500 MG/KG	NORMAL	0	7:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:36	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8686	M	500 MG/KG	NORMAL	14	9:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8686	M	500 MG/KG	DISPOSITION	14	13:55	P	PRIMARY NECROPSY (DAY 14)
8688	M	500 MG/KG	NORMAL	0	7:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8688	M	500 MG/KG	DISPOSITION	2	12:38	P	INTERIM NECROPSY (DAY 2)
8692	M	500 MG/KG	NORMAL	0	7:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:36	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8692	M	500 MG/KG	DISPOSITION	14	13:55	P	PRIMARY NECROPSY (DAY 14)
8702	M	500 MG/KG	NORMAL	2	8:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8702	M	500 MG/KG	DISPOSITION	2	12:39	P	INTERIM NECROPSY (DAY 2)
8702	M	500 MG/KG	SPECIAL II	0	7:16	P	TAIL BROKEN
8659	M	1500 MG/KG	NORMAL	0	7:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8659	M	1500 MG/KG	DISPOSITION	2	12:35	P	INTERIM NECROPSY (DAY 2)
8661	M	1500 MG/KG	NORMAL	0	7:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8661	M	1500 MG/KG	DISPOSITION	14	13:56	P	PRIMARY NECROPSY (DAY 14)
8665	M	1500 MG/KG	NORMAL	0	7:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8665	M	1500 MG/KG	DISPOSITION	2	12:36	P	INTERIM NECROPSY (DAY 2)
8671	M	1500 MG/KG	NORMAL	0	7:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8671	M	1500 MG/KG	DISPOSITION	2	12:37	P	INTERIM NECROPSY (DAY 2)
8676	M	1500 MG/KG	NORMAL	0	7:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8676	M	1500 MG/KG	DISPOSITION	14	13:56	P	PRIMARY NECROPSY (DAY 14)

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8681	M	1500 MG/KG	NORMAL	0	7:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8681	M	1500 MG/KG	DISPOSITION	14	13:56	P	PRIMARY NECROPSY (DAY 14)
8687	M	1500 MG/KG	NORMAL	0	7:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8687	M	1500 MG/KG	DISPOSITION	14	13:56	P	PRIMARY NECROPSY (DAY 14)
8691	M	1500 MG/KG	NORMAL	0	7:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8691	M	1500 MG/KG	DISPOSITION	2	12:38	P	INTERIM NECROPSY (DAY 2)
8694	M	1500 MG/KG	NORMAL	0	7:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8694	M	1500 MG/KG	DISPOSITION	14	13:57	P	PRIMARY NECROPSY (DAY 14)
8699	M	1500 MG/KG	NORMAL	0	7:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8699	M	1500 MG/KG	DISPOSITION	2	12:40	P	INTERIM NECROPSY (DAY 2)
8663	M	2000 MG/KG	NORMAL	0	7:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8663	M	2000 MG/KG	DISPOSITION	2	12:35	P	INTERIM NECROPSY (DAY 2)
8667	M	2000 MG/KG	NORMAL	0	7:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8667	M	2000 MG/KG	DISPOSITION	14	13:57	P	PRIMARY NECROPSY (DAY 14)
8669	M	2000 MG/KG	NORMAL	0	7:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8669	M	2000 MG/KG	DISPOSITION	2	12:36	P	INTERIM NECROPSY (DAY 2)
8673	M	2000 MG/KG	NORMAL	0	7:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8673	M	2000 MG/KG	NORMAL	7	12:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8673	M	2000 MG/KG	DISPOSITION	14	13:58	P	PRIMARY NECROPSY (DAY 14)
8673	M	2000 MG/KG	BODY/INTEG III	14	9:18	P	DRIED YELLOW MATERIAL UROGENITAL AREA
8679	M	2000 MG/KG	NORMAL	0	7:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8679	M	2000 MG/KG	DISPOSITION	14	13:58	P	PRIMARY NECROPSY (DAY 14)
8683	M	2000 MG/KG	NORMAL	0	7:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8683	M	2000 MG/KG	DISPOSITION	2	12:38	P	INTERIM NECROPSY (DAY 2)
8690	M	2000 MG/KG	NORMAL	0	7:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8690	M	2000 MG/KG	DISPOSITION	14	13:58	P	PRIMARY NECROPSY (DAY 14)
8695	M	2000 MG/KG	NORMAL	0	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8695	M	2000 MG/KG	DISPOSITION	2	12:39	P	INTERIM NECROPSY (DAY 2)
8701	M	2000 MG/KG	NORMAL	0	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8701	M	2000 MG/KG	DISPOSITION	2	12:40	P	INTERIM NECROPSY (DAY 2)
8703	M	2000 MG/KG	NORMAL	0	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8703	M	2000 MG/KG	DISPOSITION	14	13:58	P	PRIMARY NECROPSY (DAY 14)
8703	M	2000 MG/KG	BODY/INTEG III	7	12:49	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				14	9:19	P	WET YELLOW MATERIAL UROGENITAL AREA
8712	F	0 MG/KG	NORMAL	0	7:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8712	F	0 MG/KG	DISPOSITION	2	12:34	P	INTERIM NECROPSY (DAY 2)
8713	F	0 MG/KG	NORMAL	0	7:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8713	F	0 MG/KG	DISPOSITION	2	12:36	P	INTERIM NECROPSY (DAY 2)
8715	F	0 MG/KG	NORMAL	0	7:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8715	F	0 MG/KG	DISPOSITION	2	12:37	P	INTERIM NECROPSY (DAY 2)
8716	F	0 MG/KG	NORMAL	0	7:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8716	F	0 MG/KG	DISPOSITION	14	13:54	P	PRIMARY NECROPSY (DAY 14)
8719	F	0 MG/KG	NORMAL	0	7:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8719	F	0 MG/KG	DISPOSITION	14	13:54	P	PRIMARY NECROPSY (DAY 14)
8722	F	0 MG/KG	NORMAL	0	7:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8722	F	0 MG/KG	DISPOSITION	14	13:54	P	PRIMARY NECROPSY (DAY 14)
8728	F	0 MG/KG	NORMAL	0	7:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8728	F	0 MG/KG	DISPOSITION	14	13:54	P	PRIMARY NECROPSY (DAY 14)
8733	F	0 MG/KG	NORMAL	0	7:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8733	F	0 MG/KG	DISPOSITION	2	12:38	P	INTERIM NECROPSY (DAY 2)
8748	F	0 MG/KG	NORMAL	0	7:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8748	F	0 MG/KG	DISPOSITION	14	13:55	P	PRIMARY NECROPSY (DAY 14)
8749	F	0 MG/KG	NORMAL	0	7:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8749	F	0 MG/KG	DISPOSITION	2	12:39	P	INTERIM NECROPSY (DAY 2)
8708	F	500 MG/KG	NORMAL	0	7:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8708	F	500 MG/KG	DISPOSITION	2	12:35	P	INTERIM NECROPSY (DAY 2)
8717	F	500 MG/KG	NORMAL	0	7:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8717	F	500 MG/KG	DISPOSITION	2	12:36	P	INTERIM NECROPSY (DAY 2)
8726	F	500 MG/KG	NORMAL	0	7:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:37	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8726	F	500 MG/KG	DISPOSITION	14	13:55	P	PRIMARY NECROPSY (DAY 14)
8729	F	500 MG/KG	NORMAL	0	7:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:37	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8729	F	500 MG/KG	DISPOSITION	14	13:55	P	PRIMARY NECROPSY (DAY 14)
8730	F	500 MG/KG	NORMAL	0	7:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8730	F	500 MG/KG	DISPOSITION	2	12:37	P	INTERIM NECROPSY (DAY 2)
8735	F	500 MG/KG	NORMAL	0	7:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8735	F	500 MG/KG	DISPOSITION	2	12:38	P	INTERIM NECROPSY (DAY 2)
8737	F	500 MG/KG	NORMAL	0	7:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8737	F	500 MG/KG	DISPOSITION	14	13:56	P	PRIMARY NECROPSY (DAY 14)
8738	F	500 MG/KG	NORMAL	0	7:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8738	F	500 MG/KG	DISPOSITION	14	13:56	P	PRIMARY NECROPSY (DAY 14)

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8745	F	500 MG/KG	NORMAL	0	7:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8745	F	500 MG/KG	DISPOSITION	14	13:56	P	PRIMARY NECROPSY (DAY 14)
8747	F	500 MG/KG	NORMAL	0	7:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8747	F	500 MG/KG	DISPOSITION	2	12:39	P	INTERIM NECROPSY (DAY 2)
8707	F	1500 MG/KG	NORMAL	0	7:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8707	F	1500 MG/KG	DISPOSITION	2	12:35	P	INTERIM NECROPSY (DAY 2)
8710	F	1500 MG/KG	NORMAL	0	7:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8710	F	1500 MG/KG	DISPOSITION	14	13:57	P	PRIMARY NECROPSY (DAY 14)
8714	F	1500 MG/KG	NORMAL	0	7:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8714	F	1500 MG/KG	DISPOSITION	2	12:36	P	INTERIM NECROPSY (DAY 2)
8718	F	1500 MG/KG	NORMAL	0	7:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8718	F	1500 MG/KG	DISPOSITION	2	12:37	P	INTERIM NECROPSY (DAY 2)
8720	F	1500 MG/KG	NORMAL	0	7:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8720	F	1500 MG/KG	DISPOSITION	14	13:57	P	PRIMARY NECROPSY (DAY 14)
8721	F	1500 MG/KG	NORMAL	0	7:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8721	F	1500 MG/KG	DISPOSITION	14	13:57	P	PRIMARY NECROPSY (DAY 14)
8724	F	1500 MG/KG	NORMAL	0	7:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8724	F	1500 MG/KG	NORMAL	14	9:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8724	F	1500 MG/KG	DISPOSITION	14	13:57	P	PRIMARY NECROPSY (DAY 14)
8724	F	1500 MG/KG	EYES/EARS/NOSE	7	12:45	P	ABNORMAL PUPIL POSITION LEFT EYE
8727	F	1500 MG/KG	NORMAL	0	7:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8727	F	1500 MG/KG	DISPOSITION	2	12:39	P	INTERIM NECROPSY (DAY 2)
8732	F	1500 MG/KG	DISPOSITION	14	13:57	P	PRIMARY NECROPSY (DAY 14)
8732	F	1500 MG/KG	EYES/EARS/NOSE	0	7:24	P	ABNORMAL PUPIL POSITION LEFT EYE
				7	12:46	P	ABNORMAL PUPIL POSITION LEFT EYE
				14	9:17	P	ABNORMAL PUPIL POSITION LEFT EYE
8750	F	1500 MG/KG	NORMAL	0	7:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8750	F	1500 MG/KG	DISPOSITION	2	12:40	P	INTERIM NECROPSY (DAY 2)
8706	F	2000 MG/KG	NORMAL	0	7:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8706	F	2000 MG/KG	DISPOSITION	2	12:35	P	INTERIM NECROPSY (DAY 2)
8725	F	2000 MG/KG	NORMAL	0	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8725	F	2000 MG/KG	DISPOSITION	14	13:58	P	PRIMARY NECROPSY (DAY 14)
8734	F	2000 MG/KG	NORMAL	0	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8734	F	2000 MG/KG	DISPOSITION	2	12:37	P	INTERIM NECROPSY (DAY 2)
8736	F	2000 MG/KG	NORMAL	0	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8736	F	2000 MG/KG	DISPOSITION	2	12:38	P	INTERIM NECROPSY (DAY 2)
8739	F	2000 MG/KG	NORMAL	0	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8739	F	2000 MG/KG	DISPOSITION	14	13:58	P	PRIMARY NECROPSY (DAY 14)
8740	F	2000 MG/KG	NORMAL	0	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8740	F	2000 MG/KG	DISPOSITION	14	13:58	P	PRIMARY NECROPSY (DAY 14)
8741	F	2000 MG/KG	NORMAL	0	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8741	F	2000 MG/KG	DISPOSITION	14	13:58	P	PRIMARY NECROPSY (DAY 14)
8742	F	2000 MG/KG	NORMAL	0	7:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8742	F	2000 MG/KG	DISPOSITION	2	12:39	P	INTERIM NECROPSY (DAY 2)
8744	F	2000 MG/KG	NORMAL	0	7:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	12:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	9:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8744	F	2000 MG/KG	DISPOSITION	14	13:59	P	PRIMARY NECROPSY (DAY 14)
8746	F	2000 MG/KG	NORMAL	0	7:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8746	F	2000 MG/KG	DISPOSITION	2	12:40	P	INTERIM NECROPSY (DAY 2)

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.17
03/12/2010

TABLE I3 (AT TIME OF DOSING)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8660	M	0 MG/KG	NORMAL	0	12:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8662	M	0 MG/KG	NORMAL	0	12:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8668	M	0 MG/KG	NORMAL	0	12:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8672	M	0 MG/KG	NORMAL	0	12:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8680	M	0 MG/KG	NORMAL	0	12:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8684	M	0 MG/KG	NORMAL	0	12:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8693	M	0 MG/KG	NORMAL	0	12:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8696	M	0 MG/KG	NORMAL	0	12:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8697	M	0 MG/KG	NORMAL	0	12:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8704	M	0 MG/KG	NORMAL	0	12:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8664	M	500 MG/KG	NORMAL	0	12:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8670	M	500 MG/KG	NORMAL	0	12:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8674	M	500 MG/KG	NORMAL	0	12:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8675	M	500 MG/KG	NORMAL	0	12:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8677	M	500 MG/KG	NORMAL	0	12:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8682	M	500 MG/KG	NORMAL	0	12:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8686	M	500 MG/KG	NORMAL	0	12:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8688	M	500 MG/KG	NORMAL	0	12:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8692	M	500 MG/KG	NORMAL	0	12:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8702	M	500 MG/KG	NORMAL	0	12:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8659	M	1500 MG/KG	NORMAL	0	12:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8661	M	1500 MG/KG	NORMAL	0	12:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8665	M	1500 MG/KG	NORMAL	0	12:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8671	M	1500 MG/KG	NORMAL	0	12:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8676	M	1500 MG/KG	NORMAL	0	12:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8681	M	1500 MG/KG	NORMAL	0	12:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8687	M	1500 MG/KG	NORMAL	0	12:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8691	M	1500 MG/KG	NORMAL	0	12:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8694	M	1500 MG/KG	NORMAL	0	12:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I3 (AT TIME OF DOSING)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8699	M	1500 MG/KG	NORMAL	0	12:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8663	M	2000 MG/KG	NORMAL	0	13:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8667	M	2000 MG/KG	NORMAL	0	13:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8669	M	2000 MG/KG	NORMAL	0	13:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8673	M	2000 MG/KG	NORMAL	0	13:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8679	M	2000 MG/KG	NORMAL	0	13:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8683	M	2000 MG/KG	NORMAL	0	13:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8690	M	2000 MG/KG	NORMAL	0	13:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8695	M	2000 MG/KG	NORMAL	0	13:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8701	M	2000 MG/KG	NORMAL	0	13:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8703	M	2000 MG/KG	NORMAL	0	13:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8712	F	0 MG/KG	NORMAL	0	12:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8713	F	0 MG/KG	NORMAL	0	12:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8715	F	0 MG/KG	NORMAL	0	12:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8716	F	0 MG/KG	NORMAL	0	12:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8719	F	0 MG/KG	NORMAL	0	12:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8722	F	0 MG/KG	NORMAL	0	12:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8728	F	0 MG/KG	NORMAL	0	12:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8733	F	0 MG/KG	NORMAL	0	12:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8748	F	0 MG/KG	NORMAL	0	12:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8749	F	0 MG/KG	NORMAL	0	12:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8708	F	500 MG/KG	NORMAL	0	12:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8717	F	500 MG/KG	NORMAL	0	12:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8726	F	500 MG/KG	NORMAL	0	12:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8729	F	500 MG/KG	NORMAL	0	12:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8730	F	500 MG/KG	NORMAL	0	12:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8735	F	500 MG/KG	NORMAL	0	12:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8737	F	500 MG/KG	NORMAL	0	12:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8738	F	500 MG/KG	NORMAL	0	12:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I3 (AT TIME OF DOSING)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8745	F	500 MG/KG	NORMAL	0	12:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8747	F	500 MG/KG	NORMAL	0	12:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8707	F	1500 MG/KG	NORMAL	0	13:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8710	F	1500 MG/KG	NORMAL	0	13:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8714	F	1500 MG/KG	NORMAL	0	13:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8718	F	1500 MG/KG	NORMAL	0	13:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8720	F	1500 MG/KG	NORMAL	0	13:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8721	F	1500 MG/KG	NORMAL	0	13:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8724	F	1500 MG/KG	NORMAL	0	13:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8727	F	1500 MG/KG	NORMAL	0	13:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8732	F	1500 MG/KG	NORMAL	0	13:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8750	F	1500 MG/KG	NORMAL	0	13:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8706	F	2000 MG/KG	NORMAL	0	13:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8725	F	2000 MG/KG	NORMAL	0	13:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8734	F	2000 MG/KG	NORMAL	0	13:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8736	F	2000 MG/KG	NORMAL	0	13:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8739	F	2000 MG/KG	NORMAL	0	13:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8740	F	2000 MG/KG	NORMAL	0	13:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8741	F	2000 MG/KG	NORMAL	0	13:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8742	F	2000 MG/KG	NORMAL	0	13:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8744	F	2000 MG/KG	NORMAL	0	13:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8746	F	2000 MG/KG	NORMAL	0	13:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.17
03/12/2010

TABLE I4 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8660	M	0 MG/KG	NORMAL	0	13:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8662	M	0 MG/KG	NORMAL	0	13:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8668	M	0 MG/KG	NORMAL	0	13:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8672	M	0 MG/KG	NORMAL	0	13:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8680	M	0 MG/KG	NORMAL	0	13:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8684	M	0 MG/KG	NORMAL	0	13:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8693	M	0 MG/KG	NORMAL	0	13:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8696	M	0 MG/KG	NORMAL	0	13:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8697	M	0 MG/KG	NORMAL	0	13:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8704	M	0 MG/KG	NORMAL	0	13:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8664	M	500 MG/KG	NORMAL	0	13:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8670	M	500 MG/KG	NORMAL	0	13:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8674	M	500 MG/KG	NORMAL	0	14:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8675	M	500 MG/KG	NORMAL	0	14:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8677	M	500 MG/KG	NORMAL	0	14:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I4 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8677	M	500 MG/KG	NORMAL	0	16:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8682	M	500 MG/KG	NORMAL	0	14:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8686	M	500 MG/KG	NORMAL	0	14:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8688	M	500 MG/KG	NORMAL	0	14:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8692	M	500 MG/KG	NORMAL	0	14:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8702	M	500 MG/KG	NORMAL	0	14:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8659	M	1500 MG/KG	NORMAL	0	14:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8661	M	1500 MG/KG	NORMAL	0	14:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8665	M	1500 MG/KG	NORMAL	0	14:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8671	M	1500 MG/KG	NORMAL	0	14:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8676	M	1500 MG/KG	NORMAL	0	14:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8681	M	1500 MG/KG	NORMAL	0	14:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8687	M	1500 MG/KG	NORMAL	0	14:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8691	M	1500 MG/KG	NORMAL	0	14:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8694	M	1500 MG/KG	NORMAL	0	14:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I4 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8699	M	1500 MG/KG	NORMAL	0	14:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8663	M	2000 MG/KG	NORMAL	0	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8667	M	2000 MG/KG	NORMAL	0	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8669	M	2000 MG/KG	NORMAL	0	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8673	M	2000 MG/KG	NORMAL	0	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8679	M	2000 MG/KG	NORMAL	0	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8683	M	2000 MG/KG	NORMAL	0	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8690	M	2000 MG/KG	NORMAL	0	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8695	M	2000 MG/KG	NORMAL	0	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8701	M	2000 MG/KG	NORMAL	0	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8703	M	2000 MG/KG	NORMAL	0	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8712	F	0 MG/KG	NORMAL	0	13:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8713	F	0 MG/KG	NORMAL	0	13:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8715	F	0 MG/KG	NORMAL	0	13:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8716	F	0 MG/KG	NORMAL	0	13:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I4 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8716	F	0 MG/KG	NORMAL	0	16:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8719	F	0 MG/KG	NORMAL	0	13:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8722	F	0 MG/KG	NORMAL	0	13:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8728	F	0 MG/KG	NORMAL	0	13:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8733	F	0 MG/KG	NORMAL	0	13:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8748	F	0 MG/KG	NORMAL	0	13:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8749	F	0 MG/KG	NORMAL	0	13:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8708	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8717	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8726	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8729	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8730	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8735	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8737	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8738	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I4 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8745	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8747	F	500 MG/KG	NORMAL	0	14:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8707	F	1500 MG/KG	NORMAL	0	14:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8710	F	1500 MG/KG	NORMAL	0	14:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8714	F	1500 MG/KG	NORMAL	0	14:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8718	F	1500 MG/KG	NORMAL	0	14:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8720	F	1500 MG/KG	NORMAL	0	14:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8721	F	1500 MG/KG	NORMAL	0	14:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8724	F	1500 MG/KG	NORMAL	0	14:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8727	F	1500 MG/KG	NORMAL	0	14:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8732	F	1500 MG/KG	NORMAL	0	14:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8750	F	1500 MG/KG	NORMAL	0	14:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8706	F	2000 MG/KG	NORMAL	0	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8725	F	2000 MG/KG	NORMAL	0	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8734	F	2000 MG/KG	NORMAL	0	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I4 (DOSING DAY OBSERVATIONS)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8734	F	2000 MG/KG	NORMAL	0	17:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8736	F	2000 MG/KG	NORMAL	0	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8739	F	2000 MG/KG	NORMAL	0	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8740	F	2000 MG/KG	NORMAL	0	14:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8741	F	2000 MG/KG	NORMAL	0	14:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8742	F	2000 MG/KG	NORMAL	0	14:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8744	F	2000 MG/KG	NORMAL	0	14:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8746	F	2000 MG/KG	NORMAL	0	14:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	17:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.17
03/12/2010
R:03/07/2012

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 1

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8660	M	0 MG/KG	NORMAL	1	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8662	M	0 MG/KG	NORMAL	1	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8668	M	0 MG/KG	NORMAL	1	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8672	M	0 MG/KG	NORMAL	1	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8680	M	0 MG/KG	NORMAL	1	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8684	M	0 MG/KG	NORMAL	1	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8693	M	0 MG/KG	NORMAL	1	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 2

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8693	M	0 MG/KG	NORMAL	2	9:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8696	M	0 MG/KG	NORMAL	1	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8697	M	0 MG/KG	NORMAL	1	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 3

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8697	M	0 MG/KG	NORMAL	8	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8704	M	0 MG/KG	NORMAL	1	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8664	M	500 MG/KG	NORMAL	1	9:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8670	M	500 MG/KG	NORMAL	1	9:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8674	M	500 MG/KG	NORMAL	1	9:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8675	M	500 MG/KG	NORMAL	1	9:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8677	M	500 MG/KG	NORMAL	1	9:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 4

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8677	M	500 MG/KG	NORMAL	9	12:38	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8682	M	500 MG/KG	NORMAL	1	9:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:39	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8686	M	500 MG/KG	NORMAL	1	9:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 5

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8688	M	500 MG/KG	NORMAL	1	9:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8692	M	500 MG/KG	NORMAL	1	9:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:40	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8692	M	500 MG/KG	BODY/INTEG III	8	13:25	P	DRIED YELLOW MATERIAL UROGENITAL AREA
8702	M	500 MG/KG	NORMAL	1	9:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8659	M	1500 MG/KG	NORMAL	1	9:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8661	M	1500 MG/KG	NORMAL	1	9:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8665	M	1500 MG/KG	NORMAL	1	9:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8671	M	1500 MG/KG	NORMAL	1	9:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 6

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8676	M	1500 MG/KG	NORMAL	1	9:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8681	M	1500 MG/KG	NORMAL	1	9:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8687	M	1500 MG/KG	NORMAL	1	9:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 7

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8687	M	1500 MG/KG	NORMAL	6	10:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8691	M	1500 MG/KG	NORMAL	1	9:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8694	M	1500 MG/KG	NORMAL	1	9:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8699	M	1500 MG/KG	NORMAL	1	9:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8663	M	2000 MG/KG	NORMAL	1	9:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8667	M	2000 MG/KG	NORMAL	1	9:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 8

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8667	M	2000 MG/KG	NORMAL	9	12:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8669	M	2000 MG/KG	NORMAL	1	9:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8673	M	2000 MG/KG	NORMAL	1	9:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8673	M	2000 MG/KG	BODY/INTEG III	11	10:51	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				13	11:52	P	DRIED YELLOW MATERIAL UROGENITAL AREA
8679	M	2000 MG/KG	NORMAL	1	9:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 9

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8679	M	2000 MG/KG	NORMAL	13	11:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8683	M	2000 MG/KG	NORMAL	1	9:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8690	M	2000 MG/KG	NORMAL	1	9:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8695	M	2000 MG/KG	NORMAL	1	9:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8701	M	2000 MG/KG	NORMAL	1	9:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8703	M	2000 MG/KG	NORMAL	1	9:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8703	M	2000 MG/KG	BODY/INTEG III	5	11:59	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				6	10:59	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				8	13:28	P	WET YELLOW MATERIAL UROGENITAL AREA
				11	10:52	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				13	11:52	P	DRIED YELLOW MATERIAL UROGENITAL AREA
8712	F	0 MG/KG	NORMAL	1	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 10

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8713	F	0 MG/KG	NORMAL	1	9:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8715	F	0 MG/KG	NORMAL	1	9:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8716	F	0 MG/KG	NORMAL	1	9:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8719	F	0 MG/KG	NORMAL	1	9:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8722	F	0 MG/KG	NORMAL	1	9:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 11

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8722	F	0 MG/KG	NORMAL	4	8:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:36	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8728	F	0 MG/KG	NORMAL	1	9:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:37	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8733	F	0 MG/KG	NORMAL	1	9:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8748	F	0 MG/KG	NORMAL	1	9:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:24	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 12

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8748	F	0 MG/KG	NORMAL	9	12:37	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8749	F	0 MG/KG	NORMAL	1	9:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8708	F	500 MG/KG	NORMAL	1	9:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8717	F	500 MG/KG	NORMAL	1	9:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8726	F	500 MG/KG	NORMAL	1	9:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8729	F	500 MG/KG	NORMAL	1	9:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:41	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 13

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8729	F	500 MG/KG	NORMAL	11	10:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8730	F	500 MG/KG	NORMAL	1	9:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8735	F	500 MG/KG	NORMAL	1	9:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8737	F	500 MG/KG	NORMAL	1	9:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8738	F	500 MG/KG	NORMAL	1	9:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 14

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8745	F	500 MG/KG	NORMAL	1	9:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:32	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	8:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8747	F	500 MG/KG	NORMAL	1	9:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8707	F	1500 MG/KG	NORMAL	1	9:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8710	F	1500 MG/KG	NORMAL	1	9:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8714	F	1500 MG/KG	NORMAL	1	9:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8718	F	1500 MG/KG	NORMAL	1	9:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8720	F	1500 MG/KG	NORMAL	1	9:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 15

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8720	F	1500 MG/KG	NORMAL	2	9:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8721	F	1500 MG/KG	NORMAL	1	9:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8724	F	1500 MG/KG	NORMAL	1	9:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:33	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 16

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8724	F	1500 MG/KG	NORMAL	8	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8727	F	1500 MG/KG	NORMAL	1	9:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8732	F	1500 MG/KG	NORMAL	1	9:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8750	F	1500 MG/KG	NORMAL	1	9:55	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8706	F	2000 MG/KG	NORMAL	1	9:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8725	F	2000 MG/KG	NORMAL	1	9:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 17

SPONSOR:SYNGENTA — INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8725	F	2000 MG/KG	NORMAL	10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8734	F	2000 MG/KG	NORMAL	1	9:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8736	F	2000 MG/KG	NORMAL	1	9:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8739	F	2000 MG/KG	NORMAL	1	9:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8740	F	2000 MG/KG	NORMAL	1	9:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE I5 (DAILY OBSERVATIONS - NONDOSING DAYS)

PROJECT NO.:WIL-639061U
A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
PAGE 18

SPONSOR:SYNGENTA
INDIVIDUAL CLINICAL OBSERVATIONS

SPONSOR NO.:T007563-08

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
8740	F	2000 MG/KG	NORMAL	13	11:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8741	F	2000 MG/KG	NORMAL	1	9:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8742	F	2000 MG/KG	NORMAL	1	9:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8744	F	2000 MG/KG	NORMAL	1	9:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	9:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	11:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	10:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	13:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	12:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	14:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	10:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	14:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	11:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
8746	F	2000 MG/KG	NORMAL	1	9:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.17
03/12/2010

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	-10	-4	0	1	2	3	4	5
ANIMAL								
8660	28.2	30.3	30.8	31.3	33.3			
8662	31.4	34.0	33.2	33.0	34.0			
8668	27.3	30.0	29.9	30.2	30.9	32.1	32.1	31.3
8672	29.2	32.0	31.0	31.1	32.4	33.0	32.7	33.1
8680	25.8	26.6	27.9	28.5	29.6			
8684	27.2	28.2	29.6	28.5	30.3			
8693	29.2	32.1	32.6	32.8	33.7	33.6	33.6	33.7
8696	27.9	28.9	28.8	29.2	29.9	30.0	29.7	29.2
8697	29.7	31.2	33.4	34.0	35.1	35.5	35.8	35.7
8704	29.8	33.5	34.3	34.2	36.3			
MEAN	28.6	30.7	31.2	31.3	32.6	32.8	32.8	32.6
S.D.	1.61	2.35	2.15	2.16	2.31	2.02	2.22	2.47
S.E.	0.51	0.74	0.68	0.68	0.73	0.90	0.99	1.10
N	10	10	10	10	10	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	-10	-4	0	1	2	3	4	5
ANIMAL								
8664	29.3	29.9	29.4	30.4	31.5			
8670	26.1	27.0	26.4	27.0	27.6	28.0	27.8	27.3
8674	25.7	28.7	28.6	29.8	31.0			
8675	28.7	32.3	29.5	29.5	29.8			
8677	26.8	28.1	27.8	28.2	29.0	30.2	29.5	29.2
8682	29.1	30.3	30.8	30.9	31.5	31.8	31.6	31.1
8686	29.8	31.2	31.3	31.9	32.8	34.5	34.1	33.2
8688	30.3	31.5	31.1	31.1	32.3			
8692	31.3	33.7	33.6	34.5	34.7	35.6	35.1	34.9
8702	28.8	33.2	30.9	31.3	32.7			
MEAN	28.6	30.6	29.9	30.5	31.3	32.0	31.6	31.1
S.D.	1.84	2.21	2.05	2.06	2.06	3.10	3.06	3.04
S.E.	0.58	0.70	0.65	0.65	0.65	1.39	1.37	1.36
N	10	10	10	10	10	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	-10	-4	0	1	2	3	4	5
ANIMAL								
8659	28.0	30.0	29.2	28.7	29.1			
8661	28.2	31.8	29.8	30.8	31.1	31.7	31.5	31.3
8665	26.9	29.7	30.0	29.6	30.4			
8671	30.5	32.3	32.4	32.9	33.7			
8676	30.8	34.8	34.7	35.7	36.2	37.2	37.5	37.0
8681	27.6	28.0	28.4	28.5	29.0	29.0	29.3	29.2
8687	25.4	26.8	26.9	27.0	27.2	28.3	28.4	28.2
8691	29.7	31.0	32.3	33.0	34.2			
8694	30.7	33.1	33.2	32.7	33.4	33.8	34.1	33.2
8699	28.1	30.3	30.5	31.4	32.3			
MEAN	28.6	30.8	30.7	31.0	31.7	32.0	32.2	31.8
S.D.	1.79	2.37	2.38	2.63	2.79	3.64	3.71	3.50
S.E.	0.57	0.75	0.75	0.83	0.88	1.63	1.66	1.56
N	10	10	10	10	10	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	-10	-4	0	1	2	3	4	5
ANIMAL								
8663	26.5	29.9	28.1	28.6	30.8			
8667	25.1	27.6	28.4	29.2	30.5	30.6	30.1	29.9
8669	29.1	34.6	31.1	31.1	32.1			
8673	30.8	31.8	31.8	31.9	33.5	33.4	33.6	33.3
8679	28.6	32.8	31.6	32.0	33.5	34.6	33.8	34.3
8683	27.2	30.6	31.3	31.1	33.0			
8690	28.1	33.3	31.4	31.7	32.8	33.0	33.3	33.6
8695	29.1	29.9	31.7	33.1	34.1			
8701	27.2	28.2	29.8	30.3	31.5			
8703	25.5	30.8	30.8	31.1	33.1	33.2	33.3	33.2
MEAN	27.7	31.0	30.6	31.0	32.5	33.0	32.8	32.9
S.D.	1.76	2.21	1.37	1.34	1.22	1.46	1.54	1.71
S.E.	0.56	0.70	0.43	0.42	0.38	0.65	0.69	0.76
N	10	10	10	10	10	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	6	7	8	9	10	11	12	13
ANIMAL								
8668	31.6	31.2	32.1	31.0	31.3	31.5	30.8	31.6
8672	33.0	32.4	32.6	32.1	32.3	32.7	32.1	32.2
8693	33.5	33.8	34.3	34.2	35.1	35.5	34.6	34.6
8696	29.6	28.8	29.1	28.6	28.9	29.1	29.1	29.8
8697	36.1	36.1	37.1	36.3	36.6	37.1	37.1	37.0
MEAN	32.8	32.5	33.0	32.4	32.8	33.2	32.7	33.0
S.D.	2.40	2.74	2.94	2.96	3.06	3.18	3.16	2.80
S.E.	1.07	1.23	1.32	1.32	1.37	1.42	1.41	1.25
N	5	5	5	5	5	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	6	7	8	9	10	11	12	13
ANIMAL								
8670	27.2	27.2	28.3	27.5	27.0	28.3	27.8	28.4
8677	28.8	28.2	29.0	28.0	27.8	28.5	28.2	28.7
8682	31.1	30.9	31.7	30.8	31.3	31.4	30.5	30.9
8686	33.4	33.3	33.9	33.5	33.3	33.7	33.1	33.6
8692	35.0	34.6	34.9	34.2	33.7	34.4	34.4	34.3
MEAN	31.1	30.8	31.6	30.8	30.6	31.3	30.8	31.2
S.D.	3.20	3.18	2.91	3.07	3.09	2.84	2.92	2.72
S.E.	1.43	1.42	1.30	1.37	1.38	1.27	1.31	1.22
N	5	5	5	5	5	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	6	7	8	9	10	11	12	13
ANIMAL								
8661	31.3	31.6	32.1	31.7	31.9	32.2	31.9	32.7
8676	37.2	37.3	37.5	38.1	38.0	38.2	38.7	39.8
8681	29.7	29.5	29.6	29.2	29.1	29.4	29.2	29.6
8687	28.4	27.9	29.2	29.0	29.0	29.6	29.0	29.6
8694	33.8	33.1	34.0	33.4	33.6	34.0	33.9	34.4
MEAN	32.1	31.9	32.5	32.3	32.3	32.7	32.5	33.2
S.D.	3.50	3.62	3.42	3.73	3.72	3.63	4.00	4.22
S.E.	1.57	1.62	1.53	1.67	1.67	1.62	1.79	1.89
N	5	5	5	5	5	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	6	7	8	9	10	11	12	13
ANIMAL								
8667	30.3	30.2	31.3	30.7	31.2	31.8	30.8	31.5
8673	33.6	33.6	34.2	34.5	33.9	34.7	34.4	34.6
8679	34.6	34.0	35.2	34.4	35.2	35.6	35.2	35.8
8690	34.2	33.2	34.2	33.3	33.4	33.8	33.6	34.2
8703	33.3	33.0	34.1	33.8	34.1	34.8	34.5	34.9
MEAN	33.2	32.8	33.8	33.3	33.6	34.1	33.7	34.2
S.D.	1.70	1.50	1.47	1.55	1.47	1.46	1.72	1.62
S.E.	0.76	0.67	0.66	0.69	0.66	0.65	0.77	0.72
N	5	5	5	5	5	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 9

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	14
ANIMAL	
8668	31.4
8672	32.0
8693	35.0
8696	29.9
8697	36.7
MEAN	33.0
S.D.	2.78
S.E.	1.24
N	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	14
ANIMAL	
8670	28.5
8677	28.4
8682	30.2
8686	33.5
8692	34.8
MEAN	31.1
S.D.	2.93
S.E.	1.31
N	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	14
ANIMAL	
8661	32.6
8676	39.0
8681	29.8
8687	29.9
8694	34.6
MEAN	33.2
S.D.	3.82
S.E.	1.71
N	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 12

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	14
ANIMAL	
8667	31.8
8673	34.2
8679	35.8
8690	34.4
8703	34.9
MEAN	34.2
S.D.	1.49
S.E.	0.67
N	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	-10	-4	0	1	2	3	4	5
ANIMAL								
8712	25.0	25.7	26.4	25.7	27.6			
8713	24.0	24.7	24.4	24.6	25.4			
8715	24.7	26.2	27.0	27.1	28.3			
8716	26.1	26.8	27.8	28.1	28.8	28.9	28.5	27.8
8719	24.9	27.2	26.8	26.7	27.5	28.0	28.3	27.2
8722	24.5	25.4	26.4	25.2	26.5	27.5	26.8	26.8
8728	24.4	27.0	25.9	25.7	26.3	26.5	26.6	26.8
8733	27.8	29.1	29.1	28.6	31.1			
8748	26.1	28.0	28.1	27.5	28.5	29.3	29.4	28.7
8749	25.9	27.4	27.3	27.4	29.0			
MEAN	25.3	26.8	26.9	26.7	27.9	28.0	27.9	27.5
S.D.	1.14	1.30	1.29	1.31	1.63	1.12	1.19	0.80
S.E.	0.36	0.41	0.41	0.42	0.51	0.50	0.53	0.36
N	10	10	10	10	10	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	-10	-4	0	1	2	3	4	5
ANIMAL								
8708	22.4	24.2	24.7	25.0	26.0			
8717	24.9	26.8	26.4	26.5	26.7			
8726	24.2	26.2	25.9	25.6	26.1	27.7	27.3	27.2
8729	26.4	28.5	28.1	28.0	28.8	29.8	29.1	28.7
8730	26.1	27.5	27.8	27.5	28.6			
8735	24.0	24.7	25.4	25.6	26.7			
8737	27.1	28.6	27.8	26.8	27.4	28.5	28.2	27.8
8738	24.6	27.1	26.6	26.4	26.7	28.8	28.6	28.2
8745	23.9	26.2	26.3	27.2	27.2	27.0	27.2	27.3
8747	24.1	25.5	24.4	24.0	24.6			
MEAN	24.8	26.5	26.3	26.3	26.9	28.4	28.1	27.8
S.D.	1.40	1.47	1.29	1.22	1.23	1.07	0.82	0.63
S.E.	0.44	0.47	0.41	0.39	0.39	0.48	0.37	0.28
N	10	10	10	10	10	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	-10	-4	0	1	2	3	4	5
ANIMAL								
8707	27.5	29.6	30.4	31.0	32.4			
8710	23.5	24.7	24.2	23.3	23.5	25.1	24.9	25.3
8714	26.6	27.7	27.5	27.8	27.8			
8718	24.6	26.0	26.2	27.0	28.5			
8720	23.8	25.0	24.9	24.3	24.6	25.5	25.9	26.1
8721	24.5	27.0	26.7	26.5	26.7	26.5	26.9	27.2
8724	25.7	27.1	26.3	26.2	26.7	27.8	27.5	27.5
8727	24.1	28.5	27.8	27.9	29.8			
8732	24.8	26.5	25.9	26.0	26.9	28.3	27.4	26.8
8750	23.6	25.7	26.5	25.9	28.3			
MEAN	24.9	26.8	26.6	26.6	27.5	26.6	26.5	26.6
S.D.	1.34	1.54	1.70	2.10	2.52	1.40	1.11	0.89
S.E.	0.42	0.49	0.54	0.67	0.80	0.62	0.49	0.40
N	10	10	10	10	10	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	-10	-4	0	1	2	3	4	5
ANIMAL								
8706	28.4	29.3	28.4	28.1	28.8			
8725	27.5	28.0	28.8	28.2	29.0	28.8	29.3	28.7
8734	25.3	26.2	25.8	25.6	26.9			
8736	23.2	25.6	25.5	25.8	26.9			
8739	24.3	24.4	25.1	25.2	26.5	26.7	26.9	26.9
8740	22.5	25.9	25.3	24.8	25.1	24.2	25.7	26.2
8741	25.5	28.1	27.7	27.9	29.2	30.0	29.0	28.8
8742	23.9	26.8	25.7	25.1	26.9			
8744	25.3	27.0	28.6	28.6	29.0	30.2	30.4	30.7
8746	24.3	25.5	26.0	25.9	27.0			
MEAN	25.0	26.7	26.7	26.5	27.5	28.0	28.3	28.3
S.D.	1.82	1.47	1.50	1.49	1.38	2.53	1.91	1.77
S.E.	0.58	0.46	0.47	0.47	0.44	1.13	0.85	0.79
N	10	10	10	10	10	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 17

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	6	7	8	9	10	11	12	13
ANIMAL								
8716	27.8	27.7	28.5	28.2	28.0	28.1	27.9	28.2
8719	26.7	27.5	28.4	28.4	28.4	28.4	27.8	28.4
8722	27.0	26.9	27.1	26.3	26.8	27.5	26.5	26.3
8728	26.9	26.7	27.1	26.2	26.8	26.8	26.6	26.5
8748	28.5	28.0	29.3	27.9	27.7	28.3	28.3	28.1
MEAN	27.4	27.4	28.1	27.4	27.5	27.8	27.4	27.5
S.D.	0.75	0.55	0.96	1.07	0.72	0.67	0.82	1.01
S.E.	0.34	0.24	0.43	0.48	0.32	0.30	0.37	0.45
N	5	5	5	5	5	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 18

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	6	7	8	9	10	11	12	13
ANIMAL								
8726	27.4	26.9	27.2	26.8	27.1	27.9	27.1	27.6
8729	28.8	28.0	28.2	28.2	28.1	28.7	28.0	28.5
8737	28.8	28.1	28.5	28.1	28.5	29.5	28.7	28.6
8738	27.6	27.6	28.4	28.2	27.8	27.8	27.2	27.9
8745	28.4	27.6	27.4	26.8	27.3	28.5	27.0	27.1
MEAN	28.2	27.6	27.9	27.6	27.8	28.5	27.6	27.9
S.D.	0.66	0.47	0.60	0.75	0.57	0.69	0.73	0.63
S.E.	0.30	0.21	0.27	0.34	0.26	0.31	0.33	0.28
N	5	5	5	5	5	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	6	7	8	9	10	11	12	13
ANIMAL								
8710	24.9	24.3	25.8	25.1	25.4	26.0	25.1	25.8
8720	25.4	24.6	26.1	25.8	26.0	26.1	25.4	26.5
8721	27.1	26.2	28.3	28.2	27.7	28.0	28.1	28.8
8724	27.7	27.2	28.5	28.0	28.1	28.8	28.5	29.4
8732	28.1	28.0	28.2	27.1	28.0	28.8	27.7	27.8
MEAN	26.6	26.1	27.4	26.8	27.0	27.5	27.0	27.7
S.D.	1.42	1.61	1.31	1.36	1.25	1.40	1.59	1.51
S.E.	0.63	0.72	0.59	0.61	0.56	0.63	0.71	0.68
N	5	5	5	5	5	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 20

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	6	7	8	9	10	11	12	13
ANIMAL								
8725	29.2	29.2	28.3	28.1	28.6	29.4	28.2	28.3
8739	27.3	26.7	26.7	26.4	26.6	27.6	26.8	26.5
8740	27.2	27.4	26.8	26.1	26.6	27.8	27.0	27.1
8741	29.3	29.2	29.0	28.8	29.2	30.3	29.3	29.5
8744	29.9	30.2	29.7	29.8	29.9	29.6	29.3	30.1
MEAN	28.6	28.5	28.1	27.8	28.2	28.9	28.1	28.3
S.D.	1.24	1.44	1.33	1.58	1.51	1.18	1.20	1.53
S.E.	0.56	0.64	0.59	0.70	0.68	0.53	0.54	0.68
N	5	5	5	5	5	5	5	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 21

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	14
ANIMAL	
8716	28.0
8719	29.0
8722	26.9
8728	26.6
8748	28.2
MEAN	27.7
S.D.	0.98
S.E.	0.44
N	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 22

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	14
ANIMAL	
8726	27.3
8729	28.5
8737	28.4
8738	28.2
8745	27.4
MEAN	28.0
S.D.	0.57
S.E.	0.25
N	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 23

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	14
ANIMAL	
8710	26.0
8720	27.3
8721	28.5
8724	28.7
8732	28.2
MEAN	27.7
S.D.	1.11
S.E.	0.50
N	5

TABLE I6

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 24

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHTS [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	14
ANIMAL	
8725	29.2
8739	26.9
8740	27.9
8741	29.7
8744	30.3
MEAN	28.8
S.D.	1.38
S.E.	0.62
N	5

PBFTSv4.45
03/16/2010

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	-10 TO -4	-4 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6
ANIMAL								
8660	2.1	0.5	0.5	2.0				
8662	2.6	-0.8	-0.2	1.0				
8668	2.7	-0.1	0.3	0.7	1.2	0.0	-0.8	0.3
8672	2.8	-1.0	0.1	1.3	0.6	-0.3	0.4	-0.1
8680	0.8	1.3	0.6	1.1				
8684	1.0	1.4	-1.1	1.8				
8693	2.9	0.5	0.2	0.9	-0.1	0.0	0.1	-0.2
8696	1.0	-0.1	0.4	0.7	0.1	-0.3	-0.5	0.4
8697	1.5	2.2	0.6	1.1	0.4	0.3	-0.1	0.4
8704	3.7	0.8	-0.1	2.1				
MEAN	2.1	0.5	0.1	1.3	0.4	-0.1	-0.2	0.2
S.D.	0.99	1.00	0.51	0.52	0.50	0.25	0.48	0.29
S.E.	0.31	0.32	0.16	0.16	0.22	0.11	0.21	0.13
N	10	10	10	10	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	-10 TO -4	-4 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6
ANIMAL								
8664	0.6	-0.5	1.0	1.1				
8670	0.9	-0.6	0.6	0.6	0.4	-0.2	-0.5	-0.1
8674	3.0	-0.1	1.2	1.2				
8675	3.6	-2.8	0.0	0.3				
8677	1.3	-0.3	0.4	0.8	1.2	-0.7	-0.3	-0.4
8682	1.2	0.5	0.1	0.6	0.3	-0.2	-0.5	0.0
8686	1.4	0.1	0.6	0.9	1.7	-0.4	-0.9	0.2
8688	1.2	-0.4	0.0	1.2				
8692	2.4	-0.1	0.9	0.2	0.9	-0.5	-0.2	0.1
8702	4.4	-2.3	0.4	1.4				
MEAN	2.0	-0.7	0.5	0.8	0.9	-0.4	-0.5	0.0
S.D.	1.28	1.06	0.42	0.40	0.58	0.21	0.27	0.23
S.E.	0.41	0.33	0.13	0.13	0.26	0.09	0.12	0.10
N	10	10	10	10	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	-10 TO -4	-4 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6
ANIMAL								
8659	2.0	-0.8	-0.5	0.4				
8661	3.6	-2.0	1.0	0.3	0.6	-0.2	-0.2	0.0
8665	2.8	0.3	-0.4	0.8				
8671	1.8	0.1	0.5	0.8				
8676	4.0	-0.1	1.0	0.5	1.0	0.3	-0.5	0.2
8681	0.4	0.4	0.1	0.5	0.0	0.3	-0.1	0.5
8687	1.4	0.1	0.1	0.2	1.1	0.1	-0.2	0.2
8691	1.3	1.3	0.7	1.2				
8694	2.4	0.1	-0.5	0.7	0.4	0.3	-0.9	0.6
8699	2.2	0.2	0.9	0.9				
MEAN	2.2	0.0	0.3	0.6	0.6	0.2	-0.4	0.3
S.D.	1.08	0.86	0.61	0.31	0.45	0.22	0.33	0.24
S.E.	0.34	0.27	0.19	0.10	0.20	0.10	0.15	0.11
N	10	10	10	10	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	-10 TO -4	-4 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6
ANIMAL								
8663	3.4	-1.8	0.5	2.2				
8667	2.5	0.8	0.8	1.3	0.1	-0.5	-0.2	0.4
8669	5.5	-3.5	0.0	1.0				
8673	1.0	0.0	0.1	1.6	-0.1	0.2	-0.3	0.3
8679	4.2	-1.2	0.4	1.5	1.1	-0.8	0.5	0.3
8683	3.4	0.7	-0.2	1.9				
8690	5.2	-1.9	0.3	1.1	0.2	0.3	0.3	0.6
8695	0.8	1.8	1.4	1.0				
8701	1.0	1.6	0.5	1.2				
8703	5.3	0.0	0.3	2.0	0.1	0.1	-0.1	0.1
MEAN	3.2	-0.4	0.4	1.5	0.3	-0.1	0.0	0.3
S.D.	1.85	1.71	0.45	0.43	0.47	0.48	0.34	0.18
S.E.	0.58	0.54	0.14	0.14	0.21	0.22	0.15	0.08
N	10	10	10	10	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL								
8668	-0.4	0.9	-1.1	0.3	0.2	-0.7	0.8	-0.2
8672	-0.6	0.2	-0.5	0.2	0.4	-0.6	0.1	-0.2
8693	0.3	0.5	-0.1	0.9	0.4	-0.9	0.0	0.4
8696	-0.8	0.3	-0.5	0.3	0.2	0.0	0.7	0.1
8697	0.0	1.0	-0.8	0.3	0.5	0.0	-0.1	-0.3
MEAN	-0.3	0.6	-0.6	0.4	0.3	-0.4	0.3	0.0
S.D.	0.45	0.36	0.37	0.28	0.13	0.42	0.42	0.29
S.E.	0.20	0.16	0.17	0.13	0.06	0.19	0.19	0.13
N	5	5	5	5	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL								
8670	0.0	1.1	-0.8	-0.5	1.3	-0.5	0.6	0.1
8677	-0.6	0.8	-1.0	-0.2	0.7	-0.3	0.5	-0.3
8682	-0.2	0.8	-0.9	0.5	0.1	-0.9	0.4	-0.7
8686	-0.1	0.6	-0.4	-0.2	0.4	-0.6	0.5	-0.1
8692	-0.4	0.3	-0.7	-0.5	0.7	0.0	-0.1	0.5
MEAN	-0.3	0.7	-0.8	-0.2	0.6	-0.5	0.4	-0.1
S.D.	0.24	0.29	0.23	0.41	0.44	0.34	0.28	0.45
S.E.	0.11	0.13	0.10	0.18	0.20	0.15	0.12	0.20
N	5	5	5	5	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL								
8661	0.3	0.5	-0.4	0.2	0.3	-0.3	0.8	-0.1
8676	0.1	0.2	0.6	-0.1	0.2	0.5	1.1	-0.8
8681	-0.2	0.1	-0.4	-0.1	0.3	-0.2	0.4	0.2
8687	-0.5	1.3	-0.2	0.0	0.6	-0.6	0.6	0.3
8694	-0.7	0.9	-0.6	0.2	0.4	-0.1	0.5	0.2
MEAN	-0.2	0.6	-0.2	0.0	0.4	-0.1	0.7	0.0
S.D.	0.41	0.50	0.47	0.15	0.15	0.40	0.28	0.45
S.E.	0.18	0.22	0.21	0.07	0.07	0.18	0.12	0.20
N	5	5	5	5	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL								
8667	-0.1	1.1	-0.6	0.5	0.6	-1.0	0.7	0.3
8673	0.0	0.6	0.3	-0.6	0.8	-0.3	0.2	-0.4
8679	-0.6	1.2	-0.8	0.8	0.4	-0.4	0.6	0.0
8690	-1.0	1.0	-0.9	0.1	0.4	-0.2	0.6	0.2
8703	-0.3	1.1	-0.3	0.3	0.7	-0.3	0.4	0.0
MEAN	-0.4	1.0	-0.5	0.2	0.6	-0.4	0.5	0.0
S.D.	0.41	0.23	0.48	0.53	0.18	0.32	0.20	0.27
S.E.	0.18	0.10	0.22	0.24	0.08	0.14	0.09	0.12
N	5	5	5	5	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 9

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	-10 TO -4	-4 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6
ANIMAL								
8712	0.7	0.7	-0.7	1.9				
8713	0.7	-0.3	0.2	0.8				
8715	1.5	0.8	0.1	1.2				
8716	0.7	1.0	0.3	0.7	0.1	-0.4	-0.7	0.0
8719	2.3	-0.4	-0.1	0.8	0.5	0.3	-1.1	-0.5
8722	0.9	1.0	-1.2	1.3	1.0	-0.7	0.0	0.2
8728	2.6	-1.1	-0.2	0.6	0.2	0.1	0.2	0.1
8733	1.3	0.0	-0.5	2.5				
8748	1.9	0.1	-0.6	1.0	0.8	0.1	-0.7	-0.2
8749	1.5	-0.1	0.1	1.6				
MEAN	1.4	0.2	-0.3	1.2	0.5	-0.1	-0.5	-0.1
S.D.	0.69	0.69	0.48	0.61	0.38	0.41	0.54	0.28
S.E.	0.22	0.22	0.15	0.19	0.17	0.19	0.24	0.12
N	10	10	10	10	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	-10 TO -4	-4 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6
ANIMAL								
8708	1.8	0.5	0.3	1.0				
8717	1.9	-0.4	0.1	0.2				
8726	2.0	-0.3	-0.3	0.5	1.6	-0.4	-0.1	0.2
8729	2.1	-0.4	-0.1	0.8	1.0	-0.7	-0.4	0.1
8730	1.4	0.3	-0.3	1.1				
8735	0.7	0.7	0.2	1.1				
8737	1.5	-0.8	-1.0	0.6	1.1	-0.3	-0.4	1.0
8738	2.5	-0.5	-0.2	0.3	2.1	-0.2	-0.4	-0.6
8745	2.3	0.1	0.9	0.0	-0.2	0.2	0.1	1.1
8747	1.4	-1.1	-0.4	0.6				
MEAN	1.8	-0.2	-0.1	0.6	1.1	-0.3	-0.2	0.4
S.D.	0.53	0.58	0.50	0.38	0.86	0.33	0.23	0.70
S.E.	0.17	0.18	0.16	0.12	0.38	0.15	0.10	0.31
N	10	10	10	10	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	-10 TO -4	-4 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6
ANIMAL								
8707	2.1	0.8	0.6	1.4				
8710	1.2	-0.5	-0.9	0.2	1.6	-0.2	0.4	-0.4
8714	1.1	-0.2	0.3	0.0				
8718	1.4	0.2	0.8	1.5				
8720	1.2	-0.1	-0.6	0.3	0.9	0.4	0.2	-0.7
8721	2.5	-0.3	-0.2	0.2	-0.2	0.4	0.3	-0.1
8724	1.4	-0.8	-0.1	0.5	1.1	-0.3	0.0	0.2
8727	4.4	-0.7	0.1	1.9				
8732	1.7	-0.6	0.1	0.9	1.4	-0.9	-0.6	1.3
8750	2.1	0.8	-0.6	2.4				
MEAN	1.9	-0.1	-0.1	0.9	1.0	-0.1	0.1	0.1
S.D.	0.99	0.58	0.54	0.83	0.70	0.54	0.40	0.77
S.E.	0.31	0.18	0.17	0.26	0.31	0.24	0.18	0.34
N	10	10	10	10	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 12

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	-10 TO -4	-4 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6
ANIMAL								
8706	0.9	-0.9	-0.3	0.7				
8725	0.5	0.8	-0.6	0.8	-0.2	0.5	-0.6	0.5
8734	0.9	-0.4	-0.2	1.3				
8736	2.4	-0.1	0.3	1.1				
8739	0.1	0.7	0.1	1.3	0.2	0.2	0.0	0.4
8740	3.4	-0.6	-0.5	0.3	-0.9	1.5	0.5	1.0
8741	2.6	-0.4	0.2	1.3	0.8	-1.0	-0.2	0.5
8742	2.9	-1.1	-0.6	1.8				
8744	1.7	1.6	0.0	0.4	1.2	0.2	0.3	-0.8
8746	1.2	0.5	-0.1	1.1				
MEAN	1.7	0.0	-0.2	1.0	0.2	0.3	0.0	0.3
S.D.	1.11	0.86	0.33	0.46	0.83	0.89	0.43	0.67
S.E.	0.35	0.27	0.10	0.15	0.37	0.40	0.19	0.30
N	10	10	10	10	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 13

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL								
8716	-0.1	0.8	-0.3	-0.2	0.1	-0.2	0.3	-0.2
8719	0.8	0.9	0.0	0.0	0.0	-0.6	0.6	0.6
8722	-0.1	0.2	-0.8	0.5	0.7	-1.0	-0.2	0.6
8728	-0.2	0.4	-0.9	0.6	0.0	-0.2	-0.1	0.1
8748	-0.5	1.3	-1.4	-0.2	0.6	0.0	-0.2	0.1
MEAN	0.0	0.7	-0.7	0.1	0.3	-0.4	0.1	0.2
S.D.	0.49	0.43	0.54	0.38	0.34	0.40	0.36	0.35
S.E.	0.22	0.19	0.24	0.17	0.15	0.18	0.16	0.16
N	5	5	5	5	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL								
8726	-0.5	0.3	-0.4	0.3	0.8	-0.8	0.5	-0.3
8729	-0.8	0.2	0.0	-0.1	0.6	-0.7	0.5	0.0
8737	-0.7	0.4	-0.4	0.4	1.0	-0.8	-0.1	-0.2
8738	0.0	0.8	-0.2	-0.4	0.0	-0.6	0.7	0.3
8745	-0.8	-0.2	-0.6	0.5	1.2	-1.5	0.1	0.3
MEAN	-0.6	0.3	-0.3	0.1	0.7	-0.9	0.3	0.0
S.D.	0.34	0.36	0.23	0.38	0.46	0.36	0.33	0.28
S.E.	0.15	0.16	0.10	0.17	0.21	0.16	0.15	0.12
N	5	5	5	5	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL								
8710	-0.6	1.5	-0.7	0.3	0.6	-0.9	0.7	0.2
8720	-0.8	1.5	-0.3	0.2	0.1	-0.7	1.1	0.8
8721	-0.9	2.1	-0.1	-0.5	0.3	0.1	0.7	-0.3
8724	-0.5	1.3	-0.5	0.1	0.7	-0.3	0.9	-0.7
8732	-0.1	0.2	-1.1	0.9	0.8	-1.1	0.1	0.4
MEAN	-0.6	1.3	-0.5	0.2	0.5	-0.6	0.7	0.1
S.D.	0.31	0.69	0.38	0.50	0.29	0.48	0.37	0.59
S.E.	0.14	0.31	0.17	0.22	0.13	0.22	0.17	0.26
N	5	5	5	5	5	5	5	5

TABLE I7

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL								
8725	0.0	-0.9	-0.2	0.5	0.8	-1.2	0.1	0.9
8739	-0.6	0.0	-0.3	0.2	1.0	-0.8	-0.3	0.4
8740	0.2	-0.6	-0.7	0.5	1.2	-0.8	0.1	0.8
8741	-0.1	-0.2	-0.2	0.4	1.1	-1.0	0.2	0.2
8744	0.3	-0.5	0.1	0.1	-0.3	-0.3	0.8	0.2
MEAN	0.0	-0.4	-0.3	0.3	0.8	-0.8	0.2	0.5
S.D.	0.35	0.35	0.29	0.18	0.61	0.33	0.40	0.33
S.E.	0.16	0.16	0.13	0.08	0.27	0.15	0.18	0.15
N	5	5	5	5	5	5	5	5

PBFTSv4.45
03/16/2010

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
8660	0.5	2.5						
8662	-0.2	0.8						
8668	0.3	1.0	2.2	2.2	1.4	1.7	1.3	2.2
8672	0.1	1.4	2.0	1.7	2.1	2.0	1.4	1.6
8680	0.6	1.7						
8684	-1.1	0.7						
8693	0.2	1.1	1.0	1.0	1.1	0.9	1.2	1.7
8696	0.4	1.1	1.2	0.9	0.4	0.8	0.0	0.3
8697	0.6	1.7	2.1	2.4	2.3	2.7	2.7	3.7
8704	-0.1	2.0						
MEAN	0.1	1.4	1.7	1.6	1.5	1.6	1.3	1.9
S.D.	0.51	0.57	0.56	0.68	0.77	0.79	0.96	1.23
S.E.	0.16	0.18	0.25	0.30	0.34	0.35	0.43	0.55
N	10	10	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
8664	1.0	2.1						
8670	0.6	1.2	1.6	1.4	0.9	0.8	0.8	1.9
8674	1.2	2.4						
8675	0.0	0.3						
8677	0.4	1.2	2.4	1.7	1.4	1.0	0.4	1.2
8682	0.1	0.7	1.0	0.8	0.3	0.3	0.1	0.9
8686	0.6	1.5	3.2	2.8	1.9	2.1	2.0	2.6
8688	0.0	1.2						
8692	0.9	1.1	2.0	1.5	1.3	1.4	1.0	1.3
8702	0.4	1.8						
MEAN	0.5	1.4	2.0	1.6	1.2	1.1	0.9	1.6
S.D.	0.42	0.63	0.83	0.73	0.60	0.68	0.73	0.68
S.E.	0.13	0.20	0.37	0.33	0.27	0.30	0.32	0.30
N	10	10	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
8659	-0.5	-0.1						
8661	1.0	1.3	1.9	1.7	1.5	1.5	1.8	2.3
8665	-0.4	0.4						
8671	0.5	1.3						
8676	1.0	1.5	2.5	2.8	2.3	2.5	2.6	2.8
8681	0.1	0.6	0.6	0.9	0.8	1.3	1.1	1.2
8687	0.1	0.3	1.4	1.5	1.3	1.5	1.0	2.3
8691	0.7	1.9						
8694	-0.5	0.2	0.6	0.9	0.0	0.6	-0.1	0.8
8699	0.9	1.8						
MEAN	0.3	0.9	1.4	1.6	1.2	1.5	1.3	1.9
S.D.	0.61	0.72	0.83	0.78	0.85	0.68	1.00	0.84
S.E.	0.19	0.23	0.37	0.35	0.38	0.30	0.45	0.38
N	10	10	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
8663	0.5	2.7						
8667	0.8	2.1	2.2	1.7	1.5	1.9	1.8	2.9
8669	0.0	1.0						
8673	0.1	1.7	1.6	1.8	1.5	1.8	1.8	2.4
8679	0.4	1.9	3.0	2.2	2.7	3.0	2.4	3.6
8683	-0.2	1.7						
8690	0.3	1.4	1.6	1.9	2.2	2.8	1.8	2.8
8695	1.4	2.4						
8701	0.5	1.7						
8703	0.3	2.3	2.4	2.5	2.4	2.5	2.2	3.3
MEAN	0.4	1.9	2.2	2.0	2.1	2.4	2.0	3.0
S.D.	0.45	0.50	0.59	0.33	0.54	0.53	0.28	0.46
S.E.	0.14	0.16	0.26	0.15	0.24	0.24	0.13	0.21
N	10	10	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
8668	1.1	1.4	1.6	0.9	1.7	1.5
8672	1.1	1.3	1.7	1.1	1.2	1.0
8693	1.6	2.5	2.9	2.0	2.0	2.4
8696	-0.2	0.1	0.3	0.3	1.0	1.1
8697	2.9	3.2	3.7	3.7	3.6	3.3
MEAN	1.3	1.7	2.0	1.6	1.9	1.9
S.D.	1.12	1.19	1.31	1.32	1.03	0.98
S.E.	0.50	0.53	0.58	0.59	0.46	0.44
N	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
8670	1.1	0.6	1.9	1.4	2.0	2.1
8677	0.2	0.0	0.7	0.4	0.9	0.6
8682	0.0	0.5	0.6	-0.3	0.1	-0.6
8686	2.2	2.0	2.4	1.8	2.3	2.2
8692	0.6	0.1	0.8	0.8	0.7	1.2
MEAN	0.8	0.6	1.3	0.8	1.2	1.1
S.D.	0.88	0.80	0.82	0.83	0.92	1.16
S.E.	0.39	0.36	0.37	0.37	0.41	0.52
N	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
8661	1.9	2.1	2.4	2.1	2.9	2.8
8676	3.4	3.3	3.5	4.0	5.1	4.3
8681	0.8	0.7	1.0	0.8	1.2	1.4
8687	2.1	2.1	2.7	2.1	2.7	3.0
8694	0.2	0.4	0.8	0.7	1.2	1.4
MEAN	1.7	1.7	2.1	1.9	2.6	2.6
S.D.	1.24	1.18	1.15	1.34	1.60	1.22
S.E.	0.55	0.53	0.52	0.60	0.72	0.55
N	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
8667	2.3	2.8	3.4	2.4	3.1	3.4
8673	2.7	2.1	2.9	2.6	2.8	2.4
8679	2.8	3.6	4.0	3.6	4.2	4.2
8690	1.9	2.0	2.4	2.2	2.8	3.0
8703	3.0	3.3	4.0	3.7	4.1	4.1
MEAN	2.5	2.8	3.3	2.9	3.4	3.4
S.D.	0.44	0.71	0.70	0.70	0.70	0.76
S.E.	0.20	0.32	0.31	0.31	0.31	0.34
N	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
8712	-0.7	1.2						
8713	0.2	1.0						
8715	0.1	1.3						
8716	0.3	1.0	1.1	0.7	0.0	0.0	-0.1	0.7
8719	-0.1	0.7	1.2	1.5	0.4	-0.1	0.7	1.6
8722	-1.2	0.1	1.1	0.4	0.4	0.6	0.5	0.7
8728	-0.2	0.4	0.6	0.7	0.9	1.0	0.8	1.2
8733	-0.5	2.0						
8748	-0.6	0.4	1.2	1.3	0.6	0.4	-0.1	1.2
8749	0.1	1.7						
MEAN	-0.3	1.0	1.0	0.9	0.5	0.4	0.4	1.1
S.D.	0.48	0.60	0.25	0.46	0.33	0.45	0.43	0.38
S.E.	0.15	0.19	0.11	0.21	0.15	0.20	0.19	0.17
N	10	10	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
8708	0.3	1.3						
8717	0.1	0.3						
8726	-0.3	0.2	1.8	1.4	1.3	1.5	1.0	1.3
8729	-0.1	0.7	1.7	1.0	0.6	0.7	-0.1	0.1
8730	-0.3	0.8						
8735	0.2	1.3						
8737	-1.0	-0.4	0.7	0.4	0.0	1.0	0.3	0.7
8738	-0.2	0.1	2.2	2.0	1.6	1.0	1.0	1.8
8745	0.9	0.9	0.7	0.9	1.0	2.1	1.3	1.1
8747	-0.4	0.2						
MEAN	-0.1	0.5	1.4	1.1	0.9	1.3	0.7	1.0
S.D.	0.50	0.55	0.68	0.60	0.62	0.55	0.58	0.64
S.E.	0.16	0.17	0.31	0.27	0.28	0.25	0.26	0.29
N	10	10	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
8707	0.6	2.0						
8710	-0.9	-0.7	0.9	0.7	1.1	0.7	0.1	1.6
8714	0.3	0.3						
8718	0.8	2.3						
8720	-0.6	-0.3	0.6	1.0	1.2	0.5	-0.3	1.2
8721	-0.2	0.0	-0.2	0.2	0.5	0.4	-0.5	1.6
8724	-0.1	0.4	1.5	1.2	1.2	1.4	0.9	2.2
8727	0.1	2.0						
8732	0.1	1.0	2.4	1.5	0.9	2.2	2.1	2.3
8750	-0.6	1.8						
MEAN	-0.1	0.9	1.0	0.9	1.0	1.0	0.5	1.8
S.D.	0.54	1.09	0.98	0.50	0.29	0.76	1.06	0.46
S.E.	0.17	0.34	0.44	0.22	0.13	0.34	0.47	0.21
N	10	10	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
8706	-0.3	0.4						
8725	-0.6	0.2	0.0	0.5	-0.1	0.4	0.4	-0.5
8734	-0.2	1.1						
8736	0.3	1.4						
8739	0.1	1.4	1.6	1.8	1.8	2.2	1.6	1.6
8740	-0.5	-0.2	-1.1	0.4	0.9	1.9	2.1	1.5
8741	0.2	1.5	2.3	1.3	1.1	1.6	1.5	1.3
8742	-0.6	1.2						
8744	0.0	0.4	1.6	1.8	2.1	1.3	1.6	1.1
8746	-0.1	1.0						
MEAN	-0.2	0.8	0.9	1.2	1.2	1.5	1.4	1.0
S.D.	0.33	0.59	1.39	0.68	0.86	0.69	0.63	0.86
S.E.	0.10	0.19	0.62	0.30	0.38	0.31	0.28	0.38
N	10	10	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 13

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
8716	0.4	0.2	0.3	0.1	0.4	0.2
8719	1.6	1.6	1.6	1.0	1.6	2.2
8722	-0.1	0.4	1.1	0.1	-0.1	0.5
8728	0.3	0.9	0.9	0.7	0.6	0.7
8748	-0.2	-0.4	0.2	0.2	0.0	0.1
MEAN	0.4	0.5	0.8	0.4	0.5	0.7
S.D.	0.72	0.75	0.58	0.41	0.68	0.85
S.E.	0.32	0.34	0.26	0.18	0.30	0.38
N	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
8726	0.9	1.2	2.0	1.2	1.7	1.4
8729	0.1	0.0	0.6	-0.1	0.4	0.4
8737	0.3	0.7	1.7	0.9	0.8	0.6
8738	1.6	1.2	1.2	0.6	1.3	1.6
8745	0.5	1.0	2.2	0.7	0.8	1.1
MEAN	0.7	0.8	1.5	0.7	1.0	1.0
S.D.	0.59	0.50	0.65	0.48	0.50	0.51
S.E.	0.27	0.22	0.29	0.22	0.23	0.23
N	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
8710	0.9	1.2	1.8	0.9	1.6	1.8
8720	0.9	1.1	1.2	0.5	1.6	2.4
8721	1.5	1.0	1.3	1.4	2.1	1.8
8724	1.7	1.8	2.5	2.2	3.1	2.4
8732	1.2	2.1	2.9	1.8	1.9	2.3
MEAN	1.2	1.4	1.9	1.4	2.1	2.1
S.D.	0.36	0.48	0.74	0.68	0.62	0.31
S.E.	0.16	0.22	0.33	0.30	0.28	0.14
N	5	5	5	5	5	5

TABLE I8

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 16

SPONSOR:SYNGENTA INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
8725	-0.7	-0.2	0.6	-0.6	-0.5	0.4
8739	1.3	1.5	2.5	1.7	1.4	1.8
8740	0.8	1.3	2.5	1.7	1.8	2.6
8741	1.1	1.5	2.6	1.6	1.8	2.0
8744	1.2	1.3	1.0	0.7	1.5	1.7
MEAN	0.7	1.1	1.8	1.0	1.2	1.7
S.D.	0.83	0.72	0.96	1.00	0.97	0.81
S.E.	0.37	0.32	0.43	0.45	0.43	0.36
N	5	5	5	5	5	5

PBFTSv4.45
03/16/2010

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	-10 TO -4	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
8660	5.9	7.0	7.2					
8662	5.3	5.7	5.2					
8668	7.1	5.0	6.0	6.5	6.2	5.0	5.9	6.1
8672	5.8	6.0	4.9	5.6	5.2	6.8	5.1	7.0
8680	5.6	5.2	5.7					
8684	4.8	5.7	4.9					
8693	6.2	6.6	7.7	5.6	5.2	5.8	5.1	6.5
8696	5.0	8.1	9.4	8.2	5.7	5.0	4.3	5.0
8697	6.8	7.1	6.6	6.7	6.5	7.3	7.0	8.0
8704	5.2	7.0	7.1					
MEAN	5.8	6.3	6.5	6.5	5.8	6.0	5.5	6.5
S.D.	0.76	0.98	1.43	1.07	0.59	1.04	1.02	1.11
S.E.	0.24	0.31	0.45	0.48	0.26	0.47	0.46	0.50
N	10	10	10	5	5	5	5	5

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	-10 TO -4	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
8664	5.6	5.1	5.6					
8670	4.8	2.8	4.3	4.4	4.1	5.8	4.8	5.6
8674	5.3	5.5	5.0					
8675	4.5	4.0	4.1					
8677	6.8	5.4	5.3	5.6	5.4	5.7	4.6	4.7
8682	4.9	4.8	4.8	4.7	7.0	4.7	9.1	5.4
8686	6.7	6.3	7.3	8.8	8.8	7.5	7.2	9.1
8688	5.7	5.0	5.4					
8692	7.5	7.9	6.6	5.7	6.0	5.6	5.5	5.8
8702	7.1	4.0	5.8					
MEAN	5.9	5.1	5.4	5.8	6.3	5.9	6.2	6.1
S.D.	1.06	1.39	0.98	1.75	1.77	1.02	1.90	1.72
S.E.	0.34	0.44	0.31	0.78	0.79	0.45	0.85	0.77
N	10	10	10	5	5	5	5	5

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	-10 TO -4	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
8659	6.2	6.7	8.2					
8661	3.6	6.4	6.0	5.0	5.7	5.7	5.3	NA
8665	5.9	4.4	4.7					
8671	6.2	5.0	5.4					
8676	6.2	6.5	6.4	5.8	6.5	6.7	5.7	7.5
8681	5.2	7.1	9.2	6.9	6.4	5.8	5.4	6.2
8687	6.4	4.6	5.3	6.1	5.2	5.4	4.5	5.9
8691	5.3	6.0	6.0					
8694	6.2	7.6	5.6	6.5	7.1	5.9	5.4	6.1
8699	5.8	6.4	5.7					
MEAN	5.7	6.1	6.3	6.1	6.2	5.9	5.3	6.4
S.D.	0.84	1.07	1.39	0.72	0.74	0.48	0.45	0.73
S.E.	0.27	0.34	0.44	0.32	0.33	0.22	0.20	0.36
N	10	10	10	5	5	5	5	4

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	-10 TO -4	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
8663	6.9	5.3	6.1					
8667	5.7	5.4	5.8	6.0	7.4	6.2	5.6	7.1
8669	7.9	6.7	NA					
8673	5.3	5.4	4.7	5.9	7.4	5.8	5.4	8.3
8679	6.1	6.4	7.3	7.1	6.8	7.1	6.4	8.1
8683	5.8	6.5	5.1					
8690	5.4	4.4	5.4	5.7	7.2	6.7	6.1	6.6
8695	5.0	6.1	5.4					
8701	4.0	4.5	4.6					
8703	7.3	4.7	NA	2.4	8.8	6.8	6.2	NA
MEAN	5.9	5.5	5.6	5.4	7.5	6.5	5.9	7.5
S.D.	1.16	0.85	0.87	1.77	0.76	0.52	0.42	0.81
S.E.	0.37	0.27	0.31	0.79	0.34	0.23	0.19	0.40
N	10	10	8	5	5	5	5	4

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALE GROUP: 0 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
8668	5.9	5.5	5.5	5.4	5.8	5.0	4.5
8672	4.0	6.3	5.8	NA	6.2	4.9	5.3
8693	3.7	6.8	6.5	5.7	5.9	5.9	7.4
8696	3.3	5.2	5.3	4.4	5.7	5.1	6.5
8697	3.6	7.7	6.8	5.8	6.4	6.6	5.6
MEAN	4.1	6.3	6.0	5.3	6.0	5.5	5.9
S.D.	1.04	1.01	0.65	0.64	0.29	0.73	1.12
S.E.	0.46	0.45	0.29	0.32	0.13	0.33	0.50
N	5	5	5	4	5	5	5

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALE GROUP: 500 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
8670	8.9	5.2	5.2	4.6	4.0	5.2	4.6
8677	6.4	5.0	5.0	5.0	5.7	4.8	4.4
8682	NA	NA	5.4	4.7	5.3	5.3	4.2
8686	5.6	8.2	6.1	6.3	5.9	6.5	6.1
8692	3.9	6.4	6.3	6.9	6.7	6.6	6.4
MEAN	6.2	6.2	5.6	5.5	5.5	5.7	5.1
S.D.	2.08	1.47	0.57	1.04	0.99	0.82	1.03
S.E.	1.04	0.73	0.25	0.46	0.44	0.37	0.46
N	4	4	5	5	5	5	5

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALE GROUP: 1500 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
8661	NA	7.1	6.0	5.5	5.6	5.9	6.1
8676	5.0	7.8	6.6	5.7	7.1	6.1	5.9
8681	4.7	8.6	6.6	5.5	5.9	5.3	6.0
8687	3.3	7.7	5.7	5.2	4.8	5.9	4.8
8694	6.6	8.4	6.2	5.7	6.1	6.0	5.5
MEAN	4.9	7.9	6.2	5.5	5.9	5.8	5.7
S.D.	1.35	0.60	0.39	0.20	0.83	0.31	0.53
S.E.	0.68	0.27	0.17	0.09	0.37	0.14	0.24
N	4	5	5	5	5	5	5

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

MALE GROUP: 2000 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
8667	4.6	7.0	6.2	6.6	6.7	6.4	6.4
8673	3.4	NA	3.1	6.3	6.1	6.1	6.1
8679	7.9	NA	7.0	6.6	7.3	6.8	6.8
8690	3.7	7.1	6.1	5.6	5.7	6.7	6.4
8703	9.4	8.8	6.8	6.3	7.2	6.4	6.3
MEAN	5.8	7.6	5.8	6.3	6.6	6.5	6.4
S.D.	2.69	1.01	1.58	0.41	0.69	0.28	0.25
S.E.	1.20	0.58	0.71	0.18	0.31	0.12	0.11
N	5	3	5	5	5	5	5

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	-10 TO -4	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
8712	5.4	4.7	5.2					
8713	8.5	NA	2.6					
8715	5.6	9.0	4.7					
8716	6.2	4.9	5.3	5.9	4.7	4.7	5.0	5.7
8719	5.9	8.4	7.2	7.4	8.3	6.7	5.2	6.7
8722	8.1	NA	NA	9.8	NA	9.8	5.4	6.8
8728	6.1	5.1	5.4	6.4	6.5	8.0	6.5	8.4
8733	2.9	5.2	5.8					
8748	5.7	NA	9.6	5.6	5.5	7.5	5.4	6.0
8749	4.6	3.9	4.7					
MEAN	5.9	5.9	5.6	7.0	6.3	7.3	5.5	6.7
S.D.	1.59	1.98	1.92	1.70	1.55	1.86	0.58	1.05
S.E.	0.50	0.75	0.64	0.76	0.78	0.83	0.26	0.47
N	10	7	9	5	4	5	5	5

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	-10 TO -4	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
8708	5.7	4.6	4.8					
8717	5.3	4.9	4.9					
8726	5.2	4.4	4.8	5.0	6.1	7.0	5.1	5.0
8729	5.5	4.3	5.7	4.6	4.7	8.1	4.4	4.1
8730	4.8	4.8	6.1					
8735	5.7	5.3	5.0					
8737	5.5	5.1	5.2	4.7	5.8	6.1	5.6	7.2
8738	3.8	4.4	5.3	5.5	6.9	5.7	4.7	5.6
8745	5.2	5.4	5.8	4.6	5.0	6.9	6.0	6.5
8747	2.9	3.5	4.5					
MEAN	5.0	4.7	5.2	4.9	5.7	6.8	5.2	5.7
S.D.	0.91	0.56	0.51	0.38	0.88	0.93	0.65	1.22
S.E.	0.29	0.18	0.16	0.17	0.39	0.41	0.29	0.55
N	10	10	10	5	5	5	5	5

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	-10 TO -4	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
8707	7.9	7.0	6.8					
8710	4.9	NA	9.1	8.0	6.8	6.3	7.3	5.6
8714	6.4	5.9	5.9					
8718	5.9	5.9	5.7					
8720	5.2	3.2	5.2	4.6	5.4	5.1	4.6	4.9
8721	9.8	NA	NA	5.7	6.1	6.2	4.8	5.9
8724	6.3	4.6	4.5	5.2	5.0	5.3	4.8	6.0
8727	5.5	5.7	5.0					
8732	5.4	6.2	6.5	6.8	7.6	7.5	6.9	8.2
8750	5.9	NA	5.0					
MEAN	6.3	5.5	6.0	6.1	6.2	6.1	5.7	6.1
S.D.	1.48	1.24	1.39	1.35	1.05	0.95	1.31	1.24
S.E.	0.47	0.47	0.46	0.60	0.47	0.43	0.58	0.55
N	10	7	9	5	5	5	5	5

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 12

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	-10 TO -4	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
8706	6.0	1.1	4.9					
8725	8.0	4.5	6.0	9.3	5.7	6.1	4.9	5.1
8734	4.6	4.9	4.6					
8736	4.4	4.5	4.4					
8739	9.0	3.7	5.1	4.6	5.0	5.7	4.6	5.3
8740	5.7	3.3	3.8	2.5	5.3	5.9	5.6	6.3
8741	5.5	3.0	5.1	5.4	5.5	5.2	5.5	7.5
8742	2.6	4.5	5.4					
8744	3.4	4.9	5.6	5.8	5.8	6.5	4.9	6.4
8746	4.6	4.7	4.3					
MEAN	5.4	3.9	4.9	5.5	5.5	5.9	5.1	6.1
S.D.	1.95	1.19	0.66	2.47	0.32	0.48	0.43	0.97
S.E.	0.62	0.38	0.21	1.10	0.14	0.22	0.19	0.43
N	10	10	10	5	5	5	5	5

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

FEMALE GROUP: 0 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
8716	3.7	NA	2.0	NA	5.6	2.2	7.1
8719	4.3	7.7	6.3	6.4	4.9	5.3	7.0
8722	NA	NA	6.3	6.6	6.3	5.6	5.3
8728	7.1	9.0	6.4	5.5	6.2	5.6	5.8
8748	4.8	NA	0.9	5.3	NA	1.3	5.0
MEAN	5.0	8.4	4.4	6.0	5.8	4.0	6.0
S.D.	1.49	0.92	2.70	0.65	0.65	2.08	0.97
S.E.	0.74	0.65	1.21	0.32	0.32	0.93	0.43
N	4	2	5	4	4	5	5

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

FEMALE GROUP: 500 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
8726	8.7	6.2	5.4	4.9	4.6	5.0	4.0
8729	5.1	5.5	5.0	4.8	4.9	4.2	5.1
8737	4.2	7.6	6.2	5.4	5.8	5.7	5.7
8738	3.5	6.8	6.0	5.0	6.0	5.7	6.5
8745	5.1	9.5	6.6	6.2	5.4	4.9	5.8
MEAN	5.3	7.1	5.8	5.3	5.3	5.1	5.4
S.D.	2.01	1.54	0.64	0.57	0.59	0.63	0.94
S.E.	0.90	0.69	0.29	0.26	0.26	0.28	0.42
N	5	5	5	5	5	5	5

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

FEMALE GROUP: 1500 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
8710	3.7	7.8	8.6	9.2	7.1	6.0	5.8
8720	4.6	7.9	5.1	5.2	5.3	6.4	6.1
8721	7.6	7.8	NA	NA	NA	2.6	5.0
8724	4.9	7.4	5.6	5.8	6.1	5.5	5.8
8732	5.7	8.3	6.5	6.5	6.8	5.3	6.8
MEAN	5.3	7.8	6.5	6.7	6.3	5.2	5.9
S.D.	1.47	0.32	1.55	1.77	0.80	1.49	0.65
S.E.	0.66	0.14	0.77	0.88	0.40	0.67	0.29
N	5	5	4	4	4	5	5

NA = NOT APPLICABLE

TABLE I9

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 16

SPONSOR:SYNGENTA INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

SPONSOR NO.:T007563-08

FEMALE GROUP: 2000 MG/KG

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14
ANIMAL							
8725	5.7	6.6	6.3	5.3	9.5	5.3	5.6
8739	3.2	6.9	5.2	5.0	4.7	5.1	4.5
8740	3.9	7.2	5.6	5.5	5.7	5.5	6.6
8741	6.3	7.0	5.8	5.9	6.0	5.0	5.8
8744	3.5	6.8	5.9	4.7	5.5	5.9	5.8
MEAN	4.5	6.9	5.8	5.3	6.3	5.4	5.7
S.D.	1.39	0.22	0.40	0.46	1.86	0.36	0.75
S.E.	0.62	0.10	0.18	0.21	0.83	0.16	0.34
N	5	5	5	5	5	5	5

PBFTSv4.45
03/12/2010

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 1

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 0 MG/KG MALES										
8660	10.15	9.68	14.5	42.7	44.1	14.9	33.9	1850.	3.0	288.7
8662	4.37	9.72	15.3	45.0	46.4	15.7	33.9	1244.	2.0	190.2
8680	4.41	9.52	15.3	43.8	46.0	16.1	35.0	1389.	3.2	302.6
8684	4.12	9.60	14.7	43.1	44.9	15.3	34.0	1274.	3.5	334.0
8704	5.36	9.16	14.9	44.0	48.1	16.3	33.9	1354.	3.3	304.1
MEAN	5.68	9.54	14.9	43.7	45.9	15.7	34.1	1422.	3.0	283.9
S.D.	2.542	0.224	0.36	0.89	1.53	0.57	0.48	246.2	0.59	54.93
S.E.	1.137	0.100	0.16	0.40	0.68	0.26	0.22	110.1	0.26	24.57
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 2

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 0 MG/KG MALES						
8660	54.2	38.5	4.5	2.0	0.2	0.7
8662	14.9	76.9	2.5	5.1	0.2	0.5
8680	19.1	74.1	2.1	4.0	0.1	0.6
8684	26.7	68.7	1.0	3.2	0.1	0.4
8704	13.1	82.6	0.5	3.4	0.0	0.3
MEAN	25.6	68.2	2.1	3.5	0.1	0.5
S.D.	16.82	17.32	1.56	1.13	0.08	0.16
S.E.	7.52	7.75	0.70	0.51	0.04	0.07
N	5	5	5	5	5	5

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 0 MG/KG MALES								
8660	5.50	3.90	0.46	0.20	0.02	0.07	INCREASE	1-PLT CLUM 1-POL, 1-CRE, 1-TDC
8662	0.65	3.36	0.11	0.22	0.01	0.02	ADEQUATE	1-PLT CLUM 1-POL
8680	0.84	3.26	0.09	0.18	0.00	0.03	ADEQUATE	1-PLT CLUM 2-POL, 1-TDC
8684	1.10	2.83	0.04	0.13	0.00	0.02	INCREASE	1-PLT CLUM 2-POL, 1-TDC
8704	0.70	4.43	0.03	0.18	0.00	0.02	ADEQUATE	1-LARGE PL 1-PLT CLUM 2-POL, 1-CRE
MEAN	1.76	3.56	0.15	0.18	0.01	0.03		
S.D.	2.099	0.620	0.179	0.033	0.009	0.022		
S.E.	0.939	0.277	0.080	0.015	0.004	0.010		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, CRE = CRENATED CELL, TDC = TEAR DROP CELL

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 4

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 0 MG/KG		MALES
8660	13.6	2.18
8662	12.1	1.97
8680	13.0	1.78
8684	12.9	1.84
8704	13.2	1.91
MEAN	13.0	1.94
S.D.	0.55	0.154
S.E.	0.25	0.069
N	5	5

g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 5

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 500 MG/KG MALES										
8664	6.92	9.66	15.0	44.1	45.6	15.6	34.1	1171.	2.8	274.3
8674	4.70	9.25	15.4	45.3	49.0	16.7	34.1	1627.	2.7	248.8
8675	2.54	10.82	16.6	49.0	45.3	15.3	33.8	1290.	2.2	237.8
8688	3.83	10.12	15.1	44.7	44.1	15.0	33.9	1304.	2.3	234.0
8702	3.12	9.63	14.9	43.8	45.5	15.4	33.9	1421.	2.6	254.4
MEAN	4.22	9.90	15.4	45.4	45.9	15.6	34.0	1363.	2.5	249.9
S.D.	1.711	0.602	0.70	2.10	1.83	0.65	0.13	172.3	0.26	15.94
S.E.	0.765	0.269	0.31	0.94	0.82	0.29	0.06	77.0	0.12	7.13
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 500 MG/KG MALES						
8664	19.9	73.9	2.4	3.3	0.2	0.4
8674	23.6	70.7	1.4	3.8	0.2	0.4
8675	24.3	68.0	3.1	4.4	0.1	0.2
8688	13.5	81.2	2.0	2.6	0.1	0.6
8702	21.4	73.5	1.4	3.4	0.2	0.1
MEAN	20.5	73.5	2.1	3.5	0.2	0.3
S.D.	4.31	4.94	0.72	0.66	0.05	0.19
S.E.	1.93	2.21	0.32	0.30	0.02	0.09
N	5	5	5	5	5	5

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 7

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 500 MG/KG MALES								
8664	1.38	5.12	0.16	0.23	0.01	0.03	ADEQUATE	1-PLT CLUM 1-POL, 1-TDC, 1-HJB
8674	1.11	3.32	0.06	0.18	0.01	0.02	INCREASE	1-PLT CLUM 2-POL
8675	0.62	1.73	0.08	0.11	0.00	0.00	ADEQUATE	1-PLT CLUM 1-POL
8688	0.52	3.11	0.08	0.10	0.00	0.02	ADEQUATE	2-POL
8702	0.67	2.30	0.04	0.11	0.01	0.00	ADEQUATE	1-LARGE PL 2-POL, 1-CRE, 1-TDC
MEAN	0.86	3.12	0.08	0.15	0.01	0.01		
S.D.	0.368	1.289	0.046	0.057	0.005	0.013		
S.E.	0.165	0.576	0.020	0.025	0.002	0.006		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY, CRE = CRENATED CELL

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 8

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 500 MG/KG		MALES
8664	12.7	2.08
8674	14.4	1.89
8675	12.2	1.77
8688	12.1	1.84
8702	12.6	1.77
MEAN	12.8	1.87
S.D.	0.93	0.128
S.E.	0.42	0.057
N	5	5

g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 9

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 1500 MG/KG MALES										
8659	4.43	10.33	15.5	45.4	44.0	15.0	34.0	1091.	2.8	287.4
8665	3.18	10.03	15.2	44.0	43.8	15.2	34.6	807.	2.4	237.1
8671	4.59	9.51	15.3	44.3	46.5	16.1	34.6	1460.	2.5	234.6
8691	4.18	8.62	14.2	41.9	48.7	16.5	33.9	1252.	2.6	226.0
8699	3.83	9.38	15.3	43.9	46.8	16.3	34.8	1740.	2.6	244.1
MEAN	4.04	9.57	15.1	43.9	46.0	15.8	34.4	1270.	2.6	245.8
S.D.	0.561	0.658	0.51	1.27	2.06	0.68	0.40	354.9	0.15	24.12
S.E.	0.251	0.294	0.23	0.57	0.92	0.30	0.18	158.7	0.07	10.79
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 1500 MG/KG MALES						
8659	30.7	63.2	1.6	4.0	0.2	0.3
8665	14.2	80.4	1.5	3.5	0.2	0.3
8671	15.7	78.9	1.5	3.4	0.1	0.4
8691	18.3	77.3	1.0	2.7	0.1	0.5
8699	16.5	78.7	1.3	3.1	0.1	0.3
MEAN	19.1	75.7	1.4	3.3	0.1	0.4
S.D.	6.66	7.07	0.24	0.48	0.05	0.09
S.E.	2.98	3.16	0.11	0.22	0.02	0.04
N	5	5	5	5	5	5

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 11

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 1500 MG/KG MALES								
8659	1.36	2.80	0.07	0.18	0.01	0.01	ADEQUATE	1-LARGE PL 2-POL, 1-TDC
8665	0.45	2.56	0.05	0.11	0.01	0.01	ADEQUATE	1-LARGE PL 1-POL, 1-TDC
8671	0.72	3.62	0.07	0.16	0.00	0.02	ADEQUATE	1-PLT CLUM 1-POL, 1-CRE, 1-TDC
8691	0.77	3.23	0.04	0.11	0.00	0.02	ADEQUATE	1-PLT CLUM 1-POL, 1-HJB
8699	0.63	3.01	0.05	0.12	0.00	0.01	INCREASE	1-PLT CLUM 1-POL, 1-TDC
MEAN	0.79	3.04	0.06	0.14	0.00	0.01		
S.D.	0.343	0.407	0.013	0.032	0.005	0.005		
S.E.	0.154	0.182	0.006	0.014	0.002	0.002		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, TDC = TEAR DROP CELL, CRE = CRENATED CELL, HJB = HOWELL-JOLLY BODY

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 12

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 1500 MG/KG		MALES
8659	12.3	1.95
8665	12.2	1.77
8671	12.5	1.69
8691	12.8	1.81
8699	12.8	1.77
MEAN	12.5	1.80
S.D.	0.28	0.095
S.E.	0.12	0.043
N	5	5

g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 13

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 2000 MG/KG MALES										
8663	3.53	9.74	14.9	43.7	44.9	15.3	34.1	2025.	2.9	279.0
8669	6.11	9.33	15.2	43.6	46.8	16.3	34.8	1054.	2.6	246.2
8683	3.89	9.16	15.0	44.4	48.5	16.4	33.8	1408.	3.1	284.5
8695	4.12	9.05	14.9	42.9	47.4	16.5	34.7	1525.	3.8	340.0
8701	5.00	8.49	14.0	41.4	48.8	16.5	33.9	1770.	3.3	277.3
MEAN	4.53	9.15	14.8	43.2	47.3	16.2	34.3	1556.	3.1	285.4
S.D.	1.036	0.454	0.46	1.14	1.56	0.51	0.46	367.6	0.45	34.00
S.E.	0.463	0.203	0.21	0.51	0.70	0.23	0.21	164.4	0.20	15.21
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 14

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 2000 MG/KG		MALES				
8663	24.4	66.6	2.0	6.6	0.2	0.2
8669	22.3	71.8	2.5	2.7	0.2	0.6
8683	15.3	80.2	1.7	2.1	0.1	0.6
8695	17.6	79.6	0.8	1.6	0.2	0.3
8701	25.7	70.3	0.8	2.9	0.1	0.3
MEAN	21.1	73.7	1.6	3.2	0.2	0.4
S.D.	4.45	5.97	0.75	1.98	0.05	0.19
S.E.	1.99	2.67	0.34	0.89	0.02	0.08
N	5	5	5	5	5	5

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 15

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 2000 MG/KG MALES								
8663	0.86	2.35	0.07	0.23	0.01	0.01	INCREASE	1-LARGE PL 1-PLT CLUM 1-POL, 1-CRE
8669	1.36	4.39	0.15	0.16	0.01	0.04	ADEQUATE	1-LARGE PL 1-POL, 1-TDC, 1-CRE
8683	0.60	3.12	0.07	0.08	0.00	0.02	ADEQUATE	1-LARGE PL 2-POL, 1-TDC, 1-CRE
8695	0.72	3.28	0.03	0.07	0.01	0.01	INCREASE	1-LARGE PL 1-PLT CLUM 1-POL, 1-TDC, 1-HJB
8701	1.28	3.51	0.04	0.14	0.01	0.01	INCREASE	1-LARGE PL 1-PLT CLUM 1-POL, 1-CRE, 1-TDC, 1-HJB
MEAN	0.96	3.33	0.07	0.14	0.01	0.02		
S.D.	0.339	0.735	0.047	0.065	0.004	0.013		
S.E.	0.152	0.329	0.021	0.029	0.002	0.006		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, CRE = CRENATED CELL, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 16

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 2000 MG/KG		MALES
8663	13.2	1.97
8669	12.8	1.94
8683	13.0	1.74
8695	13.0	1.81
8701	13.3	1.90
MEAN	13.1	1.87
S.D.	0.19	0.095
S.E.	0.09	0.043
N	5	5

g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 17

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 0 MG/KG		FEMALES								
8712	5.55	10.16	16.3	46.0	45.3	16.1	35.5	1222.	3.6	361.1
8713	3.99	10.26	15.8	44.9	43.7	15.4	35.2	1209.	2.2	225.2
8715	3.21	9.68	15.0	43.3	44.7	15.5	34.7	1192.	2.5	244.5
8733	4.04	9.16	14.9	43.2	47.1	16.3	34.5	996.	3.3	306.3
8749	3.91	9.74	15.7	46.0	47.2	16.1	34.0	1232.	3.3	324.2
MEAN	4.14	9.80	15.5	44.7	45.6	15.9	34.8	1170.	3.0	292.3
S.D.	0.857	0.438	0.59	1.38	1.53	0.40	0.59	98.5	0.60	56.42
S.E.	0.383	0.196	0.26	0.62	0.68	0.18	0.26	44.1	0.27	25.23
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 18

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 0 MG/KG FEMALES						
8712	19.9	74.0	1.3	4.2	0.2	0.5
8713	26.9	67.3	1.1	3.9	0.1	0.8
8715	12.0	83.7	1.0	3.0	0.2	0.2
8733	14.9	79.0	1.0	4.3	0.2	0.5
8749	19.9	75.1	2.1	2.3	0.2	0.4
MEAN	18.7	75.8	1.3	3.5	0.2	0.5
S.D.	5.69	6.10	0.46	0.86	0.04	0.22
S.E.	2.54	2.73	0.21	0.39	0.02	0.10
N	5	5	5	5	5	5

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 19

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 0 MG/KG FEMALES								
8712	1.10	4.11	0.07	0.24	0.01	0.03	ADEQUATE	1-POL, 1-TDC, 1-HJB
8713	1.07	2.68	0.04	0.16	0.00	0.03	ADEQUATE	1-POL, 1-TDC
8715	0.38	2.68	0.03	0.09	0.00	0.01	ADEQUATE	1-LARGE PL 1-POL, 1-TDC
8733	0.60	3.20	0.04	0.18	0.01	0.02	ADEQUATE	1-POL, 1-TDC, 1-HJB
8749	0.78	2.94	0.08	0.09	0.01	0.02	ADEQUATE	1-LARGE PL 1-POL, 1-TDC, 1-HJB
MEAN	0.79	3.12	0.05	0.15	0.01	0.02		
S.D.	0.308	0.593	0.022	0.064	0.005	0.008		
S.E.	0.138	0.265	0.010	0.029	0.002	0.004		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, LARGE PL = LARGE PLATELET, POL = POLYCHROMASIA, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 20

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 0 MG/KG		FEMALES
8712	12.8	2.09
8713	12.3	1.89
8715	12.8	2.32
8733	14.3	2.22
8749	12.9	2.09
MEAN	13.0	2.12
S.D.	0.75	0.162
S.E.	0.34	0.072
N	5	5

g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 21

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 500 MG/KG		FEMALES								
8708	5.20	9.48	15.5	45.3	47.8	16.4	34.2	1226.	3.2	304.6
8717	4.19	9.85	15.8	46.2	46.9	16.1	34.3	1229.	3.1	305.5
8730	3.40	9.70	15.7	45.3	46.7	16.2	34.7	1469.	3.2	310.1
8735	2.37	9.60	15.3	43.4	45.2	16.0	35.3	1195.	3.7	350.5
8747	5.48	9.53	15.3	44.9	47.1	16.1	34.2	974.	4.7	451.4
MEAN	4.13	9.63	15.5	45.0	46.7	16.2	34.5	1219.	3.6	344.4
S.D.	1.285	0.147	0.23	1.02	0.96	0.15	0.47	175.5	0.67	62.77
S.E.	0.575	0.066	0.10	0.46	0.43	0.07	0.21	78.5	0.30	28.07
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 22

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 500 MG/KG FEMALES						
8708	20.8	72.6	0.9	5.1	0.1	0.4
8717	24.4	63.0	1.0	11.0	0.1	0.5
8730	15.6	78.3	0.7	4.9	0.2	0.2
8735	24.4	69.1	1.1	4.8	0.2	0.4
8747	11.0	84.0	0.0	5.0	0.0	0.0
MEAN	19.2	73.4	0.7	6.2	0.1	0.3
S.D.	5.85	8.12	0.44	2.71	0.08	0.20
S.E.	2.62	3.63	0.20	1.21	0.04	0.09
N	5	5	5	5	5	5

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 23

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 500 MG/KG FEMALES								
8708	1.08	3.77	0.05	0.26	0.01	0.02	ADEQUATE	1-LARGE PL 1-POL, 1-CRE, 1-TDC, 1-HJB
8717	1.02	2.64	0.04	0.46	0.00	0.02	ADEQUATE	1-LARGE PL 1-POL, 1-CRE, 1-HJB
8730	0.53	2.66	0.02	0.17	0.01	0.01	ADEQUATE	1-POL, 1-CRE, 1-TDC, 1-HJB
8735	0.58	1.63	0.03	0.11	0.00	0.01	ADEQUATE	1-PLT CLUM 1-POL, 1-CRE
8747	0.60	4.60	0.00	0.27	0.00	0.00	ADEQUATE	1-PLT CLUM 2-POL, 1-TDC MANUAL DIFF
MEAN	0.76	3.06	0.03	0.25	0.00	0.01		
S.D.	0.265	1.146	0.019	0.133	0.005	0.008		
S.E.	0.119	0.513	0.009	0.059	0.002	0.004		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, CRE = CRENATED CELL, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 24

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 2

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 500 MG/KG		FEMALES
8708	13.3	1.89
8717	13.1	1.87
8730	13.6	2.11
8735	13.3	2.25
8747	14.5	2.34
MEAN	13.6	2.09
S.D.	0.55	0.210
S.E.	0.25	0.094
N	5	5

g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 25

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 1500 MG/KG		FEMALES								
8707	4.23	10.22	15.6	45.0	44.0	15.3	34.8	1197.	3.0	309.6
8714	7.66	10.04	15.6	46.2	46.1	15.5	33.6	926.	3.1	315.9
8718	4.36	10.02	15.7	45.0	44.9	15.6	34.8	1133.	3.1	315.1
8727	4.15	9.10	14.6	42.1	46.3	16.1	34.7	926.	4.7	426.7
8750	6.89	10.40	15.7	45.1	43.3	15.0	34.7	1404.	3.6	377.5
MEAN	5.46	9.96	15.4	44.7	44.9	15.5	34.5	1117.	3.5	349.0
S.D.	1.683	0.503	0.47	1.53	1.30	0.41	0.52	201.2	0.71	51.59
S.E.	0.752	0.225	0.21	0.68	0.58	0.18	0.23	90.0	0.32	23.07
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 26

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 1500 MG/KG FEMALES						
8707	13.4	80.6	1.4	4.0	0.2	0.5
8714	11.5	77.6	1.2	8.8	0.2	0.7
8718	16.4	75.0	0.7	7.4	0.2	0.3
8727	16.5	74.5	1.5	6.9	0.1	0.5
8750	14.7	79.2	1.0	4.3	0.1	0.6
MEAN	14.5	77.4	1.2	6.3	0.2	0.5
S.D.	2.11	2.63	0.32	2.07	0.05	0.15
S.E.	0.94	1.18	0.14	0.92	0.02	0.07
N	5	5	5	5	5	5

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 27

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 1500 MG/KG FEMALES								
8707	0.57	3.41	0.06	0.17	0.01	0.02	ADEQUATE	1-POL, 1-CRE 1-HJB
8714	0.88	5.94	0.09	0.67	0.02	0.06	ADEQUATE	1-POL, 1-CRE
8718	0.72	3.27	0.03	0.32	0.01	0.01	ADEQUATE	1-LARGE PL 2-POL, 1-CRE
8727	0.69	3.09	0.06	0.29	0.01	0.02	ADEQUATE	2-POL, 1-CRE, 1-TDC
8750	1.02	5.46	0.07	0.30	0.01	0.04	ADEQUATE	1-POL, 1-CRE, 1-HJB
MEAN	0.78	4.23	0.06	0.35	0.01	0.03		
S.D.	0.176	1.354	0.022	0.188	0.004	0.020		
S.E.	0.079	0.605	0.010	0.084	0.002	0.009		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, POL = POLYCHROMASIA, CRE = CRENATED CELL, HJB = HOWELL-JOLLY BODY, TDC = TEAR DROP CELL

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 28

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 1500 MG/KG		FEMALES
8707	13.4	2.19
8714	14.2	2.26
8718	13.3	2.12
8727	13.6	2.24
8750	12.9	2.12
MEAN	13.5	2.19
S.D.	0.48	0.065
S.E.	0.21	0.029
N	5	5

g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 29

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 2000 MG/KG		FEMALES								
8706	4.60	10.57	16.2	45.2	42.8	15.4	35.9	1236.	3.6	383.5
8734	2.51	10.06	15.8	45.9	45.7	15.7	34.3	954.	3.1	314.1
8736	3.42	10.17	15.6	44.7	43.9	15.3	34.9	1290.	2.6	260.2
8742	5.23	10.18	15.7	45.7	44.9	15.4	34.4	1148.	3.4	341.4
8746	2.86	9.73	15.5	44.1	45.3	15.9	35.1	1224.	2.7	263.4
MEAN	3.72	10.14	15.8	45.1	44.5	15.5	34.9	1170.	3.1	312.5
S.D.	1.156	0.301	0.27	0.74	1.17	0.25	0.64	131.2	0.43	52.50
S.E.	0.517	0.135	0.12	0.33	0.52	0.11	0.29	58.7	0.19	23.48
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 30

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 2000 MG/KG FEMALES						
8706	17.7	73.2	1.0	7.6	0.1	0.4
8734	34.5	57.3	2.0	6.1	0.0	0.2
8736	11.0	83.3	1.7	3.5	0.2	0.4
8742	10.2	85.0	0.9	3.3	0.1	0.5
8746	18.6	73.1	2.0	6.2	0.1	0.0
MEAN	18.4	74.4	1.5	5.3	0.1	0.3
S.D.	9.77	11.04	0.54	1.87	0.07	0.20
S.E.	4.37	4.94	0.24	0.84	0.03	0.09
N	5	5	5	5	5	5

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 31

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 2

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 2000 MG/KG FEMALES								
8706	0.81	3.37	0.05	0.35	0.00	0.02	ADEQUATE	1-POL, 2-CRE, 1-TDC
8734	0.86	1.44	0.05	0.15	0.00	0.00	ADEQUATE	1-POL, 1-HJB
8736	0.37	2.85	0.06	0.12	0.01	0.01	ADEQUATE	1-POL, 1-HJB
8742	0.53	4.45	0.05	0.17	0.00	0.03	ADEQUATE	1-PLT CLUM 1-POL, 1-CRE, 1-HJB
8746	0.53	2.09	0.06	0.18	0.00	0.00	ADEQUATE	1-PLT CLUM 1-POL
MEAN	0.62	2.84	0.05	0.19	0.00	0.01		
S.D.	0.208	1.161	0.005	0.090	0.004	0.013		
S.E.	0.093	0.519	0.002	0.040	0.002	0.006		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, CRE = CRENATED CELL, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY

TABLE I10 (DAY 2 EVALUATION)

PROJECT NO.:WIL-639061 | A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE | PAGE 32

SPONSOR:SYNGENTA | INDIVIDUAL HEMATOLOGY VALUES | DAY 2

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 2000 MG/KG		FEMALES
8706	12.6	2.20
8734	12.2	1.94
8736	13.5	1.87
8742	12.9	2.00
8746	13.2	2.07
MEAN	12.9	2.02
S.D.	0.51	0.127
S.E.	0.23	0.057
N	5	5

g/dL = GRAMS/DECILITER

PHEMAv1.35
03/12/2010
R:03/07/2012

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 1

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 0 MG/KG MALES										
8668	4.99	10.10	15.7	46.1	45.7	15.5	34.1	1443.	3.2	326.3
8672	6.00	9.58	15.1	43.3	45.2	15.8	35.0	1270.	3.0	288.5
8693	4.76	8.86	14.7	42.2	47.7	16.6	34.8	1428.	3.8	339.3
8696	4.31	9.67	15.5	44.0	45.5	16.0	35.2	1317.	2.5	237.2
8697	5.94	10.58	15.9	44.8	42.3	15.0	35.4	1187.	2.3	241.3
MEAN	5.20	9.76	15.4	44.1	45.3	15.8	34.9	1329.	3.0	286.5
S.D.	0.745	0.640	0.48	1.48	1.93	0.59	0.50	107.9	0.59	47.04
S.E.	0.333	0.286	0.22	0.66	0.87	0.27	0.22	48.3	0.27	21.03
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 0 MG/KG MALES						
8668	20.8	73.3	3.6	1.8	0.1	0.3
8672	16.8	75.9	2.2	4.5	0.3	0.4
8693	11.3	85.5	1.5	1.1	0.1	0.6
8696	21.5	73.7	1.7	2.5	0.1	0.5
8697	10.9	84.2	1.6	2.8	0.1	0.3
MEAN	16.3	78.5	2.1	2.5	0.1	0.4
S.D.	5.04	5.88	0.87	1.28	0.09	0.13
S.E.	2.25	2.63	0.39	0.57	0.04	0.06
N	5	5	5	5	5	5

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 3

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 0 MG/KG MALES								
8668	1.04	3.66	0.18	0.09	0.01	0.01	ADEQUATE	1-POL, 1-CRE, 1-HJB
8672	1.01	4.55	0.13	0.27	0.02	0.02	ADEQUATE	1-POL, 1-TDC
8693	0.54	4.07	0.07	0.05	0.00	0.03	ADEQUATE	2-POL, 1-CRE, 1-HJB
8696	0.92	3.18	0.07	0.11	0.01	0.02	ADEQUATE	1-LARGE PL 1-PLT CLUM 1-POL, 1-TDC, 1-HJB
8697	0.65	5.00	0.09	0.17	0.01	0.02	ADEQUATE	1-LARGE PL 1-PLT CLUM 1-POL
MEAN	0.83	4.09	0.11	0.14	0.01	0.02		
S.D.	0.224	0.716	0.047	0.086	0.007	0.007		
S.E.	0.100	0.320	0.021	0.038	0.003	0.003		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, CRE = CRENATED CELL, HJB = HOWELL-JOLLY BODY, TDC = TEAR DROP CELL

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 | A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE | PAGE 4

SPONSOR:SYNGENTA | INDIVIDUAL HEMATOLOGY VALUES | DAY 14

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 0 MG/KG		MALES
8668	13.0	2.23
8672	12.1	2.03
8693	12.6	2.27
8696	11.5	1.94
8697	12.0	2.09
MEAN	12.2	2.11
S.D.	0.58	0.138
S.E.	0.26	0.062
N	5	5

g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 500 MG/KG MALES										
8670	8.02	10.48	14.7	44.0	42.0	14.0	33.3	1130.	2.8	294.1
8677	5.53	10.19	15.1	43.6	42.8	14.8	34.6	1166.	2.6	266.6
8682	6.63	10.53	15.4	44.0	41.8	14.6	35.0	1258.	2.0	206.4
8686	5.25	10.63	15.9	45.6	42.9	14.9	34.8	1540.	2.1	223.9
8692	8.26	10.70	16.5	48.5	45.3	15.4	34.0	1421.	2.6	275.9
MEAN	6.74	10.51	15.5	45.1	43.0	14.7	34.3	1303.	2.4	253.4
S.D.	1.382	0.196	0.70	2.03	1.39	0.51	0.69	173.8	0.35	36.80
S.E.	0.618	0.088	0.31	0.91	0.62	0.23	0.31	77.7	0.16	16.46
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 500 MG/KG MALES						
8670	11.7	83.3	2.7	1.5	0.2	0.6
8677	17.6	76.2	2.9	2.8	0.1	0.3
8682	17.9	76.2	1.7	3.4	0.1	0.6
8686	13.6	83.4	1.3	1.3	0.1	0.3
8692	26.5	67.4	3.2	2.2	0.1	0.6
MEAN	17.5	77.3	2.4	2.2	0.1	0.5
S.D.	5.70	6.59	0.82	0.88	0.04	0.16
S.E.	2.55	2.95	0.37	0.39	0.02	0.07
N	5	5	5	5	5	5

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 7

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 500 MG/KG MALES								
8670	0.94	6.67	0.22	0.12	0.02	0.05	ADEQUATE	1-LARGE PL 1-POL, 1-TDC
8677	0.98	4.21	0.16	0.15	0.01	0.02	ADEQUATE	1-POL, 1-HJB
8682	1.19	5.05	0.11	0.23	0.01	0.04	ADEQUATE	1-LARGE PL 1-POL, 1-HJB
8686	0.71	4.38	0.07	0.07	0.01	0.02	ADEQUATE	1-POL, 1-CRE, 1-HJB
8692	2.19	5.57	0.26	0.18	0.01	0.05	INCREASE	1-LARGE PL 1-POL, 1-TDC, 1-HJB
MEAN	1.20	5.18	0.16	0.15	0.01	0.04		
S.D.	0.578	0.996	0.078	0.060	0.004	0.015		
S.E.	0.258	0.446	0.035	0.027	0.002	0.007		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, LARGE PL = LARGE PLATELET, POL = POLYCHROMASIA, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY, CRE = CRENATED CELL

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 8

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 500 MG/KG		MALES
8670	13.0	2.29
8677	12.1	2.08
8682	11.6	1.95
8686	11.4	2.10
8692	12.3	2.06
MEAN	12.1	2.10
S.D.	0.63	0.123
S.E.	0.28	0.055
N	5	5

g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 9

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 1500 MG/KG MALES										
8661	6.97	9.51	14.7	43.1	45.4	15.5	34.2	1270.	2.2	209.5
8676	7.11	9.87	15.8	45.4	46.0	16.0	34.8	1425.	3.1	302.3
8681	6.45	9.26	14.4	41.2	44.5	15.6	35.1	1532.	2.8	263.0
8687	6.35	9.71	15.1	42.6	43.9	15.6	35.4	1379.	2.9	279.3
8694	4.68	10.29	15.5	44.4	43.2	15.1	34.9	1574.	2.4	250.9
MEAN	6.31	9.73	15.1	43.3	44.6	15.6	34.9	1436.	2.7	261.0
S.D.	0.969	0.388	0.57	1.62	1.12	0.32	0.44	121.6	0.37	34.64
S.E.	0.433	0.174	0.25	0.73	0.50	0.14	0.20	54.4	0.17	15.49
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 1500 MG/KG MALES						
8661	15.0	81.4	1.2	1.8	0.1	0.5
8676	19.7	74.3	3.2	2.0	0.2	0.6
8681	10.8	85.3	1.9	1.2	0.2	0.6
8687	15.9	79.2	2.1	2.3	0.1	0.4
8694	12.1	81.8	1.8	3.9	0.1	0.4
MEAN	14.7	80.4	2.0	2.2	0.1	0.5
S.D.	3.48	4.05	0.73	1.01	0.05	0.10
S.E.	1.56	1.81	0.33	0.45	0.02	0.04
N	5	5	5	5	5	5

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 11

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 1500 MG/KG MALES								
8661	1.04	5.68	0.08	0.12	0.01	0.03	ADEQUATE	1-POL, 1-HJB
8676	1.40	5.29	0.23	0.14	0.02	0.04	ADEQUATE	1-LARGE PL 1-POL, 1-TDC
8681	0.69	5.50	0.12	0.08	0.01	0.04	ADEQUATE	1-PLT CLUM 1-POL
8687	1.01	5.03	0.13	0.15	0.01	0.02	ADEQUATE	1-LARGE PL 1-PLT CLUM 1-POL, 1-TDC, 1-HJB
8694	0.57	3.83	0.08	0.18	0.00	0.02	ADEQUATE	1-PLT CLUM 1-POL, 1-CRE, 1-TDC
MEAN	0.94	5.07	0.13	0.13	0.01	0.03		
S.D.	0.326	0.732	0.061	0.037	0.007	0.010		
S.E.	0.146	0.327	0.027	0.017	0.003	0.004		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, HJB = HOWELL-JOLLY BODY, TDC = TEAR DROP CELL, CRE = CRENATED CELL

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 | A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE | PAGE 12

SPONSOR:SYNGENTA | INDIVIDUAL HEMATOLOGY VALUES | DAY 14

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 1500 MG/KG		MALES
8661	11.6	1.95
8676	12.6	1.99
8681	12.0	1.99
8687	12.2	2.08
8694	12.0	2.03
MEAN	12.1	2.01
S.D.	0.36	0.049
S.E.	0.16	0.022
N	5	5

g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 13

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 2000 MG/KG MALES										
8667	8.97	9.93	15.0	44.8	45.1	15.1	33.5	1099.	2.7	265.8
8673	7.67	9.92	15.4	44.9	45.2	15.5	34.3	1437.	2.9	288.6
8679	6.94	9.15	14.8	42.9	46.9	16.2	34.5	1232.	3.1	285.2
8690	4.05	10.19	15.6	44.9	44.1	15.3	34.7	1427.	2.3	238.7
8703	5.05	9.69	15.2	44.8	46.2	15.7	34.0	1079.	3.7	355.9
MEAN	6.54	9.78	15.2	44.5	45.5	15.6	34.2	1255.	2.9	286.8
S.D.	1.985	0.392	0.32	0.87	1.08	0.42	0.47	172.2	0.52	43.40
S.E.	0.888	0.175	0.14	0.39	0.48	0.19	0.21	77.0	0.23	19.41
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 14

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 2000 MG/KG MALES						
8667	10.3	84.6	3.0	1.4	0.1	0.6
8673	17.1	78.7	2.4	1.3	0.1	0.4
8679	14.4	80.9	1.7	2.5	0.1	0.5
8690	24.0	73.0	1.0	2.0	0.0	0.0
8703	12.6	81.9	2.2	2.6	0.3	0.4
MEAN	15.7	79.8	2.1	2.0	0.1	0.4
S.D.	5.28	4.36	0.75	0.60	0.11	0.23
S.E.	2.36	1.95	0.34	0.27	0.05	0.10
N	5	5	5	5	5	5

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 15

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 2000 MG/KG MALES								
8667	0.93	7.59	0.27	0.12	0.01	0.05	ADEQUATE	1-POL, 1-TDC, 1-HJB
8673	1.31	6.04	0.18	0.10	0.01	0.03	ADEQUATE	1-LARGE PL 1-POL, 1-TDC, 1-HJB
8679	1.00	5.61	0.12	0.17	0.00	0.04	ADEQUATE	1-PLT CLUM 1-POL, 1-HJB
8690	0.97	2.96	0.04	0.08	0.00	0.00	ADEQUATE	1-LARGE PL 1-PLT CLUM 1-POL, 1-TDC, 1-HJB MANUAL DIFF
8703	0.63	4.14	0.11	0.13	0.01	0.02	ADEQUATE	1-PLT CLUM 2-POL, 1-TDC
MEAN	0.97	5.27	0.14	0.12	0.01	0.03		
S.D.	0.242	1.782	0.086	0.034	0.005	0.019		
S.E.	0.108	0.797	0.039	0.015	0.002	0.009		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 16

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 2000 MG/KG		MALES
8667	12.1	1.83
8673	13.4	2.05
8679	12.6	2.08
8690	12.4	2.16
8703	12.3	1.92
MEAN	12.6	2.01
S.D.	0.50	0.132
S.E.	0.22	0.059
N	5	5

g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 17

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 0 MG/KG		FEMALES								
8716	7.50	10.47	16.2	46.9	44.8	15.5	34.6	1347.	2.1	218.9
8719	7.72	9.78	15.6	44.8	45.8	15.9	34.7	825.	2.1	207.2
8722	5.57	10.45	16.2	46.6	44.6	15.5	34.6	1076.	2.5	261.0
8728	5.29	10.43	16.3	47.0	45.1	15.6	34.6	1127.	2.1	224.1
8748	8.61	9.67	15.5	44.6	46.1	16.0	34.8	1077.	2.4	235.7
MEAN	6.94	10.16	16.0	46.0	45.3	15.7	34.7	1090.	2.2	229.4
S.D.	1.441	0.399	0.38	1.18	0.65	0.23	0.09	185.7	0.19	20.43
S.E.	0.645	0.179	0.17	0.53	0.29	0.10	0.04	83.1	0.09	9.14
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 18

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 0 MG/KG FEMALES						
8716	11.0	87.0	0.0	2.0	0.0	0.0
8719	15.0	81.0	0.0	4.0	0.0	0.0
8722	11.0	86.0	3.0	0.0	0.0	0.0
8728	11.8	82.3	3.0	2.0	0.2	0.7
8748	10.3	85.3	1.2	2.3	0.2	0.6
MEAN	11.8	84.3	1.4	2.1	0.1	0.3
S.D.	1.86	2.55	1.51	1.42	0.11	0.36
S.E.	0.83	1.14	0.67	0.64	0.05	0.16
N	5	5	5	5	5	5

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 19

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 0 MG/KG FEMALES								
8716	0.83	6.53	0.00	0.15	0.00	0.00	ADEQUATE	1-POL, 1-TDC MANUAL DIFF
8719	1.16	6.25	0.00	0.31	0.00	0.00	ADEQUATE	2-PLT CLUM 1-POL, 1-CRE, 1-TDC, 1-HJB MANUAL DIFF
8722	0.61	4.79	0.17	0.00	0.00	0.00	ADEQUATE	1-PLT CLUM 1-POL, 1-CRE, 1-HJB MANUAL DIFF
8728	0.62	4.35	0.16	0.10	0.01	0.04	ADEQUATE	1-LARGE PL 1-POL, 1-TDC, 1-CRE
8748	0.89	7.35	0.11	0.19	0.02	0.05	ADEQUATE	1-LARGE PL 1-POL
MEAN	0.82	5.85	0.09	0.15	0.01	0.02		
S.D.	0.226	1.250	0.083	0.114	0.009	0.025		
S.E.	0.101	0.559	0.037	0.051	0.004	0.011		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, CRE = CRENATED CELL, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 20

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 0 MG/KG		FEMALES
8716	13.0	2.07
8719	13.0	2.10
8722	12.7	1.99
8728	13.2	2.11
8748	13.4	2.16
MEAN	13.1	2.09
S.D.	0.26	0.063
S.E.	0.12	0.028
N	5	5

g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 21

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 500 MG/KG		FEMALES								
8726	5.60	10.44	16.0	44.7	42.8	15.3	35.8	1030.	2.6	271.1
8729	5.66	10.04	15.6	45.5	45.4	15.6	34.3	1272.	2.4	236.4
8737	5.96	9.36	15.0	43.2	46.2	16.1	34.8	1181.	2.5	237.4
8738	5.06	9.77	15.2	44.1	45.1	15.5	34.4	1083.	3.0	297.1
8745	6.61	9.46	14.9	42.7	45.2	15.8	35.0	1001.	2.3	220.5
MEAN	5.78	9.81	15.3	44.0	44.9	15.7	34.9	1113.	2.6	252.5
S.D.	0.567	0.441	0.46	1.13	1.27	0.30	0.60	112.1	0.27	31.01
S.E.	0.254	0.197	0.20	0.50	0.57	0.14	0.27	50.1	0.12	13.87
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 22

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 500 MG/KG FEMALES						
8726	18.0	76.0	0.0	6.0	0.0	0.0
8729	15.9	77.1	1.4	5.1	0.1	0.4
8737	14.5	81.9	1.0	1.8	0.3	0.6
8738	12.8	82.8	2.2	1.2	0.1	0.8
8745	8.3	87.2	1.6	1.8	0.2	0.9
MEAN	13.9	81.0	1.2	3.2	0.1	0.5
S.D.	3.67	4.55	0.82	2.20	0.11	0.36
S.E.	1.64	2.03	0.37	0.98	0.05	0.16
N	5	5	5	5	5	5

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 23

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 500 MG/KG FEMALES								
8726	1.01	4.26	0.00	0.34	0.00	0.00	ADEQUATE	1-POL, 1-TDC, 1-HJB MANUAL DIFF
8729	0.90	4.36	0.08	0.29	0.01	0.02	ADEQUATE	1-POL, 1-TDC, 1-HJB
8737	0.86	4.88	0.06	0.11	0.02	0.03	ADEQUATE	1-LARGE PL 1-POL, 1-TDC, 1-CRE, 1-HJB
8738	0.65	4.19	0.11	0.06	0.00	0.04	ADEQUATE	1-POL, 1-TDC, 1-HJB
8745	0.55	5.76	0.10	0.12	0.01	0.06	ADEQUATE	1-LARGE PL 1-PLT CLUM 1-POL, 1-TDC
MEAN	0.79	4.69	0.07	0.18	0.01	0.03		
S.D.	0.189	0.657	0.044	0.123	0.008	0.022		
S.E.	0.084	0.294	0.019	0.055	0.004	0.010		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY, CRE = CRENATED CELL

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 | A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE | PAGE 24

SPONSOR:SYNGENTA | INDIVIDUAL HEMATOLOGY VALUES | DAY 14

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 500 MG/KG		FEMALES
8726	13.0	2.34
8729	12.8	2.10
8737	13.5	2.15
8738	13.9	2.28
8745	13.0	2.02
MEAN	13.2	2.18
S.D.	0.45	0.131
S.E.	0.20	0.059
N	5	5

g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 25

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 1500 MG/KG FEMALES										
8710	6.97	10.31	15.7	45.6	44.2	15.2	34.5	1366.	2.0	209.5
8720	6.86	9.82	14.8	44.0	44.8	15.1	33.6	1160.	2.5	249.3
8721	8.63	9.29	14.8	42.4	45.6	15.9	34.9	1026.	3.2	300.7
8724	6.73	9.72	15.1	42.9	44.1	15.6	35.3	1377.	3.7	354.8
8732	5.31	9.55	15.0	43.3	45.3	15.7	34.6	1250.	2.5	242.6
MEAN	6.90	9.74	15.1	43.6	44.8	15.5	34.6	1236.	2.8	271.4
S.D.	1.179	0.378	0.37	1.24	0.66	0.34	0.63	147.4	0.67	56.93
S.E.	0.527	0.169	0.17	0.56	0.29	0.15	0.28	65.9	0.30	25.46
N	5	5	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 26

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 1500 MG/KG FEMALES						
8710	10.9	85.0	1.2	2.3	0.2	0.5
8720	25.5	68.1	2.6	2.6	0.2	0.9
8721	26.4	69.5	1.1	2.3	0.1	0.6
8724	10.9	81.1	0.4	6.8	0.2	0.5
8732	9.0	83.5	5.1	1.8	0.0	0.6
MEAN	16.5	77.4	2.1	3.2	0.1	0.6
S.D.	8.63	8.02	1.87	2.05	0.09	0.16
S.E.	3.86	3.59	0.84	0.92	0.04	0.07
N	5	5	5	5	5	5

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 27

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 1500 MG/KG FEMALES								
8710	0.76	5.92	0.08	0.16	0.01	0.03	ADEQUATE	1-PLT CLUM 1-POL, 1-TDC, 1-HJB
8720	1.75	4.67	0.18	0.18	0.01	0.06	ADEQUATE	1-PLT CLUM 1-POL
8721	2.28	6.00	0.09	0.20	0.01	0.05	ADEQUATE	2-POL, 1-TDC, 1-HJB
8724	0.74	5.45	0.03	0.46	0.02	0.04	ADEQUATE	1-PLT CLUM 1-POL, 1-TDC, 1-HJB
8732	0.48	4.43	0.27	0.09	0.00	0.03	ADEQUATE	1-PLT CLUM 1-POL, 1-TDC, 1-HJB
MEAN	1.20	5.29	0.13	0.22	0.01	0.04		
S.D.	0.773	0.716	0.095	0.141	0.007	0.013		
S.E.	0.346	0.320	0.043	0.063	0.003	0.006		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, 2 = MODERATE, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 | A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE | PAGE 28

SPONSOR:SYNGENTA | INDIVIDUAL HEMATOLOGY VALUES | DAY 14

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 1500 MG/KG		FEMALES
8710	12.7	2.20
8720	13.4	2.05
8721	13.6	2.01
8724	13.5	2.14
8732	13.7	2.13
MEAN	13.4	2.11
S.D.	0.40	0.076
S.E.	0.18	0.034
N	5	5

g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 — A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE — PAGE 29

SPONSOR:SYNGENTA — INDIVIDUAL HEMATOLOGY VALUES — DAY 14

SPONSOR NO.:T007563-08

ANIMAL	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLATELET	RETIC	RETIC ABSOLUTE
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL	%	thous/uL
GROUP: 2000 MG/KG FEMALES										
8725	6.49	9.53	14.7	42.4	44.6	15.4	34.5	1090.	2.7	259.7
8739	5.37	9.55	15.2	43.8	45.9	15.9	34.7	1351.	2.5	241.1
8740	5.21	8.98	14.5	42.0	46.7	16.2	34.6	1143.	2.8	253.2
8741	7.40	9.44	15.0	43.6	46.2	15.8	34.3	1211.	2.8	262.9
8744	CLT	CLT	CLT	CLT	CLT	CLT	CLT	CLT	CLT	CLT
MEAN	6.12	9.38	14.9	43.0	45.9	15.8	34.5	1199.	2.7	254.2
S.D.	1.027	0.268	0.31	0.89	0.90	0.33	0.17	112.9	0.14	9.64
S.E.	0.514	0.134	0.16	0.44	0.45	0.17	0.09	56.5	0.07	4.82
N	4	4	4	4	4	4	4	4	4	4

CLT = CLOTTED

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 30

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU	LYMPH	MONO	EOS	BASO	LUC
	%	%	%	%	%	%
GROUP: 2000 MG/KG FEMALES						
8725	16.5	78.3	2.7	1.7	0.2	0.7
8739	23.0	72.0	1.0	4.0	0.0	0.0
8740	15.5	79.2	2.2	2.3	0.1	0.7
8741	12.2	82.3	2.0	2.7	0.2	0.7
8744	CLT	CLT	CLT	CLT	CLT	CLT
MEAN	16.8	78.0	2.0	2.7	0.1	0.5
S.D.	4.52	4.32	0.71	0.97	0.10	0.35
S.E.	2.26	2.16	0.36	0.49	0.05	0.17
N	4	4	4	4	4	4

CLT = CLOTTED

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 31

SPONSOR:SYNGENTA INDIVIDUAL HEMATOLOGY VALUES DAY 14

SPONSOR NO.:T007563-08

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP: 2000 MG/KG FEMALES								
8725	1.07	5.08	0.17	0.11	0.01	0.05	ADEQUATE	1-LARGE PL 1-POL, 1-HJB
8739	1.24	3.87	0.05	0.21	0.00	0.00	ADEQUATE	1-LARGE PL 1-PLT CLUM 1-POL, 1-TDC, 1-HJB MANUAL DIFF
8740	0.81	4.12	0.12	0.12	0.00	0.04	ADEQUATE	1-PLT CLUM 1-POL, 1-TDC, 1-HJB
8741	0.90	6.09	0.15	0.20	0.01	0.05	ADEQUATE	1-LARGE PL 1-POL, 1-TDC
8744	CLT	CLT	CLT	CLT	CLT	CLT	PLATELET ESTIMATE AND MORPHOLOGY NOT REVIEWED	
MEAN	1.01	4.79	0.12	0.16	0.01	0.04		
S.D.	0.190	1.012	0.053	0.052	0.006	0.024		
S.E.	0.095	0.506	0.026	0.026	0.003	0.012		
N	4	4	4	4	4	4		

CLT = CLOTTED

thous/uL = THOUSANDS/MICROLITER

------ MORPHOLOGY CODE ------

1 = FEW, LARGE PL = LARGE PLATELET, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, TDC = TEAR DROP CELL, HJB = HOWELL-JOLLY BODY

TABLE I11 (DAY 14 EVALUATION)

PROJECT NO.:WIL-639061 | A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE | PAGE 32

SPONSOR:SYNGENTA | INDIVIDUAL HEMATOLOGY VALUES | DAY 14

SPONSOR NO.:T007563-08

ANIMAL	RDW	HDW
	%	g/dL
GROUP: 2000 MG/KG		FEMALES
8725	13.2	2.34
8739	13.7	2.08
8740	12.7	2.17
8741	13.4	2.02
8744	CLT	CLT
MEAN	13.3	2.15
S.D.	0.42	0.139
S.E.	0.21	0.070
N	4	4

CLT = CLOTTED

g/dL = GRAMS/DECILITER

PHEMAv1.35
03/12/2010
R:03/07/2012

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8660 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

			GRADE
FINAL BODY WT(G) 33.3	LIVER	MICRO: INFLAMMATION, SUBACUTE MULTIFOCAL	1
		NECROSIS, HEPATOCELLULAR MULTIFOCAL	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8662 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

								GRADE
FINAL BODY WT(G)	34.0	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
				JOINT	BRAIN	CECUM	COLON	
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES	
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM	
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC	
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS	
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD	
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN	
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES	
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER	
				LN, AXILLARY				
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS	
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR	
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN	
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8680 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	29.6	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8684 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
FINAL BODY WT(G)	30.3	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8704 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
FINAL BODY WT(G)	36.3	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8664 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	31.5	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8674 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES				1
FINAL BODY WT(G)	31.0	NO SIGNIFICANT					
		CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	LN, MANDIBULAR	LIVER
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8675 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES FOCAL				1
FINAL BODY WT(G)	29.8						
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
		NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
				RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
				PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 9
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8688 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
FINAL BODY WT(G)	32.3	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8702 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		TAIL	GROSS: FRACTURED DISTAL				P
FINAL BODY WT(G)	32.7	^==>	TAIL: FRACTURE				
		TAIL	MICRO: FRACTURE				P
		NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT
^==> INDICATES MICRO CONFIRMATION OF ABOVE GROSS FINDING

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8659 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	29.1	THYMUS	MICRO: HEMORRHAGE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 12

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8665 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
FINAL BODY WT(G)	30.4	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 13
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8671 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
FINAL BODY WT(G)	33.7	GENERAL COMMENT	GROSS: ORGAN DAMAGED AT NECROPSY BRAIN	P
		ESOPHAGUS	MICRO: DEGENERATION, MUSCLE FOCAL IN WALL	2
		LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ILEUM
	JEJUNUM	KIDNEYS	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 14
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8691 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
FINAL BODY WT(G) 34.2	KIDNEYS	MICRO:	BASOPHILIC TUBULES	1
			INFLAMMATION, SUBACUTE	1
	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	
			JOINT	
			DUODENUM	
			NERVES, OPTIC	
			KIDNEYS	
			LUNGS	
			PITUITARY	
			SAL. GLAND MAND	
			SPLEEN	
			THYROID GLANDS	
			LN, AXILLARY	
		MICRO:	CECUM	
			ILEUM	
			LN, MESENTERIC	
			SPLEEN	

AORTA	STERNUM	FEMUR
BRAIN	CECUM	COLON
EPIDIDYMIDES	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM
LN, MANDIBULAR	LIVER	LN, MESENTERIC
GALLBLADDER	NERVE, SCIATIC	PANCREAS
PROSTATE	RECTUM	SPINAL CORD
STOMACH	SKELETAL MUSCLE	SKIN
SEMINAL VESICLES	TESTES	PEYER'S PATCHES
THYMUS	TRACHEA	URINARY BLADDER
COLON	DUODENUM	ESOPHAGUS
JEJUNUM	LN, MANDIBULAR	LIVER
RECTUM	STOMACH, GLAN	STOMACH, NON
PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 15
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8699 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
	RECTUM	MICRO: INFLAMMATION, SUBACUTE AFFECTS PERIANAL GLANDS					1
FINAL BODY WT(G) 32.3	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
			JOINT	BRAIN	CECUM	COLON	
			DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES	
			NERVES, OPTIC	HEART	ILEUM	JEJUNUM	
			KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC	
			LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS	
			PITUITARY	PROSTATE	RECTUM	SPINAL CORD	
			SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN	
			SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES	
			THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER	
			LN, AXILLARY				
		MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS	
			ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR	
			LIVER	LN, MESENTERIC	STOMACH, GLAN	STOMACH, NON	
			SPLEEN	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 16
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8663 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
FINAL BODY WT(G)	30.8	LIVER	MICRO: NECROSIS, HEPATOCELLULAR FOCAL	1
		THYMUS	MICRO: HEMORRHAGE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

ANIMAL NO. 8669 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		KIDNEYS	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	32.1	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 18
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8683 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
FINAL BODY WT(G)	33.0	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8695 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
	LIVER	MICRO: INFLAMMATION, SUBACUTE		1
FINAL BODY WT(G) 34.1	NO SIGNIFICANT CHANGES OBSERVED			

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 20
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8701 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
FINAL BODY WT(G) 31.5	KIDNEYS	MICRO: INFARCT	FOCAL; CHRONIC; HAS MINERALIZATION	3
	NO SIGNIFICANT CHANGES OBSERVED			

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LIVER
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 21
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8712 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
FINAL BODY WT(G) 27.6	LIVER	GROSS:	ACCESSORY LOBULE(S) ONE, 7 X 7 X 1 MM	P
	^==>	LIVER:	NECROSIS, HEPATOCELLULAR	
	LIVER	MICRO:	INFLAMMATION, SUBACUTE	1
			NECROSIS, HEPATOCELLULAR IN ACCESSORY LOBULE	2
	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS, AORTA, STERNUM, FEMUR	
			JOINT, BRAIN, CECUM, COLON	
			DUODENUM, ESOPHAGUS, EYES, NERVES, OPTIC	
			HEART, ILEUM, JEJUNUM, KIDNEYS	
			LN, MANDIBULAR, LN, MESENTERIC, LUNGS, GALLBLADDER	
			MAMMARY GLAND, NERVE, SCIATIC, OVIDUCTS, OVARIES	
			PANCREAS, PITUITARY, RECTUM, SPINAL CORD	
			SAL. GLAND MAND, STOMACH, SKELETAL MUSCLE, SKIN	
			SPLEEN, PEYER'S PATCHES, THYROID GLANDS, THYMUS	
			TRACHEA, URINARY BLADDER, UTERUS, VAGINA	
			CERVIX, LN, AXILLARY	
		MICRO:	CECUM, COLON, DUODENUM, ESOPHAGUS	
			ILEUM, JEJUNUM, KIDNEYS, LN, MANDIBULAR	
			LN, MESENTERIC, RECTUM, STOMACH, GLAN, STOMACH, NON	
			SPLEEN, PEYER'S PATCHES, THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT
^==> INDICATES MICRO CONFIRMATION OF ABOVE GROSS FINDING

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 22
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8713 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	25.4	UTERUS	GROSS: CONTENTS, CLEAR FLUID BOTH HORNS				P
		^==>	UTERUS: DILATATION, LUMEN				
		UTERUS	MICRO: DILATATION, LUMEN				1
		NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	VAGINA
				CERVIX	LN, AXILLARY		
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT
^==> INDICATES MICRO CONFIRMATION OF ABOVE GROSS FINDING

TABLE I12 (DAY 2 INTERIM NECROPSY)
A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PROJECT NO.:WIL-639061
SPONSOR:SYNGENTA
SPONSOR NO.:T007563-08

ANIMAL NO. 8715 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

			GRADE
	KIDNEYS	MICRO: BASOPHILIC TUBULES	1
FINAL BODY WT(G) 28.3	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	PEYER'S PATCHES	MICRO: NOT PRESENT FOR EXAMINATION PEYER'S PATCHES NOT IN PLANE; RECUT EVALUATED	
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:ADRENAL GLANDS, AORTA, STERNUM, FEMUR, JOINT, BRAIN, CECUM, COLON, DUODENUM, ESOPHAGUS, EYES, NERVES, OPTIC, HEART, ILEUM, JEJUNUM, KIDNEYS, LN, MANDIBULAR, LIVER, LN, MESENTERIC, LUNGS, GALLBLADDER, MAMMARY GLAND, NERVE, SCIATIC, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, RECTUM, SPINAL CORD, SAL. GLAND MAND, STOMACH, SKELETAL MUSCLE, SKIN, SPLEEN, PEYER'S PATCHES, THYROID GLANDS, THYMUS, TRACHEA, URINARY BLADDER, UTERUS, VAGINA, CERVIX, LN, AXILLARY

MICRO:CECUM, COLON, DUODENUM, ESOPHAGUS, ILEUM, JEJUNUM, LN, MANDIBULAR, LN, MESENTERIC, RECTUM, STOMACH, GLAN, STOMACH, NON, SPLEEN, THYMUS

NOT PRESENT FOR EXAMINATION

MICRO:PEYER'S PATCHES

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 24
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8733 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES	1
FINAL BODY WT(G)	31.1	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 25
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8749 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		LN, MANDIBULAR	MICRO: HEMORRHAGE	1
FINAL BODY WT(G)	29.0	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 26
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8708 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

			GRADE
FINAL BODY WT(G) 26.0	ESOPHAGUS	MICRO: DEGENERATION, MUSCLE FOCAL IN WALL	1
	LIVER	MICRO: NECROSIS, HEPATOCELLULAR FOCAL	1
		INFLAMMATION, SUBACUTE	1
	THYMUS	MICRO: HEMORRHAGE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ILEUM
	JEJUNUM	KIDNEYS	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 27

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8717 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES	1
FINAL BODY WT(G)	26.7	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 28
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8730 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		KIDNEYS	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	28.6	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 29
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8735 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		THYMUS	MICRO: HEMORRHAGE				1
FINAL BODY WT(G)	26.7	NO SIGNIFICANT					
		CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 30
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8747 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		ESOPHAGUS	MICRO: INFLAMMATION, SUBACUTE IN PERI-ESOPHAGEAL CONNECTIVE TISSUE				1
FINAL BODY WT(G)	24.6						
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
		NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ILEUM
				JEJUNUM	KIDNEYS	LN, MANDIBULAR	LN, MESENTERIC
				RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
				PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8707 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES	1
FINAL BODY WT(G)	32.4	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 32
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8714 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES	1
FINAL BODY WT(G)	27.8	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 33
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8718 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
FINAL BODY WT(G)	28.5	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8727 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

							GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES				1
FINAL BODY WT(G)	29.8	NO SIGNIFICANT					
		CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	LN, MANDIBULAR	LIVER
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 35
SPONSOR:SYGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8750 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
FINAL BODY WT(G)	28.3	KIDNEYS	MICRO: CYST FOCAL; CORTEX	P
		LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 36
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8706 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
	KIDNEYS	MICRO:	BASOPHILIC TUBULES	1
FINAL BODY WT(G) 28.8	LIVER	MICRO:	INFLAMMATION, SUBACUTE	1
	PEYER'S PATCHES	MICRO:	NOT PRESENT FOR EXAMINATION PEYER'S PATCHES NOT IN PLANE; RECUT EVALUATED	
	UTERUS	GROSS:	CONTENTS, CLEAR FLUID BOTH HORNS	P
	^==>	UTERUS:	DILATATION, LUMEN	
	UTERUS	MICRO:	DILATATION, LUMEN	2
	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS, AORTA, STERNUM, FEMUR, JOINT, BRAIN, CECUM, COLON, DUODENUM, ESOPHAGUS, EYES, NERVES, OPTIC, HEART, ILEUM, JEJUNUM, KIDNEYS, LN, MANDIBULAR, LIVER, LN, MESENTERIC, LUNGS, GALLBLADDER, MAMMARY GLAND, NERVE, SCIATIC, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, RECTUM, SPINAL CORD, SAL. GLAND MAND, STOMACH, SKELETAL MUSCLE, SKIN, SPLEEN, PEYER'S PATCHES, THYROID GLANDS, THYMUS, TRACHEA, URINARY BLADDER, VAGINA, CERVIX, LN, AXILLARY	
		MICRO:	CECUM, COLON, DUODENUM, ESOPHAGUS, ILEUM, JEJUNUM, LN, MANDIBULAR, LN, MESENTERIC, RECTUM, STOMACH, GLAN, STOMACH, NON, SPLEEN, THYMUS	

NOT PRESENT FOR EXAMINATION

MICRO:PEYER'S PATCHES

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT
^==> INDICATES MICRO CONFIRMATION OF ABOVE GROSS FINDING

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 37
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8734 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
FINAL BODY WT(G)	26.9	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
			MINERALIZATION	1
			FOCAL	
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 38

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8736 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	26.9	THYMUS	MICRO: HEMORRHAGE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8742 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

				GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES	1
FINAL BODY WT(G)	26.9	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		PEYER'S PATCHES	MICRO: NOT PRESENT FOR EXAMINATION PEYER'S PATCHES NOT IN PLANE; RECUT EVALUATED	
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:ADRENAL GLANDS, AORTA, STERNUM, FEMUR, JOINT, BRAIN, CECUM, COLON, DUODENUM, ESOPHAGUS, EYES, NERVES, OPTIC, HEART, ILEUM, JEJUNUM, KIDNEYS, LN, MANDIBULAR, LIVER, LN, MESENTERIC, LUNGS, GALLBLADDER, MAMMARY GLAND, NERVE, SCIATIC, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, RECTUM, SPINAL CORD, SAL. GLAND MAND, STOMACH, SKELETAL MUSCLE, SKIN, SPLEEN, PEYER'S PATCHES, THYROID GLANDS, THYMUS, TRACHEA, URINARY BLADDER, UTERUS, VAGINA, CERVIX, LN, AXILLARY

MICRO:CECUM, COLON, DUODENUM, ESOPHAGUS, ILEUM, JEJUNUM, LN, MANDIBULAR, LN, MESENTERIC, RECTUM, STOMACH, GLAN, STOMACH, NON, SPLEEN, THYMUS

NOT PRESENT FOR EXAMINATION

MICRO:PEYER'S PATCHES

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I12 (DAY 2 INTERIM NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 40
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8746 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 01/20/10 DATE OF DEATH: 01/20/10 STUDY DAY: 2

			GRADE
FINAL BODY WT(G) 27.0	KIDNEYS	MICRO: CYST FOCAL; CORTEX	P
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	THYMUS	MICRO: NOT PRESENT FOR EXAMINATION THYMUS NOT EXAMINED; NOT IN PLANE; RECUT EVALUATED	
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:ADRENAL GLANDS, AORTA, STERNUM, FEMUR, JOINT, BRAIN, CECUM, COLON, DUODENUM, ESOPHAGUS, EYES, NERVES, OPTIC, HEART, ILEUM, JEJUNUM, KIDNEYS, LN, MANDIBULAR, LIVER, LN, MESENTERIC, LUNGS, GALLBLADDER, MAMMARY GLAND, NERVE, SCIATIC, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, RECTUM, SPINAL CORD, SAL. GLAND MAND, STOMACH, SKELETAL MUSCLE, SKIN, SPLEEN, PEYER'S PATCHES, THYROID GLANDS, THYMUS, TRACHEA, URINARY BLADDER, UTERUS, VAGINA, CERVIX, LN, AXILLARY

MICRO:CECUM, COLON, DUODENUM, ESOPHAGUS, ILEUM, JEJUNUM, LN, MANDIBULAR, LN, MESENTERIC, RECTUM, STOMACH, GLAN, STOMACH, NON, SPLEEN, PEYER'S PATCHES

NOT PRESENT FOR EXAMINATION

MICRO:THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

PGRHv4.64
03/16/2010

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 1

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8668 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 31.4	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	THYMUS	MICRO: HEMORRHAGE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 2

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8672 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 32.0	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LN, MANDIBULAR	MICRO: HEMORRHAGE	1
	THYMUS	MICRO: HEMORRHAGE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LIVER	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 3

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8693 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

		GRADE
FINAL BODY WT(G) 35.0	KIDNEYS MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LIVER MICRO: INFLAMMATION, SUBACUTE	1
	NO SIGNIFICANT CHANGES OBSERVED	

GROSS:

ADRENAL GLANDS	AORTA	STERNUM	FEMUR
JOINT	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
NERVES, OPTIC	HEART	ILEUM	JEJUNUM
KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
PITUITARY	PROSTATE	RECTUM	SPINAL CORD
SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
LN, AXILLARY			

MICRO:

CECUM	COLON	DUODENUM	ESOPHAGUS
ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 4

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8696 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	29.9	THYMUS	MICRO: HEMORRHAGE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 5

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8697 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
	KIDNEYS	MICRO: BASOPHILIC TUBULES	1
FINAL BODY WT(G) 36.7		INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 6

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8670 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
FINAL BODY WT(G)	28.5	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LIVER	LN, MESENTERIC	RECTUM	STOMACH, GLAN
				STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 7

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8677 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
		KIDNEYS	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	28.4	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 8
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8682 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
FINAL BODY WT(G) 30.2	ESOPHAGUS	MICRO:	INFLAMMATION, SUBACUTE FOCAL IN SUBMUCOSA	1
	KIDNEYS	MICRO:	HYDRONEPHROSIS UNILATERAL	1
			INFLAMMATION, SUBACUTE	1
	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS, AORTA, STERNUM, FEMUR, JOINT, BRAIN, CECUM, COLON, DUODENUM, EPIDIDYMIDES, ESOPHAGUS, EYES, NERVES, OPTIC, HEART, ILEUM, JEJUNUM, KIDNEYS, LN, MANDIBULAR, LIVER, LN, MESENTERIC, LUNGS, GALLBLADDER, NERVE, SCIATIC, PANCREAS, PITUITARY, PROSTATE, RECTUM, SPINAL CORD, SAL. GLAND MAND, STOMACH, SKELETAL MUSCLE, SKIN, SPLEEN, SEMINAL VESICLES, TESTES, PEYER'S PATCHES, THYROID GLANDS, THYMUS, TRACHEA, URINARY BLADDER, LN, AXILLARY	
		MICRO:	CECUM, COLON, DUODENUM, ILEUM, JEJUNUM, LN, MANDIBULAR, LIVER, LN, MESENTERIC, RECTUM, STOMACH, GLAN, STOMACH, NON, SPLEEN, PEYER'S PATCHES, THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 9

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8686 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	33.5	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 10

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8692 GROUP 2: 500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	34.8	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 11

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8661 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 32.6	KIDNEYS	MICRO: DILATATION, TUBULAR FOCAL; MEDULLA	1
		BASOPHILIC TUBULES	1
		INFLAMMATION, SUBACUTE	1
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NECROSIS, HEPATOCELLULAR FOCAL	1
	THYMUS	MICRO: HEMORRHAGE	1
	NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS, AORTA, STERNUM, FEMUR, JOINT, BRAIN, CECUM, COLON, DUODENUM, EPIDIDYMIDES, ESOPHAGUS, EYES, NERVES, OPTIC, HEART, ILEUM, JEJUNUM, KIDNEYS, LN, MANDIBULAR, LIVER, LN, MESENTERIC, LUNGS, GALLBLADDER, NERVE, SCIATIC, PANCREAS, PITUITARY, PROSTATE, RECTUM, SPINAL CORD, SAL. GLAND MAND, STOMACH, SKELETAL MUSCLE, SKIN, SPLEEN, SEMINAL VESICLES, TESTES, PEYER'S PATCHES, THYROID GLANDS, THYMUS, TRACHEA, URINARY BLADDER, LN, AXILLARY	
		MICRO: CECUM, COLON, DUODENUM, ESOPHAGUS, ILEUM, JEJUNUM, LN, MANDIBULAR, LN, MESENTERIC, RECTUM, STOMACH, GLAN, STOMACH, NON, SPLEEN, PEYER'S PATCHES	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 12
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8676 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		KIDNEYS	MICRO:	INFLAMMATION, SUBACUTE			1
FINAL BODY WT(G)	39.0			BASOPHILIC TUBULES			1
		LIVER	MICRO:	INFLAMMATION, SUBACUTE			1
		NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
				RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
				PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 13
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8681 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
FINAL BODY WT(G) 29.8	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE					1
	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
			JOINT	BRAIN	CECUM	COLON	
			DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES	
			NERVES, OPTIC	HEART	ILEUM	JEJUNUM	
			KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC	
			LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS	
			PITUITARY	PROSTATE	RECTUM	SPINAL CORD	
			SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN	
			SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES	
			THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER	
			LN, AXILLARY				
		MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS	
			ILEUM	JEJUNUM	LN, MANDIBULAR	LIVER	
			LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON	
			SPLEEN	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 14

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8687 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
FINAL BODY WT(G) 29.9	STOMACH, GLAN	MICRO: CELLULAR DEBRIS IN GASTRIC PIT					1
	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
			JOINT	BRAIN	CECUM	COLON	
			DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES	
			NERVES, OPTIC	HEART	ILEUM	JEJUNUM	
			KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC	
			LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS	
			PITUITARY	PROSTATE	RECTUM	SPINAL CORD	
			SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN	
			SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES	
			THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER	
			LN, AXILLARY				
		MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS	
			ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR	
			LIVER	LN, MESENTERIC	RECTUM	STOMACH, NON	
			SPLEEN	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 15
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8694 GROUP 3: 1500 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 34.6	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 16
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8667 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE				1
FINAL BODY WT(G)	31.8						
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
		NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
				NERVES, OPTIC	HEART	ILEUM	JEJUNUM
				KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
				LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
				PITUITARY	PROSTATE	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
				THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
				LN, AXILLARY			
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
				RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
				PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 17

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8673 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 34.2	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	THYMUS	MICRO: HEMORRHAGE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 18

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8679 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
		KIDNEYS	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	35.8	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		THYMUS	MICRO: HEMORRHAGE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8690 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 34.4	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
	NERVES, OPTIC	HEART	ILEUM	JEJUNUM
	KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
	LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
	PITUITARY	PROSTATE	RECTUM	SPINAL CORD
	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
	SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
	THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
	LN, AXILLARY			
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LIVER
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 20
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8703 GROUP 4: 2000 MG/KG MALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

		GRADE
FINAL BODY WT(G) 34.9	KIDNEYS MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LIVER MICRO: INFLAMMATION, SUBACUTE	1
	NO SIGNIFICANT CHANGES OBSERVED	

GROSS:

ADRENAL GLANDS	AORTA	STERNUM	FEMUR
JOINT	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
NERVES, OPTIC	HEART	ILEUM	JEJUNUM
KIDNEYS	LN, MANDIBULAR	LIVER	LN, MESENTERIC
LUNGS	GALLBLADDER	NERVE, SCIATIC	PANCREAS
PITUITARY	PROSTATE	RECTUM	SPINAL CORD
SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
SPLEEN	SEMINAL VESICLES	TESTES	PEYER'S PATCHES
THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER
LN, AXILLARY			

MICRO:

CECUM	COLON	DUODENUM	ESOPHAGUS
ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 21
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8716 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 28.0	ESOPHAGUS	MICRO: DEGENERATION, MUSCLE FOCAL IN WALL	1
	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LN, MANDIBULAR	MICRO: HEMORRHAGE	1
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ILEUM
	JEJUNUM	LN, MESENTERIC	RECTUM	STOMACH, GLAN
	STOMACH, NON	SPLEEN	PEYER'S PATCHES	THYMUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 22
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8719 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
	KIDNEYS	MICRO:	BASOPHILIC TUBULES	1
FINAL BODY WT(G) 29.0	LIVER	MICRO:	INFLAMMATION, SUBACUTE	1
	THYMUS	MICRO:	HEMORRHAGE	1
	TAIL	GROSS:	SCABBING	P
			DISTAL	
	^==>	TAIL:	HYPERKERATOSIS	
	^==>	TAIL:	NECROSIS, EPIDERMAL	
	TAIL	MICRO:	HYPERKERATOSIS	2
			NECROSIS, EPIDERMAL	2
			FOCAL	

NO SIGNIFICANT CHANGES OBSERVED

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT
^==> INDICATES MICRO CONFIRMATION OF ABOVE GROSS FINDING

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8722 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	26.9	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8728 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	26.6	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 25

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8748 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	28.2	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8726 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
		LN, MANDIBULAR	MICRO: HEMORRHAGE	1
FINAL BODY WT(G)	27.3	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8729 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
		KIDNEYS	MICRO: BASOPHILIC TUBULES	1
FINAL BODY WT(G)	28.5	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 28

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8737 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE					1
FINAL BODY WT(G) 28.4	LIVER	MICRO: INFLAMMATION, SUBACUTE					1
	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
			JOINT	BRAIN	CECUM	COLON	
			DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC	
			HEART	ILEUM	JEJUNUM	KIDNEYS	
			LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS	
			GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	
			OVARIES	PANCREAS	PITUITARY	RECTUM	
			SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	
			SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS	
			THYMUS	TRACHEA	URINARY BLADDER	UTERUS	
			VAGINA	CERVIX	LN, AXILLARY		
		MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS	
			ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC	
			RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN	
			PEYER'S PATCHES	THYMUS			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 29
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8738 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
		LN, MANDIBULAR	MICRO: HEMORRHAGE	1
FINAL BODY WT(G)	28.2	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
			NECROSIS, HEPATOCELLULAR	1
			FOCAL	
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 30

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8745 GROUP 2: 500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	27.4	RECTUM	MICRO: INFLAMMATION, SUBACUTE IN PERIANAL CONNECTIVE TISSUE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8710 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	26.0	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8720 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 27.3	KIDNEYS	MICRO: VACUOLATION, TUBULAR EPITHELIUM PARS RECTA; BILATERAL	2
	LIVER	MICRO: INFLAMMATION, SUBACUTE MULTIFOCAL	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 33
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8721 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 28.5	LIVER	GROSS: DISCOLORATION, DARK RED CAUDATE LOBE	P
	^==>	LIVER: NECROSIS, HEPATOCELLULAR	
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
		NECROSIS, HEPATOCELLULAR CAUDATE LOBE	4
	THYMUS	MICRO: HEMORRHAGE	1
	LN, AXILLARY	GROSS: ENLARGED RIGHT	P
	^==>	GROSS UNCONFIRMED	
	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	

ADRENAL GLANDS	AORTA	STERNUM	FEMUR
JOINT	BRAIN	CECUM	COLON
DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
HEART	ILEUM	JEJUNUM	KIDNEYS
LN, MANDIBULAR	LN, MESENTERIC	LUNGS	GALLBLADDER
MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
PANCREAS	PITUITARY	RECTUM	SPINAL CORD
SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
SPLEEN	PEYER'S PATCHES	THYROID GLANDS	THYMUS
TRACHEA	URINARY BLADDER	UTERUS	VAGINA
CERVIX			

MICRO:

CECUM	COLON	DUODENUM	ESOPHAGUS
ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
SPLEEN	PEYER'S PATCHES	LN, AXILLARY	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT
^==> INDICATES MICRO CONFIRMATION OF ABOVE GROSS FINDING

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 34

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8724 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G)	28.7	RECTUM	MICRO: INFLAMMATION, ACUTE IN PERIANAL CONNECTIVE TISSUE	1
		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8732 GROUP 3: 1500 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 28.2	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
		BASOPHILIC TUBULES	1
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, GLAN	STOMACH, NON	SPLEEN
	PEYER'S PATCHES	THYMUS		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 36

SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

SPONSOR NO.:T007563-08

ANIMAL NO. 8725 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

							GRADE
		LIVER	MICRO: INFLAMMATION, SUBACUTE				1
FINAL BODY WT(G)	29.2	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
				JOINT	BRAIN	CECUM	COLON
				DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
				GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
				SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS
				VAGINA	CERVIX	LN, AXILLARY	
			MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
				ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
				LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
				SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)
A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PROJECT NO.:WIL-639061
SPONSOR:SYNGENTA
SPONSOR NO.:T007563-08

ANIMAL NO. 8739 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
FINAL BODY WT(G)	26.9	LIVER NO SIGNIFICANT CHANGES OBSERVED	MICRO: INFLAMMATION, SUBACUTE	1

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)
A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PROJECT NO.:WIL-639061
SPONSOR:SYNGENTA
SPONSOR NO.:T007563-08

ANIMAL NO. 8740 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

		GRADE
KIDNEYS	MICRO: INFLAMMATION, SUBACUTE	1
FINAL BODY WT(G) 27.9	NO SIGNIFICANT CHANGES OBSERVED	

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LIVER
	LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
	SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8741 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

				GRADE
	LIVER	MICRO: INFLAMMATION, SUBACUTE		1
FINAL BODY WT(G) 29.7	NO SIGNIFICANT CHANGES OBSERVED	GROSS:		

ADRENAL GLANDS	AORTA	STERNUM	FEMUR
JOINT	BRAIN	CECUM	COLON
DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
HEART	ILEUM	JEJUNUM	KIDNEYS
LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	RECTUM
SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
THYMUS	TRACHEA	URINARY BLADDER	UTERUS
VAGINA	CERVIX	LN, AXILLARY	
MICRO: CECUM	COLON	DUODENUM	ESOPHAGUS
ILEUM	JEJUNUM	KIDNEYS	LN, MANDIBULAR
LN, MESENTERIC	RECTUM	STOMACH, GLAN	STOMACH, NON
SPLEEN	PEYER'S PATCHES	THYMUS	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

TABLE I13 (DAY 14 PRIMARY NECROPSY)

PROJECT NO.:WIL-639061 A SINGLE-DOSE ORAL GAVAGE STUDY OF AVHPPD-03 IN MICE PAGE 40
SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS
SPONSOR NO.:T007563-08

ANIMAL NO. 8744 GROUP 4: 2000 MG/KG FEMALE SCHEDULED EUTH 02/01/10 DATE OF DEATH: 02/01/10 STUDY DAY: 14

			GRADE
FINAL BODY WT(G) 30.3	KIDNEYS	MICRO: INFLAMMATION, SUBACUTE ADJACENT TO URINARY SPACE	1
	LIVER	MICRO: INFLAMMATION, SUBACUTE	1
	STOMACH, GLAN	MICRO: CELLULAR DEBRIS IN GASTRIC PIT	1
	THYMUS	MICRO: HEMORRHAGE	1
	NO SIGNIFICANT CHANGES OBSERVED		

GROSS:	ADRENAL GLANDS	AORTA	STERNUM	FEMUR
	JOINT	BRAIN	CECUM	COLON
	DUODENUM	ESOPHAGUS	EYES	NERVES, OPTIC
	HEART	ILEUM	JEJUNUM	KIDNEYS
	LN, MANDIBULAR	LIVER	LN, MESENTERIC	LUNGS
	GALLBLADDER	MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS
	OVARIES	PANCREAS	PITUITARY	RECTUM
	SPINAL CORD	SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE
	SKIN	SPLEEN	PEYER'S PATCHES	THYROID GLANDS
	THYMUS	TRACHEA	URINARY BLADDER	UTERUS
	VAGINA	CERVIX	LN, AXILLARY	
MICRO:	CECUM	COLON	DUODENUM	ESOPHAGUS
	ILEUM	JEJUNUM	LN, MANDIBULAR	LN, MESENTERIC
	RECTUM	STOMACH, NON	SPLEEN	PEYER'S PATCHES

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL; 2-MILD; 3-MODERATE; 4-SEVERE; P-PRESENT

PGRHv4.64
03/16/2010